Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32622784,Tmax),"Peak ΔΔQTcF values observed at 5 h postdose (Tmax) were 2.9 msec (upper 95% confidence limit, 4.9 msec) with the therapeutic dose and 3.1 msec (upper 95% confidence limit, 5.1 msec) with the supratherapeutic dose, with both upper 95% confidence limits well below the 10-msec threshold.",A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622784/),ms,2.9,2005,DB00218,Moxifloxacin
,32622784,Tmax),"Peak ΔΔQTcF values observed at 5 h postdose (Tmax) were 2.9 msec (upper 95% confidence limit, 4.9 msec) with the therapeutic dose and 3.1 msec (upper 95% confidence limit, 5.1 msec) with the supratherapeutic dose, with both upper 95% confidence limits well below the 10-msec threshold.",A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622784/),ms,3.1,2006,DB00218,Moxifloxacin
,32622784,peak ΔΔQTcF,Assay sensitivity was confirmed by peak ΔΔQTcF in the positive control (12.8 ms at 2 h postdose).,A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622784/),ms,12.8,2007,DB00218,Moxifloxacin
,17517835,AUC(0-24),"Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC(0-24), 1.29 versus 2.79 mug.h/ml).",Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517835/),[h·μg] / [ml],1.29,5662,DB00218,Moxifloxacin
,17517835,AUC(0-24),"Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC(0-24), 1.29 versus 2.79 mug.h/ml).",Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517835/),[h·μg] / [ml],2.79,5663,DB00218,Moxifloxacin
less,21986820,half-lives,All four agents distributed rapidly from plasma to tissue with equilibration half-lives of less than 1 min to an hour.,Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986820/),min,1,6330,DB00218,Moxifloxacin
,17532709,maximum concentrations (C(max)),Both antibacterials showed a high level of intracellular penetration exhibiting PMNs/plasma ratios of 17.34 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for maximum concentrations (C(max)) and 14.72 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for the area under the plasma concentration-time curve.,In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,8.15,6636,DB00218,Moxifloxacin
,17532709,area under the plasma concentration-time curve,Both antibacterials showed a high level of intracellular penetration exhibiting PMNs/plasma ratios of 17.34 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for maximum concentrations (C(max)) and 14.72 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for the area under the plasma concentration-time curve.,In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,14.72,6637,DB00218,Moxifloxacin
,17532709,area under the plasma concentration-time curve,Both antibacterials showed a high level of intracellular penetration exhibiting PMNs/plasma ratios of 17.34 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for maximum concentrations (C(max)) and 14.72 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for the area under the plasma concentration-time curve.,In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,8.15,6638,DB00218,Moxifloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,287.3,6639,DB00218,Moxifloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,718.2,6640,DB00218,Moxifloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,25.6,6641,DB00218,Moxifloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,205.1,6642,DB00218,Moxifloxacin
,27742641,AUC0-24/MIC ratios,"The linezolid and moxifloxacin exposure targets were AUC0-24/MIC ratios of 62 and 122, and a faropenem percentage of time above MIC >60%, in combination therapy.","Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742641/),,62,7375,DB00218,Moxifloxacin
,27742641,AUC0-24/MIC ratios,"The linezolid and moxifloxacin exposure targets were AUC0-24/MIC ratios of 62 and 122, and a faropenem percentage of time above MIC >60%, in combination therapy.","Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742641/),,122,7376,DB00218,Moxifloxacin
>,27742641,percentage of time above MIC,"The linezolid and moxifloxacin exposure targets were AUC0-24/MIC ratios of 62 and 122, and a faropenem percentage of time above MIC >60%, in combination therapy.","Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742641/),%,60,7377,DB00218,Moxifloxacin
,27742641,AUC0-24,A linezolid AUC0-24 of 93.4 mg × hour/L was target for toxicity.,"Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742641/),[h·mg] / [l],93.4,7378,DB00218,Moxifloxacin
,9687407,maximum concentrations of moxifloxacin in plasma (Cmax),The mean maximum concentrations of moxifloxacin in plasma (Cmax) ranged from 0.29 mg/liter (50-mg dose) to 4.73 mg/liter (800-mg dose) and were reached 0.5 to 4 h following drug administration.,"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687407/),[mg] / [l],0.29,7584,DB00218,Moxifloxacin
,9687407,maximum concentrations of moxifloxacin in plasma (Cmax),The mean maximum concentrations of moxifloxacin in plasma (Cmax) ranged from 0.29 mg/liter (50-mg dose) to 4.73 mg/liter (800-mg dose) and were reached 0.5 to 4 h following drug administration.,"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687407/),[mg] / [l],4.73,7585,DB00218,Moxifloxacin
,9687407,terminal half-life,"Within 4 to 5 h they fell to about 30 to 55% of the Cmax, and thereafter a terminal half-life of 11 to 14 h accounted for the major part of the area under the concentration-time curve (AUC).","Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687407/),h,11 to 14,7586,DB00218,Moxifloxacin
,9687407,protein binding level,"During the absorption phase concentrations in saliva were even higher than those in plasma, whereas in the terminal phase a constant ratio of the concentration in saliva/concentration in plasma of between 0.5 and 1 was observed, indicating a correlation between unbound concentrations in plasma and levels in saliva (protein binding level, approximately 48%).","Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687407/),,48,7587,DB00218,Moxifloxacin
,9687407,Urinary excretion,Urinary excretion amounted to approximately 20% of the dose.,"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687407/),%,20,7588,DB00218,Moxifloxacin
,9687407,renal clearance,Data on renal clearance (40 to 51 ml/min/1.73 m2) indicated partial tubular reabsorption of the drug.,"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687407/),[ml] / [1.73·m2·min],40 to 51,7589,DB00218,Moxifloxacin
,21847518,"area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))","The mean area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))], maximum plasma concentration (C(max)), and trough plasma level (C(trough)) of moxifloxacin at steady state was 52.0 μg h/ml, 4.5, and 0.9 μg/ml, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),[h·μg] / [ml],52.0,7645,DB00218,Moxifloxacin
,21847518,maximum plasma concentration (C(max)),"The mean area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))], maximum plasma concentration (C(max)), and trough plasma level (C(trough)) of moxifloxacin at steady state was 52.0 μg h/ml, 4.5, and 0.9 μg/ml, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),[μg] / [ml],4.5,7646,DB00218,Moxifloxacin
,21847518,trough plasma level (C(trough)),"The mean area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))], maximum plasma concentration (C(max)), and trough plasma level (C(trough)) of moxifloxacin at steady state was 52.0 μg h/ml, 4.5, and 0.9 μg/ml, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),[μg] / [ml],0.9,7647,DB00218,Moxifloxacin
,21847518,"AUC(0-24 h,ss)","Mean AUC(0-24 h,ss)/mimimum inhibitory concentration (MIC), and C(max)/MIC ratios for patients in whom MICs of moxifloxacin were determined for pathogenic bacteria were 723 and 62, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,723,7648,DB00218,Moxifloxacin
,21847518,mi,"Mean AUC(0-24 h,ss)/mimimum inhibitory concentration (MIC), and C(max)/MIC ratios for patients in whom MICs of moxifloxacin were determined for pathogenic bacteria were 723 and 62, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,723,7649,DB00218,Moxifloxacin
,21847518,MICs,"Mean AUC(0-24 h,ss)/mimimum inhibitory concentration (MIC), and C(max)/MIC ratios for patients in whom MICs of moxifloxacin were determined for pathogenic bacteria were 723 and 62, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,62,7650,DB00218,Moxifloxacin
,21847518,"AUC(0-24 h,ss)/MIC","The median AUC(0-24 h,ss)/MIC and C(max)/MIC ratios (based on Monte Carlo simulation employing MICs for 257 strains of S. pneumoniae collected during a respiratory infection survey by the Japanese Society of Chemotherapy in 2007) were 209.56 and 17.88, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,209.56,7651,DB00218,Moxifloxacin
≥,21847518,AUC/MIC ratio,"Thus, when the target for the AUC/MIC ratio was set at ≥30 and that for the C(max)/MIC ratio at ≥5, the achievement rate for these two parameters was 97.36% and 96.71%, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,30,7652,DB00218,Moxifloxacin
≥,21847518,C(max)/MIC ratio,"Thus, when the target for the AUC/MIC ratio was set at ≥30 and that for the C(max)/MIC ratio at ≥5, the achievement rate for these two parameters was 97.36% and 96.71%, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,5,7653,DB00218,Moxifloxacin
,33400845,ΔΔQTcF,"After a single savolitinib 600-mg dose, the highest least-squares mean ΔΔQTcF of 12 milliseconds was observed 5 hours postdose.","A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400845/),,12,8947,DB00218,Moxifloxacin
≤,34131942,maximum observed plasma concentration,"Only subjects with maximum observed plasma concentration ≤ 350 ng/mL (n = 60) were randomized into part B, where they received a single oral dose of placebo, 50 mg OM and 400 mg moxifloxacin in a 3-period, 3-treatment, 6-sequence crossover study with continuous ECG collection.",Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34131942/),[ng] / [ml],350,10009,DB00218,Moxifloxacin
,34131942,peak value,"Moxifloxacin resulted in a clear increase in mean ∆∆QTcF, with a peak value of 13.1 ms (90% CI: 11.71-14.57) at 3 hours; lower bound of the 1-sided 95% CI was > 5 ms at all of the 3 prespecified time points.",Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34131942/),ms,13.1,10010,DB00218,Moxifloxacin
,24798753,flow rate,"An Inertsil(®) ODS3 C18 column (150mm×4.6mm, 5μm), a mobile phase composed of methanol-0.03% TEA (triethylamine) in water (85:15, v/v), and a flow rate of 0.5mL/min were employed, and the total run time was 6.0min.","LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798753/),[ml] / [min],0.5,11507,DB00218,Moxifloxacin
,24798753,total run time,"An Inertsil(®) ODS3 C18 column (150mm×4.6mm, 5μm), a mobile phase composed of methanol-0.03% TEA (triethylamine) in water (85:15, v/v), and a flow rate of 0.5mL/min were employed, and the total run time was 6.0min.","LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798753/),min,6.0,11508,DB00218,Moxifloxacin
≥,24798753,recoveries,"The recoveries obtained for PA-824, moxifloxacin and pyrazinamide were ≥85%.","LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798753/),%,85,11509,DB00218,Moxifloxacin
,29505101,peak plasma concentrations (Cmax ),"In the MAD study, doses up to 90 mg once daily for 7 days resulted in JNJ-54861911 peak plasma concentrations (Cmax ) comparable to those in the SAD study (∼750 ng/mL), but ER by HPQT failed to detect a QT effect and resulted in negative estimations.","Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505101/),[ng] / [ml],∼750,12034,DB00218,Moxifloxacin
,29505101,Cmax,"Adding a higher dose cohort (150 mg; Cmax , 1125 ng/mL) demonstrated a QT effect, with a slightly lower ER slope than the TQT study.","Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505101/),[ng] / [ml],1125,12035,DB00218,Moxifloxacin
,26423621,placebo-corrected change from baseline (ΔΔQTcF),"Analysis by IUT revealed that the maximum mean (90 % confidence interval (CI)) placebo-corrected change from baseline (ΔΔQTcF) in the SAD study and the TQT study were remarkably similar (10.7 (6.5; 14.9) ms vs. 9.09 (6.20; 11.98) ms, respectively).",Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26423621/),ms,10.7,12383,DB00218,Moxifloxacin
,26423621,placebo-corrected change from baseline (ΔΔQTcF),"Analysis by IUT revealed that the maximum mean (90 % confidence interval (CI)) placebo-corrected change from baseline (ΔΔQTcF) in the SAD study and the TQT study were remarkably similar (10.7 (6.5; 14.9) ms vs. 9.09 (6.20; 11.98) ms, respectively).",Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26423621/),ms,9.09,12384,DB00218,Moxifloxacin
,26423621,effects,Bootstrap-predicted effects of moxifloxacin at geometric mean concentrations of ~3000 ng/mL were 8.19 (90 % CI 5.86; 10.7) ms in the SAD study and 7.33 (90 % CI 5.69; 9.70) ms in the TQT study.,Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26423621/),m,8,12385,DB00218,Moxifloxacin
,26423621,effects,Bootstrap-predicted effects of moxifloxacin at geometric mean concentrations of ~3000 ng/mL were 8.19 (90 % CI 5.86; 10.7) ms in the SAD study and 7.33 (90 % CI 5.69; 9.70) ms in the TQT study.,Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26423621/),m,7,12386,DB00218,Moxifloxacin
>,23546399,half-life,"Experiment 2: Concentrations at baseline were 52% at 1 and 15% at 3 h respectively, suggesting that the half-life of intracameral MFLX was >1 h.",Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23546399/),h,1,12810,DB00218,Moxifloxacin
>,23546399,half-life,"Considering that the half-life of MFLX was >1 h, a final concentration of 150 μg/ml results in a 2 h concentration of 38 μg/ml, which was beyond the minimum inhibitory concentration required to inhibit the growth of 90% of bacteria (MIC90) for most resistant pathogens.",Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23546399/),h,1,12811,DB00218,Moxifloxacin
,20813346,peak level,"Azithromycin 1% provided high concentrations (peak level, 559.7 μg/g) in human conjunctiva that were sustained at levels 1 to 2 orders of magnitude higher than those of moxifloxacin 0.5% throughout the 7-day dosing period and for at least 7 days thereafter.",Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813346/),[μg] / [g],559.7,15746,DB00218,Moxifloxacin
,20813346,half-life,Azithromycin also showed an extended half-life (65.7 hours) in conjunctiva relative to that of moxifloxacin (28.6 hours).,Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813346/),h,65.7,15747,DB00218,Moxifloxacin
,20813346,half-life,Azithromycin also showed an extended half-life (65.7 hours) in conjunctiva relative to that of moxifloxacin (28.6 hours).,Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813346/),h,28.6,15748,DB00218,Moxifloxacin
,20813346,Peak aqueous humor concentration,Peak aqueous humor concentration of moxifloxacin was higher (0.77 μg/mL) than that of azithromycin (0.053 μg/mL).,Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813346/),[μg] / [ml],0.77,15749,DB00218,Moxifloxacin
,20813346,Peak aqueous humor concentration,Peak aqueous humor concentration of moxifloxacin was higher (0.77 μg/mL) than that of azithromycin (0.053 μg/mL).,Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813346/),[μg] / [ml],0.053,15750,DB00218,Moxifloxacin
<,17643323,C(max),"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),μM,40,15927,DB00218,Moxifloxacin
<,17643323,C(max),"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),μM,0.36,15928,DB00218,Moxifloxacin
<,17643323,C(max),"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),nM,825,15929,DB00218,Moxifloxacin
,17643323,peak increases,"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),ms,45,15930,DB00218,Moxifloxacin
,17643323,peak increases,"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),ms,31,15931,DB00218,Moxifloxacin
,17643323,peak increases,"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),ms,45,15932,DB00218,Moxifloxacin
,14506015,areas under the concentration-time curves (AUCs) from 0 to 8 h (AUC(0-8)s),"For healthy and inflamed adipose tissues for the diabetic subgroup, the mean moxifloxacin areas under the concentration-time curves (AUCs) from 0 to 8 h (AUC(0-8)s) were 8.1 +/- 7.1 and 3.7 +/- 1.9 mg.h/liter, respectively (P was not significant).",Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506015/),[h·mg] / [l],8.1,17865,DB00218,Moxifloxacin
,14506015,areas under the concentration-time curves (AUCs) from 0 to 8 h (AUC(0-8)s),"For healthy and inflamed adipose tissues for the diabetic subgroup, the mean moxifloxacin areas under the concentration-time curves (AUCs) from 0 to 8 h (AUC(0-8)s) were 8.1 +/- 7.1 and 3.7 +/- 1.9 mg.h/liter, respectively (P was not significant).",Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506015/),[h·mg] / [l],3.7,17866,DB00218,Moxifloxacin
>,14506015,ratios of the AUCs from 0 to 24 h,"The ratios of the AUCs from 0 to 24 h for free moxifloxacin in plasma/MIC at which 90% of isolates are inhibited were >58 and 121 h for Streptococcus species and methicillin-sensitive Staphylococcus aureus, respectively.",Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506015/),h,58,17867,DB00218,Moxifloxacin
,14506015,ratios of the AUCs from 0 to 24 h,"The ratios of the AUCs from 0 to 24 h for free moxifloxacin in plasma/MIC at which 90% of isolates are inhibited were >58 and 121 h for Streptococcus species and methicillin-sensitive Staphylococcus aureus, respectively.",Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506015/),h,121,17868,DB00218,Moxifloxacin
,16895940,exudate/plasma concentration ratio,"The exudate/plasma concentration ratio rose from 1.45 at 2 h to 1.91 at 24 h; the 95% confidence intervals for the ratio excluded unity at all time points, suggesting that moxifloxacin penetrates and accumulates in peritoneal exudate.",Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895940/),,1,18172,DB00218,Moxifloxacin
,19108788,concentrations concentrations,"Mean concentrations concentrations of moxifloxacin in conjunctival tissue (LLOQ, 0.05 microg/g for 1-mg biopsy sample) were 1.92 (2.03), 3.77 (8.98), 0.02 (0.04), and 0.01 (0.02) microg/g at 30 minutes and 2, 12, and 24 hours, respectively (median values, 1.12, 0.12, <0.05, and <0.05 microg/g).","Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108788/),,3.77,19221,DB00218,Moxifloxacin
,19108788,concentrations concentrations,"Mean concentrations concentrations of moxifloxacin in conjunctival tissue (LLOQ, 0.05 microg/g for 1-mg biopsy sample) were 1.92 (2.03), 3.77 (8.98), 0.02 (0.04), and 0.01 (0.02) microg/g at 30 minutes and 2, 12, and 24 hours, respectively (median values, 1.12, 0.12, <0.05, and <0.05 microg/g).","Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108788/),,0.02,19222,DB00218,Moxifloxacin
,19108788,concentrations concentrations,"Mean concentrations concentrations of moxifloxacin in conjunctival tissue (LLOQ, 0.05 microg/g for 1-mg biopsy sample) were 1.92 (2.03), 3.77 (8.98), 0.02 (0.04), and 0.01 (0.02) microg/g at 30 minutes and 2, 12, and 24 hours, respectively (median values, 1.12, 0.12, <0.05, and <0.05 microg/g).","Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108788/),,0.01,19223,DB00218,Moxifloxacin
,24691742,ΔΔQTcI,"The largest time-matched ΔΔQTc occurred approximately 4 h after dosing, with ΔΔQTcI (QT interval corrected by individual QT-RR regression model) values of 11.66 ms (moxifloxacin 400 mg) and 20.96 ms (800 mg).",The effects of moxifloxacin on QTc interval in healthy Korean male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24691742/),ms,11.66,20614,DB00218,Moxifloxacin
,24691742,ΔΔQTcI,"The largest time-matched ΔΔQTc occurred approximately 4 h after dosing, with ΔΔQTcI (QT interval corrected by individual QT-RR regression model) values of 11.66 ms (moxifloxacin 400 mg) and 20.96 ms (800 mg).",The effects of moxifloxacin on QTc interval in healthy Korean male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24691742/),m,20.96,20615,DB00218,Moxifloxacin
,10508004,area under the concentration-time curve (AUC),"An almost-complete equilibration of the free unbound plasma fraction of moxifloxacin with the interstitial space fluid was observed, with mean area under the concentration-time curve (AUC)(interstitial fluid)/AUC(total-plasma) ratios ranging from 0.38 to 0.55 and mean AUC(interstitial fluid)/AUC(free-plasma) ratios ranging from 0.81 to 0.86.",Penetration of moxifloxacin into peripheral compartments in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508004/),,0.38 to 0.55,20820,DB00218,Moxifloxacin
above,10508004,concentration/plasma concentration ratio,"The skin blister concentration/plasma concentration ratio reached values above 1.5 after 24 h, indicating a preferential penetration of moxifloxacin into inflamed lesions.",Penetration of moxifloxacin into peripheral compartments in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508004/),,1.5,20821,DB00218,Moxifloxacin
,20385862,serum half-life,"Moxifloxacin doses, based on a serum half-life of 12 h, were administered, and the 0- to 24-h area under the concentration-time curve (AUC(0-24)) to MIC ratios associated with 1.0 log(10) CFU/ml per week kill and 90% of maximal kill (EC(90)) were identified.",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),h,12,22676,DB00218,Moxifloxacin
,20385862,AUC(0-24)/MIC ratio,"The AUC(0-24)/MIC ratio associated with 1.0 log(10) CFU/ml kill was 17.12, and that with EC(90) was 391.56 (r(2) = 0.97).",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),,17.12,22677,DB00218,Moxifloxacin
,20385862,AUC(0-24)/MIC ratio,"The AUC(0-24)/MIC ratio associated with 1.0 log(10) CFU/ml kill was 17.12, and that with EC(90) was 391.56 (r(2) = 0.97).",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),,391.56,22678,DB00218,Moxifloxacin
,20385862,EC(90),"The AUC(0-24)/MIC ratio associated with 1.0 log(10) CFU/ml kill was 17.12, and that with EC(90) was 391.56 (r(2) = 0.97).",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),,391.56,22679,DB00218,Moxifloxacin
,20385862,MIC,The median MIC was 1 to 2 mg/liter.,Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),[mg] / [l],1 to 2,22680,DB00218,Moxifloxacin
,20385862,AUC(0-24)/MIC ratio,"Doses of 400 and 800 mg/day achieved the AUC(0-24)/MIC ratio of 17.12 in 64% and 92% of patients, respectively.",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),,17.12,22681,DB00218,Moxifloxacin
,20385862,AUC(0-24)/MIC ratio,"Doses of 400 and 800 mg/day achieved the AUC(0-24)/MIC ratio of 17.12 in 64% and 92% of patients, respectively.",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),,64,22682,DB00218,Moxifloxacin
,20385862,AUC(0-24)/MIC ratio,"Doses of 400 and 800 mg/day achieved the AUC(0-24)/MIC ratio of 17.12 in 64% and 92% of patients, respectively.",Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),,92,22683,DB00218,Moxifloxacin
,20385862,critical concentration,The critical concentration of moxifloxacin against MAC was identified as 0.25 mg/liter in Middlebrook media.,Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20385862/),[mg] / [l],0.25,22684,DB00218,Moxifloxacin
,31061152,time to culture conversion,"New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012).",Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31061152/),weeks,16,25010,DB00218,Moxifloxacin
,31061152,time to culture conversion,"New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012).",Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31061152/),weeks,40,25011,DB00218,Moxifloxacin
,27028459,metabolic rate,The rat liver microsome incubation experiment indicated that moxifloxacin could increase the metabolic rate of rifampicin from 23.7 to 38.7 min.,Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028459/),min,23.7,25110,DB00218,Moxifloxacin
,27028459,metabolic rate,The rat liver microsome incubation experiment indicated that moxifloxacin could increase the metabolic rate of rifampicin from 23.7 to 38.7 min.,Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028459/),min,38.7,25111,DB00218,Moxifloxacin
,29463526,AUC0-24,"The median moxifloxacin AUC0-24 was 46% higher and the median Cmax was 30% higher in 4 (8%) participants who had the SLCO1B1 g.-11187 AG genotype than in 45 participants who had the wild-type GG genotype (median AUC0-24 from the model, 34.4 versus 23.6 μg · h/ml [P = 0.005, ANCOVA]; median Cmax from the model, 3.5 versus 2.7 μg/ml [P = 0.009, ANCOVA]).",Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463526/),[h·μg] / [ml],34.4,25196,DB00218,Moxifloxacin
,29463526,AUC0-24,"The median moxifloxacin AUC0-24 was 46% higher and the median Cmax was 30% higher in 4 (8%) participants who had the SLCO1B1 g.-11187 AG genotype than in 45 participants who had the wild-type GG genotype (median AUC0-24 from the model, 34.4 versus 23.6 μg · h/ml [P = 0.005, ANCOVA]; median Cmax from the model, 3.5 versus 2.7 μg/ml [P = 0.009, ANCOVA]).",Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463526/),[h·μg] / [ml],23.6,25197,DB00218,Moxifloxacin
,29463526,Cmax,"The median moxifloxacin AUC0-24 was 46% higher and the median Cmax was 30% higher in 4 (8%) participants who had the SLCO1B1 g.-11187 AG genotype than in 45 participants who had the wild-type GG genotype (median AUC0-24 from the model, 34.4 versus 23.6 μg · h/ml [P = 0.005, ANCOVA]; median Cmax from the model, 3.5 versus 2.7 μg/ml [P = 0.009, ANCOVA]).",Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463526/),[μg] / [ml],3.5,25198,DB00218,Moxifloxacin
,29463526,Cmax,"The median moxifloxacin AUC0-24 was 46% higher and the median Cmax was 30% higher in 4 (8%) participants who had the SLCO1B1 g.-11187 AG genotype than in 45 participants who had the wild-type GG genotype (median AUC0-24 from the model, 34.4 versus 23.6 μg · h/ml [P = 0.005, ANCOVA]; median Cmax from the model, 3.5 versus 2.7 μg/ml [P = 0.009, ANCOVA]).",Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463526/),[μg] / [ml],2.7,25199,DB00218,Moxifloxacin
,19306136,AUC (area under the curve),Calculated AUC (area under the curve) ratios tissue:plasma were M. masseter:plasma = 2.64 and mandibles:plasma = 1.13.,Penetration of moxifloxacin into rat mandibular bone and soft tissue. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19306136/),,2.,25316,DB00218,Moxifloxacin
,19306136,AUC (area under the curve),Calculated AUC (area under the curve) ratios tissue:plasma were M. masseter:plasma = 2.64 and mandibles:plasma = 1.13.,Penetration of moxifloxacin into rat mandibular bone and soft tissue. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19306136/),,1,25317,DB00218,Moxifloxacin
,32043623,elimination half-life (t1/2β ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),h,2.27,25343,DB00218,Moxifloxacin
,32043623,total body clearance (ClT ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [h·kg],0.56,25344,DB00218,Moxifloxacin
,32043623,total body clearance (ClT ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [kg],1.66,25345,DB00218,Moxifloxacin
,32043623,volume of distribution at steady state (Vdss ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [h·kg],0.56,25346,DB00218,Moxifloxacin
,32043623,volume of distribution at steady state (Vdss ),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[l] / [kg],1.66,25347,DB00218,Moxifloxacin
,32043623,area under the curve (AUC),"Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2β ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1 kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively.",Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043623/),[h·μg] / [ml],8.91,25348,DB00218,Moxifloxacin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],41.1,25631,DB00218,Moxifloxacin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],15.2,25632,DB00218,Moxifloxacin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],380,25633,DB00218,Moxifloxacin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],25.5,25634,DB00218,Moxifloxacin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],33.6,25635,DB00218,Moxifloxacin
,11352444,times to Cmax(tmax),"At steady state, the plasma pharmacokinetics of theophylline for treatments B and C proved equivalent in terms of maximum concentration (Css(max)) and bodyweight- and dose-normalised Css(max) lestimated true ratio 96%, 90% confidence interval (CI) 87 to 105%] and also in terms of area under the concentration-time curve from 0 to 12 hours (AUCss(tau)) and normalised AUCss(tau) (ratio 95%, 90% CI 85 to 107%); the median times to Cmax(tmax) were also similar (5.0 and 6.0 hours for treatments B and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,5.0,27163,DB00218,Moxifloxacin
,11352444,times to Cmax(tmax),"At steady state, the plasma pharmacokinetics of theophylline for treatments B and C proved equivalent in terms of maximum concentration (Css(max)) and bodyweight- and dose-normalised Css(max) lestimated true ratio 96%, 90% confidence interval (CI) 87 to 105%] and also in terms of area under the concentration-time curve from 0 to 12 hours (AUCss(tau)) and normalised AUCss(tau) (ratio 95%, 90% CI 85 to 107%); the median times to Cmax(tmax) were also similar (5.0 and 6.0 hours for treatments B and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,6.0,27164,DB00218,Moxifloxacin
,11352444,tmax,"The plasma pharmacokinetics of moxifloxacin for treatments A and C were equivalent with respect to Css(max) (estimated true ratio 109%, 90% CI 97 to 123%) and AUCss(tau) (ratio 104%, 90% CI 100 to 108%); the median tmax values were also similar (0.5 and 1.0 hour for treatments A and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,0.5,27165,DB00218,Moxifloxacin
,11352444,tmax,"The plasma pharmacokinetics of moxifloxacin for treatments A and C were equivalent with respect to Css(max) (estimated true ratio 109%, 90% CI 97 to 123%) and AUCss(tau) (ratio 104%, 90% CI 100 to 108%); the median tmax values were also similar (0.5 and 1.0 hour for treatments A and C, respectively).","Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352444/),h,1.0,27166,DB00218,Moxifloxacin
,28785879,area under the time-concentration curve from dosing until 24 h post-dose (AUC0-24),"Doravirine geometric mean area under the time-concentration curve from dosing until 24 h post-dose (AUC0-24) and maximum plasma concentration (C max) were 119 µM·h and 9240 nM, respectively, which exceeded values expected following therapeutic dose administration of doravirine 100 mg, even in the setting of intrinsic and extrinsic factors that may cause increases in doravirine concentrations.",A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28785879/),h·μM,119,27558,DB00218,Moxifloxacin
,28785879,maximum plasma concentration (C max),"Doravirine geometric mean area under the time-concentration curve from dosing until 24 h post-dose (AUC0-24) and maximum plasma concentration (C max) were 119 µM·h and 9240 nM, respectively, which exceeded values expected following therapeutic dose administration of doravirine 100 mg, even in the setting of intrinsic and extrinsic factors that may cause increases in doravirine concentrations.",A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28785879/),nM,9240,27559,DB00218,Moxifloxacin
,30256537,Tmax,"Among 184 adults, rolapitant was absorbed following oral administration under fasting conditions, with a median Tmax of 4 to 6 hours (range, 2-8 hours) and was safe at all doses up to 720 mg.","A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30256537/),h,4 to 6,27891,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],24.9,28221,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],242.3,28222,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],65.9,28223,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],5.3,28224,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],6.6,28225,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],4.7,28226,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],42.0,28227,DB00218,Moxifloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],34.5,28228,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],242.3,28229,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],6.6,28230,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],64.4,28231,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],4.7,28232,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],54.2,28233,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],42.0,28234,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],196.7,28235,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],34.5,28236,DB00218,Moxifloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],153.5,28237,DB00218,Moxifloxacin
,25000831,apparent clearance (CL),"The typical population values of moxifloxacin for the pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 12.9 L/h and 115 L, respectively.",Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25000831/),[l] / [h],12.9,28882,DB00218,Moxifloxacin
,25000831,apparent distribution volume (V),"The typical population values of moxifloxacin for the pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 12.9 L/h and 115 L, respectively.",Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25000831/),l,115,28883,DB00218,Moxifloxacin
,15478070,target-attainment rates,"For patients taking moxifloxacin doses of 400, 600, or 800 mg/day, the calculated target-attainment rates to suppress drug resistance were 59%, 86%, and 93%, respectively.","Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15478070/),%,59,29024,DB00218,Moxifloxacin
,15478070,target-attainment rates,"For patients taking moxifloxacin doses of 400, 600, or 800 mg/day, the calculated target-attainment rates to suppress drug resistance were 59%, 86%, and 93%, respectively.","Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15478070/),%,86,29025,DB00218,Moxifloxacin
,15478070,target-attainment rates,"For patients taking moxifloxacin doses of 400, 600, or 800 mg/day, the calculated target-attainment rates to suppress drug resistance were 59%, 86%, and 93%, respectively.","Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15478070/),%,93,29026,DB00218,Moxifloxacin
,18406644,Steady-state volume of distribution (V(ss)),"Steady-state volume of distribution (V(ss)) and clearance (Cl) of moxifloxacin after IV administration were 2.03+/-0.36L/kg and 0.39+/-0.04L/hkg, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406644/),[l] / [kg],2.03,32991,DB00218,Moxifloxacin
,18406644,clearance (Cl),"Steady-state volume of distribution (V(ss)) and clearance (Cl) of moxifloxacin after IV administration were 2.03+/-0.36L/kg and 0.39+/-0.04L/hkg, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406644/),[l] / [hkg],0.39,32992,DB00218,Moxifloxacin
,18406644,maximum plasma concentration,"Following IM and SC administration, moxifloxacin achieved maximum plasma concentration of 1.66+/-0.62mg/L and 0.90+/-0.19mg/L at 2.25+/-0.88h and 3.25+/-1.17h, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406644/),[mg] / [l],1.66,32993,DB00218,Moxifloxacin
,18406644,maximum plasma concentration,"Following IM and SC administration, moxifloxacin achieved maximum plasma concentration of 1.66+/-0.62mg/L and 0.90+/-0.19mg/L at 2.25+/-0.88h and 3.25+/-1.17h, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406644/),[mg] / [l],0.90,32994,DB00218,Moxifloxacin
,18406644,absolute bioavailabilities,"The absolute bioavailabilities after IM and SC routes were 96.12+/-32.70% and 102.20+/-23.76%, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406644/),%,96.12,32995,DB00218,Moxifloxacin
,18406644,absolute bioavailabilities,"The absolute bioavailabilities after IM and SC routes were 96.12+/-32.70% and 102.20+/-23.76%, respectively.","Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406644/),%,102.20,32996,DB00218,Moxifloxacin
>,22334358,recoveries,The recoveries from spiked control samples were >75% for MFX and >79% for KTC.,Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22334358/),%,75,35960,DB00218,Moxifloxacin
>,22334358,recoveries,The recoveries from spiked control samples were >75% for MFX and >79% for KTC.,Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22334358/),%,79,35961,DB00218,Moxifloxacin
,25832425,peak effect,"The peak effect on QTcF was 9.35 ms (90% CI: 6.36, 12.34) at 3 h post-dose.","Orally administered moxifloxacin prolongs QTc in healthy Chinese volunteers: a randomized, single-blind, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832425/),ms,9.35,36624,DB00218,Moxifloxacin
,23373761,half-life,The half-life of moxifloxacin in the AH was 2.2 h.,"Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373761/),h,2.2,36976,DB00218,Moxifloxacin
,12879119,peak drug plasma concentration (C(max)),"It is rapidly absorbed following oral administration, reaching a mean peak drug plasma concentration (C(max)) of approximately 3.56 mg/l within 2 h after a 400 mg dose.",Pharmacokinetics and metabolism of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879119/),[mg] / [l],3.56,38304,DB00218,Moxifloxacin
,12879119,plasma elimination half-life,The plasma elimination half-life ranges from 8.2-15.1 h in healthy individuals.,Pharmacokinetics and metabolism of moxifloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879119/),h,8.2-15.1,38305,DB00218,Moxifloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB00218,Moxifloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB00218,Moxifloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB00218,Moxifloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB00218,Moxifloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB00218,Moxifloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB00218,Moxifloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB00218,Moxifloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB00218,Moxifloxacin
,15747753,concentrations,"Mean moxifloxacin concentrations in the every-2-hour group for aqueous (n = 9) and vitreous (n = 10) were 2.28 +/- 1.23 microg/mL and 0.11 +/- 0.05 microg/mL, respectively.",Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747753/),[μg] / [ml],2.28,39834,DB00218,Moxifloxacin
,15747753,concentrations,"Mean moxifloxacin concentrations in the every-2-hour group for aqueous (n = 9) and vitreous (n = 10) were 2.28 +/- 1.23 microg/mL and 0.11 +/- 0.05 microg/mL, respectively.",Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747753/),[μg] / [ml],0.11,39835,DB00218,Moxifloxacin
,15747753,concentrations,"Mean moxifloxacin concentrations in the every-6-hour group for aqueous (n = 10) and vitreous (n = 9) were 0.88 +/- 0.88 microg/mL and 0.06 +/- 0.06 microg/mL, respectively.",Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747753/),μ,0.88,39836,DB00218,Moxifloxacin
,15747753,concentrations,"Mean moxifloxacin concentrations in the every-6-hour group for aqueous (n = 10) and vitreous (n = 9) were 0.88 +/- 0.88 microg/mL and 0.06 +/- 0.06 microg/mL, respectively.",Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747753/),[μg] / [ml],0.06,39837,DB00218,Moxifloxacin
,15747753,aqueous concentration,Delivery of moxifloxacin via a collagen shield revealed a mean aqueous concentration of 0.30 +/- 0.17 microg/mL 4 hours after placement (n = 5).,Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747753/),[μg] / [ml],0.30,39838,DB00218,Moxifloxacin
,32499095,Cmax,"Initially, moxifloxacin was intravenously administered in doses of 60 mg/kg/2 h, 60 mg/kg/1 h and 105 mg/kg/1.75 h with an interval of >1 week (n = 3), which provided Cmax of 19.7, 25.4 and 37.8 μg/mL, and induced torsade de pointes in 1, 0 and 3 out of 3 animals, respectively.",In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32499095/),[μg] / [ml],19.7,39897,DB00218,Moxifloxacin
,32499095,Cmax,"Initially, moxifloxacin was intravenously administered in doses of 60 mg/kg/2 h, 60 mg/kg/1 h and 105 mg/kg/1.75 h with an interval of >1 week (n = 3), which provided Cmax of 19.7, 25.4 and 37.8 μg/mL, and induced torsade de pointes in 1, 0 and 3 out of 3 animals, respectively.",In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32499095/),[μg] / [ml],25.4,39898,DB00218,Moxifloxacin
,32499095,Cmax,"Initially, moxifloxacin was intravenously administered in doses of 60 mg/kg/2 h, 60 mg/kg/1 h and 105 mg/kg/1.75 h with an interval of >1 week (n = 3), which provided Cmax of 19.7, 25.4 and 37.8 μg/mL, and induced torsade de pointes in 1, 0 and 3 out of 3 animals, respectively.",In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32499095/),[μg] / [ml],37.8,39899,DB00218,Moxifloxacin
,32499095,Cmax,"Next, moxifloxacin was orally administered in doses of 10, 30 and 100 mg/kg with an interval of >1 week (n = 6), which provided Cmax of 1.8, 4.2 and 8.9 μg/mL, and induced torsade de pointes in 0, 0 and 2 out of 6 animals, respectively.",In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32499095/),[μg] / [ml],1.8,39900,DB00218,Moxifloxacin
,32499095,Cmax,"Next, moxifloxacin was orally administered in doses of 10, 30 and 100 mg/kg with an interval of >1 week (n = 6), which provided Cmax of 1.8, 4.2 and 8.9 μg/mL, and induced torsade de pointes in 0, 0 and 2 out of 6 animals, respectively.",In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32499095/),[μg] / [ml],4.2,39901,DB00218,Moxifloxacin
,32499095,Cmax,"Next, moxifloxacin was orally administered in doses of 10, 30 and 100 mg/kg with an interval of >1 week (n = 6), which provided Cmax of 1.8, 4.2 and 8.9 μg/mL, and induced torsade de pointes in 0, 0 and 2 out of 6 animals, respectively.",In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32499095/),[μg] / [ml],8.9,39902,DB00218,Moxifloxacin
,17242152,Postantibiotic effects (PAEs),"Postantibiotic effects (PAEs) of 2.0 and 1.7 h for methicillin-susceptible S. aureus and MRSA strains, respectively, were observed, and these were similar to those seen with moxifloxacin at 10x MIC.",In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17242152/),h,2.0,40835,DB00218,Moxifloxacin
,17242152,Postantibiotic effects (PAEs),"Postantibiotic effects (PAEs) of 2.0 and 1.7 h for methicillin-susceptible S. aureus and MRSA strains, respectively, were observed, and these were similar to those seen with moxifloxacin at 10x MIC.",In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17242152/),h,1.7,40836,DB00218,Moxifloxacin
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,1.4,41849,DB00218,Moxifloxacin
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,4.0,41850,DB00218,Moxifloxacin
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,2.5,41851,DB00218,Moxifloxacin
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,1300,41852,DB00218,Moxifloxacin
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,1800,41853,DB00218,Moxifloxacin
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,"12,200",41854,DB00218,Moxifloxacin
,17689270,CE10ms,"For cisapride, the CE10ms values were 8.0 and 4.4 nM in the conscious telemetered and conscious paced dog models.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,8.0,41855,DB00218,Moxifloxacin
,17689270,CE10ms,"For cisapride, the CE10ms values were 8.0 and 4.4 nM in the conscious telemetered and conscious paced dog models.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,4.4,41856,DB00218,Moxifloxacin
,20426751,flow rate,"The chromatographic separation was achieved on a Zorbax Eclipse XDB-C18 column (150 mm x 4.6 mm i.d.) connected to a Phenomenex C(18) column (4 mm x 3.0 mm i.d.) using a mixture of acetonitrile: 15 mM citrate buffer (pH 3) (23:77, v/v) as the mobile phase with isocratic system at a flow rate of 1 mL/min.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[ml] / [min],1,42476,DB00218,Moxifloxacin
,20426751,recovery,"The results of the validation parameters were: linearity range, 3-6000 ng/mL (R(2) = 0.9994); mean recovery, 100.48 %; limit of quantification, 5 ng/mL; limit of detection, 1 ng/mL; and intra- and inter-day precision less than 3.2% and 5.1%, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),%,100.48,42477,DB00218,Moxifloxacin
,20426751,limit of detection,"The results of the validation parameters were: linearity range, 3-6000 ng/mL (R(2) = 0.9994); mean recovery, 100.48 %; limit of quantification, 5 ng/mL; limit of detection, 1 ng/mL; and intra- and inter-day precision less than 3.2% and 5.1%, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[ng] / [ml],1,42478,DB00218,Moxifloxacin
,20426751,Peak serum concentrations,"Peak serum concentrations of non-pregnant and caesarean-sectioned women at the arterial port after the infusion were 4.95 +/- 1.50 and 1.56 +/- 0.16 microg/mL, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[μg] / [ml],4.95,42479,DB00218,Moxifloxacin
,20426751,Peak serum concentrations,"Peak serum concentrations of non-pregnant and caesarean-sectioned women at the arterial port after the infusion were 4.95 +/- 1.50 and 1.56 +/- 0.16 microg/mL, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[μg] / [ml],1.56,42480,DB00218,Moxifloxacin
,20426751,elimination half-life,"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),h,5.54,42481,DB00218,Moxifloxacin
,20426751,volume of distribution,"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),l,215.85,42482,DB00218,Moxifloxacin
,20426751,area under the concentration-time curve (AUC)(0-infinity),"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[h·μg] / [ml],49.95,42483,DB00218,Moxifloxacin
,20426751,area under the concentration-time curve (AUC)(0-infinity),"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[h·μg] / [ml],10.53,42484,DB00218,Moxifloxacin
,11389113,Maximum kills,Maximum kills ranged from 5 to >6 logs.,"Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389113/),logs,5 to >6,42722,DB00218,Moxifloxacin
,11352439,area under the plasma concentration-time curve from zero to infinity [AUCinfinity,"There was no difference in the area under the plasma concentration-time curve from zero to infinity [AUCinfinity; geometric mean (SD)] of moxifloxacin [32.2 (1.24) vs 33.0 (1.26) mg/L x h, with vs without Ca2+].",Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352439/),[mg] / [h·l],32.2,43644,DB00218,Moxifloxacin
,11352439,area under the plasma concentration-time curve from zero to infinity [AUCinfinity,"There was no difference in the area under the plasma concentration-time curve from zero to infinity [AUCinfinity; geometric mean (SD)] of moxifloxacin [32.2 (1.24) vs 33.0 (1.26) mg/L x h, with vs without Ca2+].",Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352439/),[mg] / [h·l],33.0,43645,DB00218,Moxifloxacin
,11352439,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) [2.29 (1.27) vs 2.71 (1.33) mg/L, with vs without Ca2+] slightly decreased by approximately 16% and the time to Cmax [median (range)] tended to be slightly prolonged [2.5 (0.8 to 3) vs 0.9 (0.5 to 2.5) hours, with vs without Ca2+].",Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352439/),[mg] / [l],2.29,43646,DB00218,Moxifloxacin
,11352439,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) [2.29 (1.27) vs 2.71 (1.33) mg/L, with vs without Ca2+] slightly decreased by approximately 16% and the time to Cmax [median (range)] tended to be slightly prolonged [2.5 (0.8 to 3) vs 0.9 (0.5 to 2.5) hours, with vs without Ca2+].",Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352439/),[mg] / [l],2.71,43647,DB00218,Moxifloxacin
,11352439,time to Cmax,"Maximum plasma concentration (Cmax) [2.29 (1.27) vs 2.71 (1.33) mg/L, with vs without Ca2+] slightly decreased by approximately 16% and the time to Cmax [median (range)] tended to be slightly prolonged [2.5 (0.8 to 3) vs 0.9 (0.5 to 2.5) hours, with vs without Ca2+].",Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352439/),h,2.5,43648,DB00218,Moxifloxacin
,11352439,time to Cmax,"Maximum plasma concentration (Cmax) [2.29 (1.27) vs 2.71 (1.33) mg/L, with vs without Ca2+] slightly decreased by approximately 16% and the time to Cmax [median (range)] tended to be slightly prolonged [2.5 (0.8 to 3) vs 0.9 (0.5 to 2.5) hours, with vs without Ca2+].",Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352439/),h,0.9,43649,DB00218,Moxifloxacin
,16122283,AUC(infinity),"The AUC(infinity) was slightly, but not statistically significantly, decreased in treatments with regimens B and C. AUC(infinity) (geometric means 39.6 [regimen A] vs 36.1 [regimen B] vs 36.1 mg.h/L [regimen C] and point estimates 91% for B : A and C : A) indicated bioequivalence of the treatments.",Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),[h·mg] / [l],39.6,43780,DB00218,Moxifloxacin
,16122283,AUC(infinity),"The AUC(infinity) was slightly, but not statistically significantly, decreased in treatments with regimens B and C. AUC(infinity) (geometric means 39.6 [regimen A] vs 36.1 [regimen B] vs 36.1 mg.h/L [regimen C] and point estimates 91% for B : A and C : A) indicated bioequivalence of the treatments.",Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),[h·mg] / [l],36.1,43781,DB00218,Moxifloxacin
,16122283,C(max),"Likewise C(max) after moxifloxacin administration through nasogastric tube with water (regimen B) and with tube feed (regimen C) were slightly decreased (geometric means 3.20 [regimen A] vs 3.05 [regimen B] vs 2.83 mg/L [regimen C]; point estimates 88% for B : A, and 95% for C : A).",Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),[mg] / [l],3.20,43782,DB00218,Moxifloxacin
,16122283,C(max),"Likewise C(max) after moxifloxacin administration through nasogastric tube with water (regimen B) and with tube feed (regimen C) were slightly decreased (geometric means 3.20 [regimen A] vs 3.05 [regimen B] vs 2.83 mg/L [regimen C]; point estimates 88% for B : A, and 95% for C : A).",Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),[mg] / [l],3.05,43783,DB00218,Moxifloxacin
,16122283,C(max),"Likewise C(max) after moxifloxacin administration through nasogastric tube with water (regimen B) and with tube feed (regimen C) were slightly decreased (geometric means 3.20 [regimen A] vs 3.05 [regimen B] vs 2.83 mg/L [regimen C]; point estimates 88% for B : A, and 95% for C : A).",Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),[mg] / [l],2.83,43784,DB00218,Moxifloxacin
,16122283,time to reach C(max) (t(max),No statistically significant differences were observed in time to reach C(max) (t(max); median 1.75 [regimen A] vs 1.00 [regimen B] vs 1.75 hours [regimen C]).,Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),h,1.75,43785,DB00218,Moxifloxacin
,16122283,time to reach C(max) (t(max),No statistically significant differences were observed in time to reach C(max) (t(max); median 1.75 [regimen A] vs 1.00 [regimen B] vs 1.75 hours [regimen C]).,Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122283/),h,1.00,43786,DB00218,Moxifloxacin
,30803965,plasma AUC/MIC ratio,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,46 to 86,45480,DB00218,Moxifloxacin
,30803965,plasma AUC/MIC ratio,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,74 to 258,45481,DB00218,Moxifloxacin
,30803965,area under the concentration-time curve over 24 h in the steady state divided by the MIC,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,46 to 86,45482,DB00218,Moxifloxacin
,30803965,area under the concentration-time curve over 24 h in the steady state divided by the MIC,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,74 to 258,45483,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.2,47024,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],1.0,47025,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],100,47026,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],5.0,47027,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],50,47028,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.0312,47029,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.125,47030,DB00218,Moxifloxacin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.0625,47031,DB00218,Moxifloxacin
,17900948,distribution half-life (t(1/2alpha)),"Following IV administration, the distribution half-life (t(1/2alpha)) was 0.22+/-0.02 h.",Disposition kinetics of moxifloxacin in lactating ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),h,0.22,47636,DB00218,Moxifloxacin
,17900948,elimination half-life,The elimination half-life was 1.77+/-0.23 h.,Disposition kinetics of moxifloxacin in lactating ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),h,1.77,47637,DB00218,Moxifloxacin
,17900948,volume of distribution at steady state (V(dss)),"The volume of distribution at steady state (V(dss)) was 0.84+/-0.12L/kg, the total body clearance (Cl(tot)) was 0.34+/-0.04 L/h/kg and the area under the curve (AUC) was 14.74+/-2.16 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[l] / [kg],0.84,47638,DB00218,Moxifloxacin
,17900948,total body clearance (Cl(tot)),"The volume of distribution at steady state (V(dss)) was 0.84+/-0.12L/kg, the total body clearance (Cl(tot)) was 0.34+/-0.04 L/h/kg and the area under the curve (AUC) was 14.74+/-2.16 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[l] / [h·kg],0.34,47639,DB00218,Moxifloxacin
,17900948,area under the curve (AUC),"The volume of distribution at steady state (V(dss)) was 0.84+/-0.12L/kg, the total body clearance (Cl(tot)) was 0.34+/-0.04 L/h/kg and the area under the curve (AUC) was 14.74+/-2.16 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[h·μg] / [ml],14.74,47640,DB00218,Moxifloxacin
,17900948,T(max),"Following IM administration, the mean T(max), C(max), t(1/2el) and AUC values for plasma data were 1.45+/-0.02 h, 2.21+/-0.27 microg/mL, 2.68+/-0.19 h and 14.21+/-2.35 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),h,1.45,47641,DB00218,Moxifloxacin
,17900948,C(max),"Following IM administration, the mean T(max), C(max), t(1/2el) and AUC values for plasma data were 1.45+/-0.02 h, 2.21+/-0.27 microg/mL, 2.68+/-0.19 h and 14.21+/-2.35 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[μg] / [ml],2.21,47642,DB00218,Moxifloxacin
,17900948,C(max),"Following IM administration, the mean T(max), C(max), t(1/2el) and AUC values for plasma data were 1.45+/-0.02 h, 2.21+/-0.27 microg/mL, 2.68+/-0.19 h and 14.21+/-2.35 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),h,2.68,47643,DB00218,Moxifloxacin
,17900948,t(1/2el),"Following IM administration, the mean T(max), C(max), t(1/2el) and AUC values for plasma data were 1.45+/-0.02 h, 2.21+/-0.27 microg/mL, 2.68+/-0.19 h and 14.21+/-2.35 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[μg] / [ml],2.21,47644,DB00218,Moxifloxacin
,17900948,t(1/2el),"Following IM administration, the mean T(max), C(max), t(1/2el) and AUC values for plasma data were 1.45+/-0.02 h, 2.21+/-0.27 microg/mL, 2.68+/-0.19 h and 14.21+/-2.35 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),h,2.68,47645,DB00218,Moxifloxacin
,17900948,AUC,"Following IM administration, the mean T(max), C(max), t(1/2el) and AUC values for plasma data were 1.45+/-0.02 h, 2.21+/-0.27 microg/mL, 2.68+/-0.19 h and 14.21+/-2.35 microg h/mL.",Disposition kinetics of moxifloxacin in lactating ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[h·μg] / [ml],14.21,47646,DB00218,Moxifloxacin
,17900948,bioavailability,The IM bioavailability was 96.35+/-17.23% and the in vitro protein binding of moxifloxacin ranged from 32-37%.,Disposition kinetics of moxifloxacin in lactating ewes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),%,96.35,47647,DB00218,Moxifloxacin
,17900948,protein binding,The IM bioavailability was 96.35+/-17.23% and the in vitro protein binding of moxifloxacin ranged from 32-37%.,Disposition kinetics of moxifloxacin in lactating ewes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),%,32-37,47648,DB00218,Moxifloxacin
,17900948,minimum inhibitory concentration (MIC),The in vitro minimum inhibitory concentration (MIC) of moxifloxacin for Mannheimia haemolytica was found to be 0.035 microg/mL.,Disposition kinetics of moxifloxacin in lactating ewes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17900948/),[μg] / [ml],0.035,47649,DB00218,Moxifloxacin
,26445139,Cmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445139/),[ng] / [ml],177,49888,DB00218,Moxifloxacin
,26445139,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445139/),min,2,49889,DB00218,Moxifloxacin
,26445139,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445139/),h,2.03,49890,DB00218,Moxifloxacin
,11181363,area under the concentration-time curve (AUC)/MIC ratios,Moxifloxacin regimens produced a range of area under the concentration-time curve (AUC)/MIC ratios ranging from 9.2 to 444 and peak/MIC ratios ranging from 1.3 to 102.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,9.2 to 444,50392,DB00218,Moxifloxacin
,11181363,peak/MIC ratios,Moxifloxacin regimens produced a range of area under the concentration-time curve (AUC)/MIC ratios ranging from 9.2 to 444 and peak/MIC ratios ranging from 1.3 to 102.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,1.3 to 102,50393,DB00218,Moxifloxacin
,11181363,AUC/MIC ratios,Levofloxacin doses produced AUC/MIC ratios of 5.1 to 85.5 and peak/MIC ratio of 0.9 to 14.8.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,5.1 to 85.5,50394,DB00218,Moxifloxacin
,11181363,peak/MIC ratio,Levofloxacin doses produced AUC/MIC ratios of 5.1 to 85.5 and peak/MIC ratio of 0.9 to 14.8.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,0.9 to 14.8,50395,DB00218,Moxifloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,12,50495,DB00218,Moxifloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,7,50496,DB00218,Moxifloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,6.8,50497,DB00218,Moxifloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,4,50498,DB00218,Moxifloxacin
,12709329,ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC,"The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC varied from 13 to 244 h, and the starting inoculum was 10(8) CFU/ml (6 x 10(9) CFU per 60-ml central compartment).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,13 to 244,50499,DB00218,Moxifloxacin
,12709329,ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC,"The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC varied from 13 to 244 h, and the starting inoculum was 10(8) CFU/ml (6 x 10(9) CFU per 60-ml central compartment).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),,6,50500,DB00218,Moxifloxacin
,12709329,AUC(24)/MIC,"With all four quinolones, the greatest increases in MIC were observed at those AUC(24)/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,24,50501,DB00218,Moxifloxacin
,12709329,AUC(24)/MIC,"With all four quinolones, the greatest increases in MIC were observed at those AUC(24)/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,62,50502,DB00218,Moxifloxacin
,12709329,AUC(24)/MIC,"Less-pronounced increases in MIC were associated with the smallest simulated AUC(24)/MIC values (15 to 16 h) of GAT and CIP, whose C(max) exceeded the MICs.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,15 to 16,50503,DB00218,Moxifloxacin
,12709329,AUC(24)/MIC,"No such increases were observed with the smallest AUC(24)/MIC values (13 to 17 h) of MOX and LEV, whose C(max) were close to the MICs.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,13 to 17,50504,DB00218,Moxifloxacin
,12709329,AUC(24)/MIC,"Also, less pronounced but significant increases in MIC occurred at AUC(24)/MIC values (107 to 123 h) that correspond to quinolone concentrations partly overlapping the MIC-to-MPC range.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,107 to 123,50505,DB00218,Moxifloxacin
,12709329,AUC(24)/MIC,"With all four drugs, no change in MIC was seen at the highest AUC(24)/MIC values (201 to 244 h), where quinolone concentrations exceeded the MPC over most of the dosing interval.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,201 to 244,50506,DB00218,Moxifloxacin
,16956903,concentrations,"Mean moxifloxacin concentrations in pancreatic tissue following iv or oral administration were 3.1+/-0.9 and 2.7+/-1.4 mg/kg at 3-3.7 h post-dose (first sampling) and 3.6+/-1.5 and 3.1+/-1.8 mg/kg at 4.3-5.3 h post-dose (second sampling), respectively.",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),,3.1,50819,DB00218,Moxifloxacin
,16956903,concentrations,"Mean moxifloxacin concentrations in pancreatic tissue following iv or oral administration were 3.1+/-0.9 and 2.7+/-1.4 mg/kg at 3-3.7 h post-dose (first sampling) and 3.6+/-1.5 and 3.1+/-1.8 mg/kg at 4.3-5.3 h post-dose (second sampling), respectively.",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),,2.7,50820,DB00218,Moxifloxacin
,16956903,plasma concentrations,"Corresponding mean plasma concentrations of moxifloxacin were 1.8+/-0.5 and 1.2+/-0.6 mg/L (first sampling) and 1.5+/-0.4 and 1.0+/-0.5 mg/L (second sampling), respectively.",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),[mg] / [l],1.8,50821,DB00218,Moxifloxacin
,16956903,plasma concentrations,"Corresponding mean plasma concentrations of moxifloxacin were 1.8+/-0.5 and 1.2+/-0.6 mg/L (first sampling) and 1.5+/-0.4 and 1.0+/-0.5 mg/L (second sampling), respectively.",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),[mg] / [l],1.2,50822,DB00218,Moxifloxacin
,16956903,plasma concentrations,"Corresponding mean plasma concentrations of moxifloxacin were 1.8+/-0.5 and 1.2+/-0.6 mg/L (first sampling) and 1.5+/-0.4 and 1.0+/-0.5 mg/L (second sampling), respectively.",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),[mg] / [l],1.5,50823,DB00218,Moxifloxacin
,16956903,plasma concentrations,"Corresponding mean plasma concentrations of moxifloxacin were 1.8+/-0.5 and 1.2+/-0.6 mg/L (first sampling) and 1.5+/-0.4 and 1.0+/-0.5 mg/L (second sampling), respectively.",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),[mg] / [l],1.0,50824,DB00218,Moxifloxacin
,16956903,tissue-to-plasma ratios,"From first to second sampling, the mean tissue-to-plasma ratios varied from 1.8+/-0.6 to 2.6+/-1.2 (iv) and from 2.4+/-0.8 to 3.1+/-1.2 (oral).",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),,1.8,50825,DB00218,Moxifloxacin
,16956903,tissue-to-plasma ratios,"From first to second sampling, the mean tissue-to-plasma ratios varied from 1.8+/-0.6 to 2.6+/-1.2 (iv) and from 2.4+/-0.8 to 3.1+/-1.2 (oral).",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),,2.6,50826,DB00218,Moxifloxacin
,16956903,tissue-to-plasma ratios,"From first to second sampling, the mean tissue-to-plasma ratios varied from 1.8+/-0.6 to 2.6+/-1.2 (iv) and from 2.4+/-0.8 to 3.1+/-1.2 (oral).",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),,2.4,50827,DB00218,Moxifloxacin
,16956903,tissue-to-plasma ratios,"From first to second sampling, the mean tissue-to-plasma ratios varied from 1.8+/-0.6 to 2.6+/-1.2 (iv) and from 2.4+/-0.8 to 3.1+/-1.2 (oral).",Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16956903/),,3.1,50828,DB00218,Moxifloxacin
,21093388,total time,The total time was within 10 min per run.,High performance liquid chromatography assay with ultraviolet detection for moxifloxacin: validation and application to a pharmacokinetic study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21093388/),[min] / [run],10,51060,DB00218,Moxifloxacin
,29358297,intracellular persisting fraction,"After 24 h of incubation of infected cells with antibiotics at 100× their MIC, the intracellular persisting fraction was <0.1% with moxifloxacin, 0.5% with gepotidacin, and >1% with the other drugs.",Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358297/),,0,51769,DB00218,Moxifloxacin
,29358297,kin,"The accumulation and efflux of gepotidacin in phagocytes were very fast (kin and kout, ∼0.3 min-1; the plateau was reached within 15 min) but modest (intracellular concentration-to-extracellular concentration ratio, ∼1.6).",Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358297/),1/[min],∼0.3,51770,DB00218,Moxifloxacin
,29358297,intracellular concentration-to-extracellular concentration ratio,"The accumulation and efflux of gepotidacin in phagocytes were very fast (kin and kout, ∼0.3 min-1; the plateau was reached within 15 min) but modest (intracellular concentration-to-extracellular concentration ratio, ∼1.6).",Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358297/),,∼1.6,51771,DB00218,Moxifloxacin
,17034992,Mean plasma concentrations,Mean plasma concentrations were 3.36 microg/mL and 2.93 microg/mL at 2h and 5h after the end of infusion.,Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034992/),[μg] / [ml],3.36,53688,DB00218,Moxifloxacin
,17034992,Mean plasma concentrations,Mean plasma concentrations were 3.36 microg/mL and 2.93 microg/mL at 2h and 5h after the end of infusion.,Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034992/),[μg] / [ml],2.93,53689,DB00218,Moxifloxacin
,21228407,oral clearance,"Mean (95% confidence interval) values for oral clearance, apparent volume of distribution, the first-order absorption rate constant, and mean transit time were 11.7 (11.5-11.9) L/h, 147 (144-150) L, 1.9 (1.7-2.1) 1/h, and 0.3 (0.28-0.34) hours, respectively.",Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21228407/),[l] / [h],11.7,54605,DB00218,Moxifloxacin
,21228407,apparent volume of distribution,"Mean (95% confidence interval) values for oral clearance, apparent volume of distribution, the first-order absorption rate constant, and mean transit time were 11.7 (11.5-11.9) L/h, 147 (144-150) L, 1.9 (1.7-2.1) 1/h, and 0.3 (0.28-0.34) hours, respectively.",Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21228407/),l,147,54606,DB00218,Moxifloxacin
,21228407,mean transit time,"Mean (95% confidence interval) values for oral clearance, apparent volume of distribution, the first-order absorption rate constant, and mean transit time were 11.7 (11.5-11.9) L/h, 147 (144-150) L, 1.9 (1.7-2.1) 1/h, and 0.3 (0.28-0.34) hours, respectively.",Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21228407/),h,0.3,54607,DB00218,Moxifloxacin
,9661008,MICs,"In an experimental meningitis model, we studied the pharmacokinetics of moxifloxacin in infected and uninfected rabbits and evaluated the antibiotic efficacies of moxifloxacin, ceftriaxone, and vancomycin against a penicillin-resistant Streptococcus pneumoniae strain (penicillin, ceftriaxone, vancomycin, and moxifloxacin MICs were 1, 0.5, 0.5, and 0.125 microgram/ml, respectively).","Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661008/),[μg] / [ml],1,54884,DB00218,Moxifloxacin
,9661008,MICs,"In an experimental meningitis model, we studied the pharmacokinetics of moxifloxacin in infected and uninfected rabbits and evaluated the antibiotic efficacies of moxifloxacin, ceftriaxone, and vancomycin against a penicillin-resistant Streptococcus pneumoniae strain (penicillin, ceftriaxone, vancomycin, and moxifloxacin MICs were 1, 0.5, 0.5, and 0.125 microgram/ml, respectively).","Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661008/),[μg] / [ml],0.5,54885,DB00218,Moxifloxacin
,9661008,MICs,"In an experimental meningitis model, we studied the pharmacokinetics of moxifloxacin in infected and uninfected rabbits and evaluated the antibiotic efficacies of moxifloxacin, ceftriaxone, and vancomycin against a penicillin-resistant Streptococcus pneumoniae strain (penicillin, ceftriaxone, vancomycin, and moxifloxacin MICs were 1, 0.5, 0.5, and 0.125 microgram/ml, respectively).","Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661008/),[μg] / [ml],0.125,54886,DB00218,Moxifloxacin
,9661008,percent penetration,"Moxifloxacin entered cerebrospinal fluid (CSF) readily, with peak values within 15 to 30 min after bolus intravenous infusion and with a mean percent penetration into normal and purulent CSF of approximately 50 and 80%, respectively.","Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661008/),%,50,54887,DB00218,Moxifloxacin
,9661008,percent penetration,"Moxifloxacin entered cerebrospinal fluid (CSF) readily, with peak values within 15 to 30 min after bolus intravenous infusion and with a mean percent penetration into normal and purulent CSF of approximately 50 and 80%, respectively.","Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661008/),%,80,54888,DB00218,Moxifloxacin
,19776053,maximum plasma moxifloxacin concentration,Median maximum plasma moxifloxacin concentration was 5.86 mg/L at a median time of 1.25 hours.,Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),[mg] / [l],5.86,55545,DB00218,Moxifloxacin
,19776053,time,Median maximum plasma moxifloxacin concentration was 5.86 mg/L at a median time of 1.25 hours.,Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),h,1.25,55546,DB00218,Moxifloxacin
,19776053,area under the concentration-time curve (AUC(0-->inf)),"In serum, median area under the concentration-time curve (AUC(0-->inf)) was 157.95 +/- 100.34 mg.",Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),mg,157.95,55547,DB00218,Moxifloxacin
,19776053,t(1/2),"hour/L, median t(1/2) 25.00 hours, median clearance 2.54 L/hour, and median distribution volume 94.90 L.",Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),h,25.00,55548,DB00218,Moxifloxacin
,19776053,clearance,"hour/L, median t(1/2) 25.00 hours, median clearance 2.54 L/hour, and median distribution volume 94.90 L.",Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),[l] / [h],2.54,55549,DB00218,Moxifloxacin
,19776053,distribution volume,"hour/L, median t(1/2) 25.00 hours, median clearance 2.54 L/hour, and median distribution volume 94.90 L.",Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),l,94.90,55550,DB00218,Moxifloxacin
,19776053,peritoneal fluid-to-plasma ratio,"Median peritoneal fluid-to-plasma ratio of moxifloxacin ranged between 0.84 and 1.00, denoting adequate penetration and lack of considerable moxifloxacin removal during CAPD.",Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19776053/),,0.84 and 1.00,55551,DB00218,Moxifloxacin
,25645830,kill rate,"We indexed the efficacy of the standard combination regimen, which was a kill rate of -0.08 ± 0.05 log10 CFU/ml/day (r(2) = 0.99).",Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[cfu] / [d·ml],-,56447,DB00218,Moxifloxacin
,25645830,kill rate,"We indexed the efficacy of the standard combination regimen, which was a kill rate of -0.08 ± 0.05 log10 CFU/ml/day (r(2) = 0.99).",Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[cfu] / [d·ml],0.08,56448,DB00218,Moxifloxacin
,25645830,half-life,We next performed moxifloxacin dose-effect and dose-scheduling studies at a half-life of 11.1 ± 6.47 h.,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),h,11.1,56449,DB00218,Moxifloxacin
,25645830,AUC0-24/MIC,The moxifloxacin exposure associated with 80% of maximal kill (EC80) was an AUC0-24/MIC of 317 (the non-protein-bound moxifloxacin AUC0-24/MIC was 158.5).,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),,317,56450,DB00218,Moxifloxacin
,25645830,AUC0-24/MIC,The moxifloxacin exposure associated with 80% of maximal kill (EC80) was an AUC0-24/MIC of 317 (the non-protein-bound moxifloxacin AUC0-24/MIC was 158.5).,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),,158.5,56451,DB00218,Moxifloxacin
,25645830,MIC susceptibility breakpoint,The MIC susceptibility breakpoint at this dose was 0.25 mg/liter.,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[mg] / [l],0.25,56452,DB00218,Moxifloxacin
,21544017,minimum inhibitory concentration,Median minimum inhibitory concentration of Mycobacterium tuberculosis isolates was 0.25 mg/L (interquartile range: 0.25-0.5 mg/L).,Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),[mg] / [l],0.25,58458,DB00218,Moxifloxacin
,21544017,AUC0-24h,"The geometric mean AUC0-24h was 24.5 mg·h/L (range: 8.5-72.2 mg·h/L), which resulted in a geometric mean AUC0-24h/minimum inhibitory concentration ratio of 72 (range: 21-321).",Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),[h·mg] / [l],24.5,58459,DB00218,Moxifloxacin
,21544017,AUC0-24h/minimum inhibitory concentration ratio,"The geometric mean AUC0-24h was 24.5 mg·h/L (range: 8.5-72.2 mg·h/L), which resulted in a geometric mean AUC0-24h/minimum inhibitory concentration ratio of 72 (range: 21-321).",Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),,72,58460,DB00218,Moxifloxacin
,21544017,apparent clearance (Cl),"PK analysis, based on PK profiles of 400 mg of MFX once daily, resulted in a crossvalidated population PK model with the following parameters: apparent clearance (Cl) 18.5±8.6 L/h per 1.85 m, Vd 3.0±0.7 L/kg corrected lean body mass, Ka 1.15±1.16 h, and F was fixed at 1.",Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),[l] / [1.85·h·m],18.5,58461,DB00218,Moxifloxacin
,21544017,Vd,"PK analysis, based on PK profiles of 400 mg of MFX once daily, resulted in a crossvalidated population PK model with the following parameters: apparent clearance (Cl) 18.5±8.6 L/h per 1.85 m, Vd 3.0±0.7 L/kg corrected lean body mass, Ka 1.15±1.16 h, and F was fixed at 1.",Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),[l] / [kg],3.0,58462,DB00218,Moxifloxacin
,21544017,Ka,"PK analysis, based on PK profiles of 400 mg of MFX once daily, resulted in a crossvalidated population PK model with the following parameters: apparent clearance (Cl) 18.5±8.6 L/h per 1.85 m, Vd 3.0±0.7 L/kg corrected lean body mass, Ka 1.15±1.16 h, and F was fixed at 1.",Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),h,1.15,58463,DB00218,Moxifloxacin
,21544017,F,"PK analysis, based on PK profiles of 400 mg of MFX once daily, resulted in a crossvalidated population PK model with the following parameters: apparent clearance (Cl) 18.5±8.6 L/h per 1.85 m, Vd 3.0±0.7 L/kg corrected lean body mass, Ka 1.15±1.16 h, and F was fixed at 1.",Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544017/),,1,58464,DB00218,Moxifloxacin
,34286843,Apparent clearance,Apparent clearance was 6.95 L/h for a typical 16 kg child.,"Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286843/),[l] / [h],6.95,58772,DB00218,Moxifloxacin
,34286843,maximum change,The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms.,"Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286843/),ms,16.3,58773,DB00218,Moxifloxacin
,34286843,maximum drug effect (Emax),"The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (inter-individual variability = 9.75 ms).","Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286843/),ms,8.80,58774,DB00218,Moxifloxacin
,11352438,AUCinfinity,"The geometric mean AUCinfinity values under fed and fasted conditions were almost identical, 37.7 versus 38.5 mg/L x h, respectively [90% confidence interval (CI) of the ratio of fed versus fasted based on geometric least-square means was 0.95, 1.00].",Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352438/),[mg] / [h·l],37.7,59035,DB00218,Moxifloxacin
,11352438,AUCinfinity,"The geometric mean AUCinfinity values under fed and fasted conditions were almost identical, 37.7 versus 38.5 mg/L x h, respectively [90% confidence interval (CI) of the ratio of fed versus fasted based on geometric least-square means was 0.95, 1.00].",Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352438/),[mg] / [h·l],38.5,59036,DB00218,Moxifloxacin
,11352438,Cmax,"Geometric mean Cmax values were slightly reduced by food, 2.5 versus 2.8 mg/L, respectively (90% CI of fed versus fasted based on geometric least-square means was 0.78, 0.98).",Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352438/),[mg] / [l],2.5,59037,DB00218,Moxifloxacin
,11352438,Cmax,"Geometric mean Cmax values were slightly reduced by food, 2.5 versus 2.8 mg/L, respectively (90% CI of fed versus fasted based on geometric least-square means was 0.78, 0.98).",Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352438/),[mg] / [l],2.8,59038,DB00218,Moxifloxacin
,11352438,tmax,"The absorption of moxifloxacin seems to be mildly delayed because of the effect of food; the median tmax values were 1.0 and 2.5 hours for fasted and fed conditions, respectively.",Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352438/),h,1.0,59039,DB00218,Moxifloxacin
,11352438,tmax,"The absorption of moxifloxacin seems to be mildly delayed because of the effect of food; the median tmax values were 1.0 and 2.5 hours for fasted and fed conditions, respectively.",Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352438/),h,2.5,59040,DB00218,Moxifloxacin
,10837433,peak serum concentration,"Over a 120 min period following a single parenteral administration of moxifloxacin 15 mg/kg, peak serum concentration was 3.1 (+/- 1.1) mg/L.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),[mg] / [l],3.1,60306,DB00218,Moxifloxacin
,10837433,elimination constants,"The elimination constants were: 0.019 (+/- 0. 017) microg/cm(2)/min, 0.011 (+/- 0.014) microg/cm(2)/min and 0.002 (+/- 0.002) microg/cm(2)/min in the jejunum, ileum and caecum, respectively.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),[μg] / [cm(2)·min],0.019,60307,DB00218,Moxifloxacin
,10837433,elimination constants,"The elimination constants were: 0.019 (+/- 0. 017) microg/cm(2)/min, 0.011 (+/- 0.014) microg/cm(2)/min and 0.002 (+/- 0.002) microg/cm(2)/min in the jejunum, ileum and caecum, respectively.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),[μg] / [cm(2)·min],0.011,60308,DB00218,Moxifloxacin
,10837433,elimination constants,"The elimination constants were: 0.019 (+/- 0. 017) microg/cm(2)/min, 0.011 (+/- 0.014) microg/cm(2)/min and 0.002 (+/- 0.002) microg/cm(2)/min in the jejunum, ileum and caecum, respectively.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),[μg] / [cm(2)·min],0.002,60309,DB00218,Moxifloxacin
,10837433,eliminated quantities,"Per loop, over 120 min, the respective eliminated quantities were: 9.59 (+/- 9.37) microg, 8.26 (+/- 6.74) microg and 1.92 (+/- 1.86) microg.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),μg,9.59,60310,DB00218,Moxifloxacin
,10837433,eliminated quantities,"Per loop, over 120 min, the respective eliminated quantities were: 9.59 (+/- 9.37) microg, 8.26 (+/- 6.74) microg and 1.92 (+/- 1.86) microg.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),μg,8.26,60311,DB00218,Moxifloxacin
,10837433,eliminated quantities,"Per loop, over 120 min, the respective eliminated quantities were: 9.59 (+/- 9.37) microg, 8.26 (+/- 6.74) microg and 1.92 (+/- 1.86) microg.",Trans-epithelial intestinal elimination of moxifloxacin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10837433/),μg,1.92,60312,DB00218,Moxifloxacin
,18070980,maximum plasma concentrations,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),[μg] / [ml],15.55,62438,DB00218,Moxifloxacin
,18070980,maximum plasma concentrations,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),[μg] / [ml],4.75,62439,DB00218,Moxifloxacin
,18070980,maximum plasma concentrations,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),[μg] / [ml],6.13,62440,DB00218,Moxifloxacin
,18070980,volume of distribution,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),l,81,62441,DB00218,Moxifloxacin
,18070980,volume of distribution,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),l,79,62442,DB00218,Moxifloxacin
,18070980,volume of distribution,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),l,63,62443,DB00218,Moxifloxacin
,18070980,elimination half-life,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),h,7.4,62444,DB00218,Moxifloxacin
,18070980,elimination half-life,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),h,5.0,62445,DB00218,Moxifloxacin
,18070980,elimination half-life,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),h,6.5,62446,DB00218,Moxifloxacin
,24242903,ΔΔQTcI,"Mean ΔΔQTcI was 13.2 milliseconds (90% CI: 11.4, 15.0) and 16.1 milliseconds (90% CI: 14.3, 17.9) for the 600 and 1,950 µg bid doses, respectively.","Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242903/),,13.2,62779,DB00218,Moxifloxacin
,24242903,ΔΔQTcI,"Mean ΔΔQTcI was 13.2 milliseconds (90% CI: 11.4, 15.0) and 16.1 milliseconds (90% CI: 14.3, 17.9) for the 600 and 1,950 µg bid doses, respectively.","Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242903/),,16.1,62780,DB00218,Moxifloxacin
,11600361,maximum CSF concentration (C(max)),"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),[μg] / [ml],1.8,63734,DB00218,Moxifloxacin
,11600361,maximum CSF concentration (C(max)),"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),[μg] / [ml],4.2,63735,DB00218,Moxifloxacin
,11600361,maximum CSF concentration (C(max)),"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),[μg] / [ml],4.9,63736,DB00218,Moxifloxacin
,11600361,AUC,"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),[μg] / [h·ml],13.4,63737,DB00218,Moxifloxacin
,11600361,AUC,"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),[μg] / [h·ml],25.4,63738,DB00218,Moxifloxacin
,11600361,AUC,"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),[μg] / [h·ml],27.1,63739,DB00218,Moxifloxacin
,11600361,half-life,"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),h,6.7,63740,DB00218,Moxifloxacin
,11600361,half-life,"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),h,6.6,63741,DB00218,Moxifloxacin
,11600361,half-life,"After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively.",Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600361/),h,4.7,63742,DB00218,Moxifloxacin
,22422361,ΔΔQTcF,"The maximum ΔΔQTcF values for dolutegravir and moxifloxacin were observed at 4 hours: 1.99 msec (90% CI -0.55-4.53 msec) and 9.58 msec (90% CI 7.05-12.11 msec), respectively.",Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22422361/),ms,1.99,63976,DB00218,Moxifloxacin
,22422361,ΔΔQTcF,"The maximum ΔΔQTcF values for dolutegravir and moxifloxacin were observed at 4 hours: 1.99 msec (90% CI -0.55-4.53 msec) and 9.58 msec (90% CI 7.05-12.11 msec), respectively.",Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22422361/),ms,9.58,63977,DB00218,Moxifloxacin
,31519935,CMAX,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),[ng] / [ml],"1,200",64476,DB00218,Moxifloxacin
,31519935,TMAX,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),h,2.2,64477,DB00218,Moxifloxacin
,31519935,T1/2,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),h,4.7,64478,DB00218,Moxifloxacin
,31519935,CMAX,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),[ng] / [ml],"28,900",64479,DB00218,Moxifloxacin
,31519935,T1/2,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),h,8.0,64480,DB00218,Moxifloxacin
,34331678,ΔΔQTcF,"Following daridorexant administration, mean (90% confidence interval, CI) ΔΔQTcF was 1.40 ms (0.48; 2.32 ms) and 1.84 ms (-0.12; 3.79 ms) at the Cmax of 747 ng/mL (50 mg dose) and 1809 ng/mL (200 mg dose), respectively, i.e., the upper bounds of the CIs were < 10 ms defined as threshold of regulatory concern.","Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34331678/),ms,1.40,66511,DB00218,Moxifloxacin
,34331678,ΔΔQTcF,"Following daridorexant administration, mean (90% confidence interval, CI) ΔΔQTcF was 1.40 ms (0.48; 2.32 ms) and 1.84 ms (-0.12; 3.79 ms) at the Cmax of 747 ng/mL (50 mg dose) and 1809 ng/mL (200 mg dose), respectively, i.e., the upper bounds of the CIs were < 10 ms defined as threshold of regulatory concern.","Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34331678/),ms,1.84,66512,DB00218,Moxifloxacin
,34331678,Cmax,"Following daridorexant administration, mean (90% confidence interval, CI) ΔΔQTcF was 1.40 ms (0.48; 2.32 ms) and 1.84 ms (-0.12; 3.79 ms) at the Cmax of 747 ng/mL (50 mg dose) and 1809 ng/mL (200 mg dose), respectively, i.e., the upper bounds of the CIs were < 10 ms defined as threshold of regulatory concern.","Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34331678/),[ng] / [ml],747,66513,DB00218,Moxifloxacin
,34331678,Cmax,"Following daridorexant administration, mean (90% confidence interval, CI) ΔΔQTcF was 1.40 ms (0.48; 2.32 ms) and 1.84 ms (-0.12; 3.79 ms) at the Cmax of 747 ng/mL (50 mg dose) and 1809 ng/mL (200 mg dose), respectively, i.e., the upper bounds of the CIs were < 10 ms defined as threshold of regulatory concern.","Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34331678/),[ng] / [ml],1809,66514,DB00218,Moxifloxacin
,12604546,concentration required for 50% E(max) [EC(50)],"For S. pneumoniae, the area under the bacterial kill curve up to 72 h could be related to AUC/MIC ratio using an inhibitory maximum effect (E(max)) model (concentration required for 50% E(max) [EC(50)], 45 +/- 22; r(2), 0.97).","Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604546/),,45,66619,DB00218,Moxifloxacin
,12604546,AUC/MIC ratio,"For P. aeruginosa even at the highest AUC/MIC ratio (427), bacterial clearance was insufficient for the EC(50) to be calculated.","Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604546/),,427,66620,DB00218,Moxifloxacin
,26590007,IC50,"Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50 value of 4.29 ± 1.29 mm.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),mm,4.29,66918,DB00218,Moxifloxacin
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],171,66919,DB00218,Moxifloxacin
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],244,66920,DB00218,Moxifloxacin
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],338,66921,DB00218,Moxifloxacin
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],399,66922,DB00218,Moxifloxacin
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,41.7,66923,DB00218,Moxifloxacin
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,49.2,66924,DB00218,Moxifloxacin
,18765687,half-life (t(1/2)),"For moxifloxacin, the mean area under the concentration-time curve from 0 to 24 h (AUC(0-24)) decreased by 17.2% (P = 0.0006) when the drug was coadministered with rifapentine, and the mean half-life (t(1/2)) decreased from 11.1 to 8.9 h (P = 0.0033).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,11.1,67812,DB00218,Moxifloxacin
,18765687,half-life (t(1/2)),"For moxifloxacin, the mean area under the concentration-time curve from 0 to 24 h (AUC(0-24)) decreased by 17.2% (P = 0.0006) when the drug was coadministered with rifapentine, and the mean half-life (t(1/2)) decreased from 11.1 to 8.9 h (P = 0.0033).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,8.9,67813,DB00218,Moxifloxacin
,18765687,t(1/2),"For rifapentine, the mean AUC(0-48) after seven thrice-weekly doses decreased by 20.3% (P = 0.0035) compared to the AUC(0-48) after the first dose, and the mean t(1/2) decreased from 18.5 to 14.8 h (P = 0.0004).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,18.5,67814,DB00218,Moxifloxacin
,18765687,t(1/2),"For rifapentine, the mean AUC(0-48) after seven thrice-weekly doses decreased by 20.3% (P = 0.0035) compared to the AUC(0-48) after the first dose, and the mean t(1/2) decreased from 18.5 to 14.8 h (P = 0.0004).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,14.8,67815,DB00218,Moxifloxacin
,20521033,area under the plasma concentration-time curve between time 0 and 24 h,"At Day 7, exposure for dalcetrapib 3,900 mg was approximately eightfold higher than that for dalcetrapib 600 mg [mean area under the plasma concentration-time curve between time 0 and 24 h 68,500 vs. 8,280 ng*h/mL; mean peak concentration 6,810 vs. 861 ng/mL].",Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521033/),[h·ng] / [ml],"68,500",67992,DB00218,Moxifloxacin
,20521033,area under the plasma concentration-time curve between time 0 and 24 h,"At Day 7, exposure for dalcetrapib 3,900 mg was approximately eightfold higher than that for dalcetrapib 600 mg [mean area under the plasma concentration-time curve between time 0 and 24 h 68,500 vs. 8,280 ng*h/mL; mean peak concentration 6,810 vs. 861 ng/mL].",Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521033/),[h·ng] / [ml],"8,280",67993,DB00218,Moxifloxacin
,20521033,peak concentration,"At Day 7, exposure for dalcetrapib 3,900 mg was approximately eightfold higher than that for dalcetrapib 600 mg [mean area under the plasma concentration-time curve between time 0 and 24 h 68,500 vs. 8,280 ng*h/mL; mean peak concentration 6,810 vs. 861 ng/mL].",Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521033/),[ng] / [ml],"6,810",67994,DB00218,Moxifloxacin
,20521033,peak concentration,"At Day 7, exposure for dalcetrapib 3,900 mg was approximately eightfold higher than that for dalcetrapib 600 mg [mean area under the plasma concentration-time curve between time 0 and 24 h 68,500 vs. 8,280 ng*h/mL; mean peak concentration 6,810 vs. 861 ng/mL].",Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521033/),[ng] / [ml],861,67995,DB00218,Moxifloxacin
,33109218,peak plasma concentration,"The effect of lucerastat on ΔΔQTcF was predicted as 0.39 ms (90% confidence interval [CI] - 0.13 to 0.90) and 1.69 ms (90% CI 0.33-3.05) at lucerastat peak plasma concentration after dosing with 1000 mg (5.2 µg/mL) and 4000 mg (24.3 µg/mL), respectively.",The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33109218/),[μg] / [ml],5.2,68824,DB00218,Moxifloxacin
,33109218,peak plasma concentration,"The effect of lucerastat on ΔΔQTcF was predicted as 0.39 ms (90% confidence interval [CI] - 0.13 to 0.90) and 1.69 ms (90% CI 0.33-3.05) at lucerastat peak plasma concentration after dosing with 1000 mg (5.2 µg/mL) and 4000 mg (24.3 µg/mL), respectively.",The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33109218/),[μg] / [ml],24.3,68825,DB00218,Moxifloxacin
,33109218,elimination half-life,"Across doses, absorption of lucerastat was rapid, its elimination half-life ranged from 8.0 to 10.0 h, and the pharmacokinetics (PK) of lucerastat were dose-proportional.",The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33109218/),h,8.0 to 10.0,68826,DB00218,Moxifloxacin
,20336279,C (max),"Data for 400 mg moxifloxacin i.v. were as follows (geometric mean): C (max): 3.5 mg/l, t(1/2): 7.8 h and AUC (48-72 h): 25 mg h/l.",Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20336279/),[mg] / [l],3.5,70918,DB00218,Moxifloxacin
,20336279,t(1/2),"Data for 400 mg moxifloxacin i.v. were as follows (geometric mean): C (max): 3.5 mg/l, t(1/2): 7.8 h and AUC (48-72 h): 25 mg h/l.",Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20336279/),h,7.8,70919,DB00218,Moxifloxacin
,20336279,AUC (48-72 h),"Data for 400 mg moxifloxacin i.v. were as follows (geometric mean): C (max): 3.5 mg/l, t(1/2): 7.8 h and AUC (48-72 h): 25 mg h/l.",Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20336279/),[h·mg] / [l],25,70920,DB00218,Moxifloxacin
<,20336279,AUC (48-72 h),In five individual patients AUC (48-72 h) was <20 mg h/l.,Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20336279/),[h·mg] / [l],20,70921,DB00218,Moxifloxacin
,20336279,AUC,The mean AUC of patients with severe sepsis or septic shock was lower compared to healthy volunteers (39 mg h/l).,Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20336279/),[h·mg] / [l],39,70922,DB00218,Moxifloxacin
,30396379,flow rate,"Chromatographic separation was achieved using a Shiseido C18 MGII (250×4.6mm i.d.; 5 μm) column under an isocratic mobile phase comprising of 50 mM potassium dihydrogen phosphate (pH 2.4) - acetonitrile (77:23, v/v) at a flow rate of 1.5 mL/min.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),[ml] / [min],1.5,74104,DB00218,Moxifloxacin
,30396379,total chromatographic run time,"The total chromatographic run time was 8 min with the retention times of moxifloxacin and internal standard at 6.5 and 3.0 min, respectively.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),min,8,74105,DB00218,Moxifloxacin
,30396379,retention times,"The total chromatographic run time was 8 min with the retention times of moxifloxacin and internal standard at 6.5 and 3.0 min, respectively.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),min,6.5,74106,DB00218,Moxifloxacin
,30396379,retention times,"The total chromatographic run time was 8 min with the retention times of moxifloxacin and internal standard at 6.5 and 3.0 min, respectively.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),min,3.0,74107,DB00218,Moxifloxacin
,19451404,peak DeltaDeltaQTc,"The postinfusion peak DeltaDeltaQTc values (corresponding to maximum plasma levels) were not statistically different in women (16.1 +/- 6.5 ms) and men (15.1 +/- 5.3 ms), Africans (15.3 +/- 5.3 ms) and whites (15.6 +/- 6.6 ms), and participants younger (16.5 +/- 4.8 ms) and older (14.7 +/- 6.6 ms) than the median age of 35 years.",Electrocardiographic QTc changes due to moxifloxacin infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451404/),ms,16.1,74288,DB00218,Moxifloxacin
,19451404,peak DeltaDeltaQTc,"The postinfusion peak DeltaDeltaQTc values (corresponding to maximum plasma levels) were not statistically different in women (16.1 +/- 6.5 ms) and men (15.1 +/- 5.3 ms), Africans (15.3 +/- 5.3 ms) and whites (15.6 +/- 6.6 ms), and participants younger (16.5 +/- 4.8 ms) and older (14.7 +/- 6.6 ms) than the median age of 35 years.",Electrocardiographic QTc changes due to moxifloxacin infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451404/),ms,15.1,74289,DB00218,Moxifloxacin
,19451404,peak DeltaDeltaQTc,"The postinfusion peak DeltaDeltaQTc values (corresponding to maximum plasma levels) were not statistically different in women (16.1 +/- 6.5 ms) and men (15.1 +/- 5.3 ms), Africans (15.3 +/- 5.3 ms) and whites (15.6 +/- 6.6 ms), and participants younger (16.5 +/- 4.8 ms) and older (14.7 +/- 6.6 ms) than the median age of 35 years.",Electrocardiographic QTc changes due to moxifloxacin infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451404/),ms,15.3,74290,DB00218,Moxifloxacin
,19451404,peak DeltaDeltaQTc,"The postinfusion peak DeltaDeltaQTc values (corresponding to maximum plasma levels) were not statistically different in women (16.1 +/- 6.5 ms) and men (15.1 +/- 5.3 ms), Africans (15.3 +/- 5.3 ms) and whites (15.6 +/- 6.6 ms), and participants younger (16.5 +/- 4.8 ms) and older (14.7 +/- 6.6 ms) than the median age of 35 years.",Electrocardiographic QTc changes due to moxifloxacin infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451404/),ms,15.6,74291,DB00218,Moxifloxacin
,19451404,DeltaDeltaQTc,The DeltaDeltaQTc values were different in participants with a body mass index (BMI) below (16.8 +/- 5.4 ms) and above 30 kg/m(2) (10.8 +/- 5.1 ms; P = .008).,Electrocardiographic QTc changes due to moxifloxacin infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451404/),ms,10.8,74292,DB00218,Moxifloxacin
,26169402,maximal relative efficacy (E max),"GSK1322322 demonstrated a uniform activity against the intracellular forms of all S. aureus strains tested, disregarding their resistance phenotypes, with a maximal relative efficacy (E max) of a 0.5 to 1 log10 CFU decrease compared to the original inoculum within 24 h and a static concentration (C s) close to its MIC in broth.",Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26169402/),cfu,0.5 to 1,77391,DB00218,Moxifloxacin
,14982788,MICs,"Pharmacodynamics of these drugs was investigated against three quinolone-susceptible strains of Stenotrophomonas maltophilia (MICs of ciprofloxacin and moxifloxacin of 0.5 to 2 and 0.0625 to 0.5 microg/ml, respectively).",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[μg] / [ml],0.5 to 2,79902,DB00218,Moxifloxacin
,14982788,MICs,"Pharmacodynamics of these drugs was investigated against three quinolone-susceptible strains of Stenotrophomonas maltophilia (MICs of ciprofloxacin and moxifloxacin of 0.5 to 2 and 0.0625 to 0.5 microg/ml, respectively).",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[μg] / [ml],0.0625 to 0.5,79903,DB00218,Moxifloxacin
,14982788,area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],342.3 to 401.3,79904,DB00218,Moxifloxacin
,14982788,area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],295.2 to 378.7,79905,DB00218,Moxifloxacin
,14982788,area between the control growth curve and the killing and regrowth curve from 0 to 48 h (,"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],40.4 to 101.1,79906,DB00218,Moxifloxacin
,14982788,area between the control growth curve and the killing and regrowth curve from 0 to 48 h (,"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],72.9 to 144.7,79907,DB00218,Moxifloxacin
,14982788,ABBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],40.4 to 101.1,79908,DB00218,Moxifloxacin
,14982788,ABBC(0-48),"Moreover, integral parameters of ciprofloxacin and moxifloxacin, in particular the area under the killing and regrowth curve from 0 to 48 h (AUBC(0-48), 342.3 to 401.3 versus 295.2 to 378.7 h x log CFU/ml, respectively) and the area between the control growth curve and the killing and regrowth curve from 0 to 48 h (ABBC(0-48), 40.4 to 101.1 versus 72.9 to 144.7 h x log CFU/ml, respectively), demonstrated a better antibacterial effect of moxifloxacin than ciprofloxacin on S. maltophilia.",Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14982788/),[cfu·h·log] / [ml],72.9 to 144.7,79909,DB00218,Moxifloxacin
,18333868,T(max),"The mean difference from placebo in machine-read QTcF at median T(max) for maraviroc 900 mg was 3.6 ms [90% confidence interval (CI) 1.5, 5.8].",Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333868/),ms,3.6,81193,DB00218,Moxifloxacin
,31970713,volume of distribution (Vd),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),l,190 to 204,81440,DB00218,Moxifloxacin
,31970713,terminal elimination half-life (t½),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),h,13.5-17.1,81441,DB00218,Moxifloxacin
,31970713,total clearance (CLT),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[l] / [h],8.8-10.6,81442,DB00218,Moxifloxacin
,31970713,protein binding,"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),%,21.3,81443,DB00218,Moxifloxacin
,31970713,Oral bioavailability,Oral bioavailability of omadacycline is estimated to be 34.5%.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),%,34.5,81444,DB00218,Moxifloxacin
,31970713,maximum plasma concentration (Cmax),A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[mg] / [l],0.5-0.6,81445,DB00218,Moxifloxacin
,31970713,area under the plasma concentration-time curve from 0 to infinity (AUC0-∞),A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[h·mg] / [l],9.6-11.9,81446,DB00218,Moxifloxacin
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.0,84478,DB00218,Moxifloxacin
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,5,84479,DB00218,Moxifloxacin
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.1,84480,DB00218,Moxifloxacin
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],16.6,87156,DB00218,Moxifloxacin
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],3.2,87157,DB00218,Moxifloxacin
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],21.5,87158,DB00218,Moxifloxacin
,25861340,C6hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],65.0,87159,DB00218,Moxifloxacin
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],11.4,87160,DB00218,Moxifloxacin
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],35.3,87161,DB00218,Moxifloxacin
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],1.49,87162,DB00218,Moxifloxacin
,10543767,elimination half-life,"On day 10, the mean elimination half-life was approximately 12 h.","Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543767/),h,12,89538,DB00218,Moxifloxacin
,10543767,AUC/MIC ratios,"The day 1 and day 10 mean AUC/MIC ratios were 121 and 192, respectively, and the mean C(max)/MIC ratios were 13 and 18, respectively.","Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543767/),,121,89539,DB00218,Moxifloxacin
,10543767,AUC/MIC ratios,"The day 1 and day 10 mean AUC/MIC ratios were 121 and 192, respectively, and the mean C(max)/MIC ratios were 13 and 18, respectively.","Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543767/),,192,89540,DB00218,Moxifloxacin
,10543767,C(max)/MIC ratios,"The day 1 and day 10 mean AUC/MIC ratios were 121 and 192, respectively, and the mean C(max)/MIC ratios were 13 and 18, respectively.","Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543767/),,13,89541,DB00218,Moxifloxacin
,10543767,C(max)/MIC ratios,"The day 1 and day 10 mean AUC/MIC ratios were 121 and 192, respectively, and the mean C(max)/MIC ratios were 13 and 18, respectively.","Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543767/),,18,89542,DB00218,Moxifloxacin
,10321420,peak serum concentration,"Geometric mean values for oral/IV moxifloxacin were as follows: peak serum concentration, 1.15/1.34 mg/L, and area under the concentration-time curve over 48 hours, 9.86/10.89 mg x h/L.",Absolute bioavailability of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321420/),[mg] / [l],1.15,93548,DB00218,Moxifloxacin
,10321420,area under the concentration-time curve over 48 hours,"Geometric mean values for oral/IV moxifloxacin were as follows: peak serum concentration, 1.15/1.34 mg/L, and area under the concentration-time curve over 48 hours, 9.86/10.89 mg x h/L.",Absolute bioavailability of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321420/),[h·mg] / [l],9.86,93549,DB00218,Moxifloxacin
,10321420,absolute bioavailability,The geometric mean absolute bioavailability of oral moxifloxacin was 91.8%.,Absolute bioavailability of moxifloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321420/),%,91.8,93550,DB00218,Moxifloxacin
,10321420,renal clearance,"Mean renal clearance was approximately 2.3 L/h after administration of both the single oral and IV formulations, which suggests lack of active tubular secretion of moxifloxacin.",Absolute bioavailability of moxifloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321420/),[l] / [h],2.3,93551,DB00218,Moxifloxacin
,28713157,total plasma clearance (CL/F),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),[l] / [h],8.22,94605,DB00218,Moxifloxacin
,28713157,volume of distribution of central compartment (Vc/F),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),l,37.7,94606,DB00218,Moxifloxacin
,28713157,distributional clearance in plasma (Q),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),l,104,94607,DB00218,Moxifloxacin
,28713157,distributional clearance in plasma (Q),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),[l] / [h],3.98,94608,DB00218,Moxifloxacin
,28713157,distributional clearance in plasma (Q),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),l,37.7,94609,DB00218,Moxifloxacin
,28713157,volume of distribution of peripheral compartment (Vp/F),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),l,104,94610,DB00218,Moxifloxacin
,28713157,volume of distribution of peripheral compartment (Vp/F),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),[l] / [h],3.98,94611,DB00218,Moxifloxacin
,28713157,volume of distribution of peripheral compartment (Vp/F),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),l,37.7,94612,DB00218,Moxifloxacin
,28713157,absorption rate constant (Ka),"We showed that the population pharmacokinetic parameter estimates for total plasma clearance (CL/F), the volume of distribution of central compartment (Vc/F), the distributional clearance in plasma (Q), the volume of distribution of peripheral compartment (Vp/F), and the absorption rate constant (Ka) were 8.22 L/h, 104 L, 3.98 L/h, 37.7 L, and 1.81 1/h, respectively.",Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),[1] / [h],1.81,94613,DB00218,Moxifloxacin
,28713157,maximum concentration,QT interval prolongation of MX estimates ranging from 9.77 to 12.91 ms at the mean average maximum concentration of MX (4.36 μg/mL) and a mean slope ranging from 2.33 to 2.96 ms per μg/mL.,Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28713157/),[μg] / [ml],4.36,94614,DB00218,Moxifloxacin
,18501909,Tissue to plasma ratios,Tissue to plasma ratios remained between 1.7 and 2.1 for 24 hours.,Penetration and accumulation of moxifloxacin in uterine tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501909/),,1.7,95044,DB00218,Moxifloxacin
,18501909,Tissue to plasma ratios,Tissue to plasma ratios remained between 1.7 and 2.1 for 24 hours.,Penetration and accumulation of moxifloxacin in uterine tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501909/),,2,95045,DB00218,Moxifloxacin
,30496461,AUC0-24/MIC,"In the HFS-TB, the AUC0-24/MIC associated with maximal Mtb kill was 146, while that associated with suppression of resistance was 360.","Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496461/),,146,95868,DB00218,Moxifloxacin
,30496461,AUC0-24/MIC,"In the HFS-TB, the AUC0-24/MIC associated with maximal Mtb kill was 146, while that associated with suppression of resistance was 360.","Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496461/),,360,95869,DB00218,Moxifloxacin
,30496461,AUC0-24/MIC,"AI algorithms identified an AUC0-24/MIC of 160 as predictive of microbiologic cure, followed by levofloxacin 2-hour peak concentration and body weight.","Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496461/),,160,95870,DB00218,Moxifloxacin
,19385711,half-life,"The predicted biopsy concentrations (including interstitial, intracellular, vascular space and macrophages) were slightly greater than the observed values, although the kinetic (i.e. observed biopsy half-life = 21 hours) was similar to that of moxifloxacin in macrophages (20.8 hours) and thus similar to the predicted biopsy half-life.",Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385711/),h,21,100252,DB00218,Moxifloxacin
,19385711,half-life,"The predicted biopsy concentrations (including interstitial, intracellular, vascular space and macrophages) were slightly greater than the observed values, although the kinetic (i.e. observed biopsy half-life = 21 hours) was similar to that of moxifloxacin in macrophages (20.8 hours) and thus similar to the predicted biopsy half-life.",Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385711/),h,20.8,100253,DB00218,Moxifloxacin
,24323477,maximum concentration in PF (CmaxPF),"The maximum concentration in PF (CmaxPF) in patients with empyema/PPE was 2.23±1.31 mg/liter, and it was detected 7.50±2.39 h after the initiation of the infusion.",Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24323477/),[mg] / [l],2.23,100909,DB00218,Moxifloxacin
,24323477,CmaxPF,"In patients with malignant effusion, CmaxPF was 2.96±1.45 mg/liter, but it was observed significantly earlier, at 3.58±1.38 h (P<0.001).",Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24323477/),[mg] / [l],2.96,100910,DB00218,Moxifloxacin
,24323477,AUC24PF,Both groups revealed similar values of AUC24PF (31.83±23.52 versus 32.81±12.66 mg·h/liter).,Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24323477/),[h·mg] / [l],31.83,100911,DB00218,Moxifloxacin
,24323477,AUC24PF,Both groups revealed similar values of AUC24PF (31.83±23.52 versus 32.81±12.66 mg·h/liter).,Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24323477/),[h·mg] / [l],32.81,100912,DB00218,Moxifloxacin
,24323477,Penetration,Penetration of MXF into PF was similarly good in both patient groups (1.11±0.74 versus 1.17±0.39).,Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24323477/),,1.11,100913,DB00218,Moxifloxacin
,24323477,Penetration,Penetration of MXF into PF was similarly good in both patient groups (1.11±0.74 versus 1.17±0.39).,Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24323477/),,1.17,100914,DB00218,Moxifloxacin
,23403419,maximum concentration of drug in serum (C(max)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[ng] / [ml],432,101692,DB00218,Moxifloxacin
,23403419,area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[h·ng] / [ml],"2,366",101693,DB00218,Moxifloxacin
,23403419,clearance (CL),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[l] / [h],21.1,101694,DB00218,Moxifloxacin
,23403419,volume of distribution at steady state (V(ss)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),l,610,101695,DB00218,Moxifloxacin
,23403419,terminal half-life (t(1/2)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),h,22.1,101696,DB00218,Moxifloxacin
,15358708,time to,The time to equilibration between the pleural fluid and blood antibiotic levels was more rapid for moxifloxacin (3.9 h) than for levofloxacin (4.4 h).,Penetration of newer quinolones in the empyema fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,3.9,104284,DB00218,Moxifloxacin
,15358708,time to,The time to equilibration between the pleural fluid and blood antibiotic levels was more rapid for moxifloxacin (3.9 h) than for levofloxacin (4.4 h).,Penetration of newer quinolones in the empyema fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,4.4,104285,DB00218,Moxifloxacin
,15358708,"peak pleural fluid concentration (Cmax,PF)","With moxifloxacin, the peak pleural fluid concentration (Cmax,PF) was 2.77 microg.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),μg,2.77,104286,DB00218,Moxifloxacin
,15358708,"time to maximum pleural fluid concentration (Tmax,PF)","mL(-1) and occurred at a time to maximum pleural fluid concentration (Tmax,PF) of 6 h after infusion and decreased thereafter.",Penetration of newer quinolones in the empyema fluid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,6,104287,DB00218,Moxifloxacin
,15358708,"peak blood concentration (Cmax,blood)","The peak blood concentration (Cmax,blood) was 4.81 microg.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),μg,4.81,104288,DB00218,Moxifloxacin
,15358708,peak pleural fluid level (Cmax,"With levofloxacin, the peak pleural fluid level (Cmax,PF=1.39 microg.mL(-1)) occurred at 6 h (Tmax,PF=6 h) after infusion.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),[μg] / [ml],1.39,104289,DB00218,Moxifloxacin
,15358708,Tmax,"With levofloxacin, the peak pleural fluid level (Cmax,PF=1.39 microg.mL(-1)) occurred at 6 h (Tmax,PF=6 h) after infusion.",Penetration of newer quinolones in the empyema fluid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,6,104290,DB00218,Moxifloxacin
,15358708,"Cmax,blood","The Cmax,blood was 1.88 microg.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),μg,1.88,104291,DB00218,Moxifloxacin
,18088505,hepatic extraction ratio (E),"Values for the hepatic extraction ratio (E) and clearance (Cl) were insignificantly higher in TR- rats than Wistar rats (0.193+/-0.050 vs 0.245+/-0.050 for E; 6.85+/-1.96 vs 8.73+/-1.82 mL min(-1) for Cl), whereas biliary excretion and efflux into perfusate over 60 min were significantly lower in the mutant rat strain.",Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088505/),[ml] / [min],0.193,105483,DB00218,Moxifloxacin
,18088505,clearance (Cl),"Values for the hepatic extraction ratio (E) and clearance (Cl) were insignificantly higher in TR- rats than Wistar rats (0.193+/-0.050 vs 0.245+/-0.050 for E; 6.85+/-1.96 vs 8.73+/-1.82 mL min(-1) for Cl), whereas biliary excretion and efflux into perfusate over 60 min were significantly lower in the mutant rat strain.",Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088505/),[ml] / [min],6.85,105484,DB00218,Moxifloxacin
,18088505,clearance (Cl),"Values for the hepatic extraction ratio (E) and clearance (Cl) were insignificantly higher in TR- rats than Wistar rats (0.193+/-0.050 vs 0.245+/-0.050 for E; 6.85+/-1.96 vs 8.73+/-1.82 mL min(-1) for Cl), whereas biliary excretion and efflux into perfusate over 60 min were significantly lower in the mutant rat strain.",Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088505/),[ml] / [min],8.73,105485,DB00218,Moxifloxacin
,18088505,Cl,"Values for the hepatic extraction ratio (E) and clearance (Cl) were insignificantly higher in TR- rats than Wistar rats (0.193+/-0.050 vs 0.245+/-0.050 for E; 6.85+/-1.96 vs 8.73+/-1.82 mL min(-1) for Cl), whereas biliary excretion and efflux into perfusate over 60 min were significantly lower in the mutant rat strain.",Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088505/),[ml] / [min],6.85,105486,DB00218,Moxifloxacin
,18088505,Cl,"Values for the hepatic extraction ratio (E) and clearance (Cl) were insignificantly higher in TR- rats than Wistar rats (0.193+/-0.050 vs 0.245+/-0.050 for E; 6.85+/-1.96 vs 8.73+/-1.82 mL min(-1) for Cl), whereas biliary excretion and efflux into perfusate over 60 min were significantly lower in the mutant rat strain.",Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088505/),[ml] / [min],8.73,105487,DB00218,Moxifloxacin
,25881753,maximum observed drug concentration (Cmax),"Sufficient assay sensitivity was not achieved, likely due to food effect; although the maximum observed drug concentration (Cmax) with moxifloxacin (1,410 ng/mL) was lower than expected, the slope of the regression line of moxifloxacin plasma concentrations versus placebo-subtracted ΔQTcF was similar to that reported in the literature.",Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25881753/),[ng] / [ml],"1,410",105496,DB00218,Moxifloxacin
,33247830,volume of distribution (Vd),"The pharmacokinetic properties of lefamulin include: volume of distribution (Vd) ranging from 82.9 to 202.8 L, total clearance (CLT) of 19.5 to 21.4 L/h, and terminal elimination half-life (t1/2) of 6.9-13.2 h; protein binding of lefamulin is high and non-linear.",Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),l,82.9 to 202.8,105760,DB00218,Moxifloxacin
,33247830,total clearance (CLT),"The pharmacokinetic properties of lefamulin include: volume of distribution (Vd) ranging from 82.9 to 202.8 L, total clearance (CLT) of 19.5 to 21.4 L/h, and terminal elimination half-life (t1/2) of 6.9-13.2 h; protein binding of lefamulin is high and non-linear.",Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),[l] / [h],19.5 to 21.4,105761,DB00218,Moxifloxacin
,33247830,terminal elimination half-life (t1/2),"The pharmacokinetic properties of lefamulin include: volume of distribution (Vd) ranging from 82.9 to 202.8 L, total clearance (CLT) of 19.5 to 21.4 L/h, and terminal elimination half-life (t1/2) of 6.9-13.2 h; protein binding of lefamulin is high and non-linear.",Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),h,6.9-13.2,105762,DB00218,Moxifloxacin
,33247830,oral bioavailability,The oral bioavailability of lefamulin has been estimated as 24% in fasted subjects and 19% in fed subjects.,Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),%,24,105763,DB00218,Moxifloxacin
,33247830,oral bioavailability,The oral bioavailability of lefamulin has been estimated as 24% in fasted subjects and 19% in fed subjects.,Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),%,19,105764,DB00218,Moxifloxacin
,33247830,maximum plasma concentration (Cmax),"A single oral dose of lefamulin 600 mg administered in fasted patients achieved a maximum plasma concentration (Cmax) of 1.2-1.5 mg/L with a time of maximum concentration (Tmax) ranging from 0.8 to 1.8 h, and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 8.5-8.8 mg h/L.",Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),[mg] / [l],1.2-1.5,105765,DB00218,Moxifloxacin
,33247830,time of maximum concentration (Tmax),"A single oral dose of lefamulin 600 mg administered in fasted patients achieved a maximum plasma concentration (Cmax) of 1.2-1.5 mg/L with a time of maximum concentration (Tmax) ranging from 0.8 to 1.8 h, and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 8.5-8.8 mg h/L.",Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),h,0.8 to 1.8,105766,DB00218,Moxifloxacin
,33247830,area under the plasma concentration-time curve from 0 to infinity (AUC0-∞),"A single oral dose of lefamulin 600 mg administered in fasted patients achieved a maximum plasma concentration (Cmax) of 1.2-1.5 mg/L with a time of maximum concentration (Tmax) ranging from 0.8 to 1.8 h, and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 8.5-8.8 mg h/L.",Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33247830/),[h·mg] / [l],8.5-8.8,105767,DB00218,Moxifloxacin
,21459055,recovery,"The recovery was 84.5, 85.1 and 92.6% in response to blood concentration of 0.15, 2.50 and 5.00 mg/L, respectively.",Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21459055/),%,84.5,106234,DB00218,Moxifloxacin
,21459055,recovery,"The recovery was 84.5, 85.1 and 92.6% in response to blood concentration of 0.15, 2.50 and 5.00 mg/L, respectively.",Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21459055/),%,85.1,106235,DB00218,Moxifloxacin
,21459055,recovery,"The recovery was 84.5, 85.1 and 92.6% in response to blood concentration of 0.15, 2.50 and 5.00 mg/L, respectively.",Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21459055/),%,92.6,106236,DB00218,Moxifloxacin
,16384979,half-life,The concentration of intravitreal moxifloxacin showed an exponential decay with a half-life of 1.72 hours.,Clearance of intravitreal moxifloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16384979/),h,1.72,107377,DB00218,Moxifloxacin
>,26519230,ΔΔQTcF,Assay validity was demonstrated by maximum ΔΔQTcF of >5 ms after 400 mg moxifloxacin on both on-treatment assessment days.,Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519230/),ms,5,108529,DB00218,Moxifloxacin
,24986094,tmax,Maximum plasma concentration (Cmax) of glycopyrronium was achieved shortly after inhalation (median tmax = 7 minutes).,"Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24986094/),min,7,108882,DB00218,Moxifloxacin
,23876335,Peak,"Peak and trough serum moxifloxacin concentrations were 4.84 ± 1.85 mg/L and 1.17 ± 0.73 mg/L, respectively, at the arterial port after a single i.v. 400 mg dose.",Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),[mg] / [l],4.84,109329,DB00218,Moxifloxacin
,23876335,trough serum moxifloxacin concentrations,"Peak and trough serum moxifloxacin concentrations were 4.84 ± 1.85 mg/L and 1.17 ± 0.73 mg/L, respectively, at the arterial port after a single i.v. 400 mg dose.",Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),[mg] / [l],1.17,109330,DB00218,Moxifloxacin
,23876335,elimination half-life,"The mean elimination half-life was 4.82 ± 2.13 h, the volume of distribution was 82.63 ± 24.69 L and the calculated AUC(0-12) was 26.91 ± 10.96 mgh/L.",Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),h,4.82,109331,DB00218,Moxifloxacin
,23876335,volume of distribution,"The mean elimination half-life was 4.82 ± 2.13 h, the volume of distribution was 82.63 ± 24.69 L and the calculated AUC(0-12) was 26.91 ± 10.96 mgh/L.",Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),l,82.63,109332,DB00218,Moxifloxacin
,23876335,AUC(0-12),"The mean elimination half-life was 4.82 ± 2.13 h, the volume of distribution was 82.63 ± 24.69 L and the calculated AUC(0-12) was 26.91 ± 10.96 mgh/L.",Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),[mgh] / [l],26.91,109333,DB00218,Moxifloxacin
,23876335,Total clearance,Total clearance was 14.36 ± 8.44 L/h and the clearance of haemofiltration was 1.67 ± 0.95 L/h.C(max)/MIC(90) ratios and predicted AUC(0-24)/MIC(90) ratios were above the cut-off points for common pathogens that indicate clinical success.,Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),[l] / [h],14.36,109334,DB00218,Moxifloxacin
,23876335,clearance of haemofiltration,Total clearance was 14.36 ± 8.44 L/h and the clearance of haemofiltration was 1.67 ± 0.95 L/h.C(max)/MIC(90) ratios and predicted AUC(0-24)/MIC(90) ratios were above the cut-off points for common pathogens that indicate clinical success.,Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),[l] / [h],1.67,109335,DB00218,Moxifloxacin
,23876335,MIC(90),It also should be kept in mind that the standard dose is not sufficient for this population infected with pathogens with a higher MIC(90) (0.5 mg/L).,Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876335/),[mg] / [l],0.5,109336,DB00218,Moxifloxacin
,28175315,Oral clearance (CL/F),"Oral clearance (CL/F) of moxifloxacin during rifampicin-based TB treatment was 24.3 L/h for a typical patient (fat-free mass of 47 kg), resulting in an AUC of 16.5 mg·h/L.",Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28175315/),[l] / [h],24.3,109965,DB00218,Moxifloxacin
,28175315,AUC,"Oral clearance (CL/F) of moxifloxacin during rifampicin-based TB treatment was 24.3 L/h for a typical patient (fat-free mass of 47 kg), resulting in an AUC of 16.5 mg·h/L.",Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28175315/),[h·mg] / [l],16.5,109966,DB00218,Moxifloxacin
,15062922,peak serum,"Mean (+/-S.D.) peak serum and synovial fluid concentrations were 3.46 +/- 0.78 mg/L and 3.42 +/- 0.51 mg/L, respectively.","Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15062922/),[mg] / [l],3.46,110687,DB00218,Moxifloxacin
,15062922,synovial fluid concentrations,"Mean (+/-S.D.) peak serum and synovial fluid concentrations were 3.46 +/- 0.78 mg/L and 3.42 +/- 0.51 mg/L, respectively.","Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15062922/),[mg] / [l],3.42,110688,DB00218,Moxifloxacin
,16509760,C(max),"The mean estimated pharmacokinetic parameters (C(max) 4.40 mg/L at 1.4 hours, AUC(24) 42.67 mg .",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),[mg] / [l],4.40,111389,DB00218,Moxifloxacin
,16509760,AUC(24),"The mean estimated pharmacokinetic parameters (C(max) 4.40 mg/L at 1.4 hours, AUC(24) 42.67 mg .",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),mg,42.67,111390,DB00218,Moxifloxacin
,16509760,elimination half-life,"h/L, elimination half-life 12.55 hours, total body clearance 0.16 L/h/kg) were generally similar to those observed in both young and elderly historic controls (except for higher-dose normalised C(max) and lower volume of distribution of the central compartment).",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),h,12.55,111391,DB00218,Moxifloxacin
,16509760,total body clearance,"h/L, elimination half-life 12.55 hours, total body clearance 0.16 L/h/kg) were generally similar to those observed in both young and elderly historic controls (except for higher-dose normalised C(max) and lower volume of distribution of the central compartment).",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),[l] / [h·kg],0.16,111392,DB00218,Moxifloxacin
,16509760,C(max)/MIC,"Median C(max)/MIC and AUC(24)/MIC ratios for moxifloxacin in the fully assessable cases were, respectively, 67.5 and 823.9 against",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),,67.5,111393,DB00218,Moxifloxacin
,16509760,C(max)/MIC,"Mean estimates of PDBP for achieving C(max)/MIC values of 12.2 and AUC(24)/MIC values of 125 were 0.36 and 0.35 mg/L, respectively.",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),,12.2,111394,DB00218,Moxifloxacin
,16509760,AUC(24)/MIC,"Mean estimates of PDBP for achieving C(max)/MIC values of 12.2 and AUC(24)/MIC values of 125 were 0.36 and 0.35 mg/L, respectively.",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),[mg] / [l],125,111395,DB00218,Moxifloxacin
,16509760,AUC(24)/MIC,"Mean estimates of PDBP for achieving C(max)/MIC values of 12.2 and AUC(24)/MIC values of 125 were 0.36 and 0.35 mg/L, respectively.",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),[mg] / [l],0.36,111396,DB00218,Moxifloxacin
,16509760,AUC(24)/MIC,"Mean estimates of PDBP for achieving C(max)/MIC values of 12.2 and AUC(24)/MIC values of 125 were 0.36 and 0.35 mg/L, respectively.",Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509760/),[mg] / [l],0.35,111397,DB00218,Moxifloxacin
,22567560,retention time,This validated method led to a short retention time (8.0 min) for moxifloxacin.,High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22567560/),min,8.0,113026,DB00218,Moxifloxacin
,29917079,area under the curve,"The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively).",The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29917079/),[mg] / [h·l],20,113125,DB00218,Moxifloxacin
,29917079,area under the curve,"The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively).",The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29917079/),[mg] / [h·l],175,113126,DB00218,Moxifloxacin
,16504997,C(max),"C(max) occurred at 3 h in tonsillar tissue (mean 8.96 mg/L) and in plasma (mean 3.20 mg/L), the tissue/plasma concentration ratios (mean values) being constantly >2, ranging between 2.37 (after 2 h) and 2.93 (after 24 h), which indicates a prolonged maintenance of moxifloxacin concentration in tonsillar tissue compared with plasma.",Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504997/),[mg] / [l],8.96,113369,DB00218,Moxifloxacin
,16504997,C(max),"C(max) occurred at 3 h in tonsillar tissue (mean 8.96 mg/L) and in plasma (mean 3.20 mg/L), the tissue/plasma concentration ratios (mean values) being constantly >2, ranging between 2.37 (after 2 h) and 2.93 (after 24 h), which indicates a prolonged maintenance of moxifloxacin concentration in tonsillar tissue compared with plasma.",Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504997/),[mg] / [l],3.20,113370,DB00218,Moxifloxacin
>,16504997,tissue/plasma concentration ratios,"C(max) occurred at 3 h in tonsillar tissue (mean 8.96 mg/L) and in plasma (mean 3.20 mg/L), the tissue/plasma concentration ratios (mean values) being constantly >2, ranging between 2.37 (after 2 h) and 2.93 (after 24 h), which indicates a prolonged maintenance of moxifloxacin concentration in tonsillar tissue compared with plasma.",Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504997/),,2,113371,DB00218,Moxifloxacin
>,16504997,tissue/plasma concentration ratios,"C(max) occurred at 3 h in tonsillar tissue (mean 8.96 mg/L) and in plasma (mean 3.20 mg/L), the tissue/plasma concentration ratios (mean values) being constantly >2, ranging between 2.37 (after 2 h) and 2.93 (after 24 h), which indicates a prolonged maintenance of moxifloxacin concentration in tonsillar tissue compared with plasma.",Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504997/),,2.37,113372,DB00218,Moxifloxacin
,16504997,tissue/plasma concentration ratios,"C(max) occurred at 3 h in tonsillar tissue (mean 8.96 mg/L) and in plasma (mean 3.20 mg/L), the tissue/plasma concentration ratios (mean values) being constantly >2, ranging between 2.37 (after 2 h) and 2.93 (after 24 h), which indicates a prolonged maintenance of moxifloxacin concentration in tonsillar tissue compared with plasma.",Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504997/),,2.93,113373,DB00218,Moxifloxacin
,16504997,tonsillar tissue/plasma concentration ratio,"Variability among patients was present at 6 h, with the tonsillar tissue/plasma concentration ratio ranging between 0.8 and 3.4.",Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504997/),,0.8,113374,DB00218,Moxifloxacin
,31299075,unbound fraction,Mean unbound fraction of moxifloxacin in plasma was 85.5±3.4%.,Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),%,85.5,114477,DB00218,Moxifloxacin
,31299075,Cmax,"On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0-24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),[mg] / [l],2.8,114478,DB00218,Moxifloxacin
,31299075,Cmax,"On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0-24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),[mg] / [l],2.5,114479,DB00218,Moxifloxacin
,31299075,AUC,"On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0-24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),[h·mg] / [l],24.8,114480,DB00218,Moxifloxacin
,31299075,AUC,"On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0-24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),[h·mg] / [l],21.3,114481,DB00218,Moxifloxacin
,31299075,fAUC0-24/MIC,"On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0-24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),h,100.9,114482,DB00218,Moxifloxacin
,31299075,fAUC0-24/MIC,"On day 1, Cmax in subcutis and muscle was 2.8±1.8 and 2.5±1.3 mg/L, respectively, AUC was 24.8±15.1 and 21.3±10.5 mg·h/L, respectively, and fAUC0-24/MIC was 100.9±62.9 and 86.5±38.3 h, respectively.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),h,86.5,114483,DB00218,Moxifloxacin
,31299075,Cmax,"Cmax for unbound moxifloxacin in plasma was 3.5±0.9 mg/L, AUC was 23.5±7.5 mg·h/L and fAUC0-24/MIC was 91.6±24.8 h.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),[mg] / [l],3.5,114484,DB00218,Moxifloxacin
,31299075,AUC,"Cmax for unbound moxifloxacin in plasma was 3.5±0.9 mg/L, AUC was 23.5±7.5 mg·h/L and fAUC0-24/MIC was 91.6±24.8 h.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),[h·mg] / [l],23.5,114485,DB00218,Moxifloxacin
,31299075,fAUC0-24/MIC,"Cmax for unbound moxifloxacin in plasma was 3.5±0.9 mg/L, AUC was 23.5±7.5 mg·h/L and fAUC0-24/MIC was 91.6±24.8 h.",Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299075/),h,91.6,114486,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],11.7,115518,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],7.8,115519,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],10.5,115520,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],5.7,115521,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],15.2,115522,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],10.2,115523,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],6.9,115524,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],2.9,115525,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.6,115526,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.7,115527,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.9,115528,DB00218,Moxifloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.9,115529,DB00218,Moxifloxacin
<,15006955,MIC(90)),The AM concentrations of all agents studied were more than adequate relative to the minimum concentration required to inhibit 90% of the organism population (MIC(90)) of the common intracellular pathogens (< 1 micro g/mL).,"Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],1,115530,DB00218,Moxifloxacin
,25824259,aqueous concentration,"Mean aqueous concentration of moxifloxacin attained in the oral group (n=21) was 0.504±0.30 μg/mL while that in the topical group (n=21) was 2.04±0.72 μg/mL, and this difference in levels was statistically significant (p<0.005).",Aqueous penetration of orally and topically administered moxifloxacin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824259/),[μg] / [ml],0.504,116393,DB00218,Moxifloxacin
,25824259,aqueous concentration,"Mean aqueous concentration of moxifloxacin attained in the oral group (n=21) was 0.504±0.30 μg/mL while that in the topical group (n=21) was 2.04±0.72 μg/mL, and this difference in levels was statistically significant (p<0.005).",Aqueous penetration of orally and topically administered moxifloxacin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824259/),[μg] / [ml],2.04,116394,DB00218,Moxifloxacin
,30650259,peak plasma concentration,"For the 15- and 20-mg/kg dose levels of plazomicin, mean peak plasma concentration values were 76.0 and 96.6 mg/L, and mean values of the area under the concentration-time curve over 24 hours were 263 and 327 mg·h/L, respectively.","A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650259/),[mg] / [l],76.0,118140,DB00218,Moxifloxacin
,30650259,peak plasma concentration,"For the 15- and 20-mg/kg dose levels of plazomicin, mean peak plasma concentration values were 76.0 and 96.6 mg/L, and mean values of the area under the concentration-time curve over 24 hours were 263 and 327 mg·h/L, respectively.","A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650259/),[mg] / [l],96.6,118141,DB00218,Moxifloxacin
,30650259,area under the concentration-time curve over 24 hours,"For the 15- and 20-mg/kg dose levels of plazomicin, mean peak plasma concentration values were 76.0 and 96.6 mg/L, and mean values of the area under the concentration-time curve over 24 hours were 263 and 327 mg·h/L, respectively.","A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650259/),[h·mg] / [l],263,118142,DB00218,Moxifloxacin
,30650259,area under the concentration-time curve over 24 hours,"For the 15- and 20-mg/kg dose levels of plazomicin, mean peak plasma concentration values were 76.0 and 96.6 mg/L, and mean values of the area under the concentration-time curve over 24 hours were 263 and 327 mg·h/L, respectively.","A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30650259/),[h·mg] / [l],327,118143,DB00218,Moxifloxacin
,31083593,steady state flux,Corneal steady state flux of MM3 (~32.01 µg/cm2/h) and control (~31.53 µg/cm2/h) were comparable.,Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31083593/),[μg] / [cm2·h],32.01,118353,DB00218,Moxifloxacin
,31083593,steady state flux,Corneal steady state flux of MM3 (~32.01 µg/cm2/h) and control (~31.53 µg/cm2/h) were comparable.,Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31083593/),[μg] / [cm2·h],31.53,118354,DB00218,Moxifloxacin
,31083593,aqueous humor concentration (Cmax,The greater aqueous humor concentration (Cmax; 555.73 ± 133.34 ng/mL) and delayed Tmax value (2 h) observed in MM3 suggest a reduced dosing frequency and increased therapeutic efficacy relative to control.,Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31083593/),[ng] / [ml],555.73,118355,DB00218,Moxifloxacin
,31083593,Tmax,The greater aqueous humor concentration (Cmax; 555.73 ± 133.34 ng/mL) and delayed Tmax value (2 h) observed in MM3 suggest a reduced dosing frequency and increased therapeutic efficacy relative to control.,Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31083593/),h,2,118356,DB00218,Moxifloxacin
,31083593,area under the aqueous humor concentration versus time curve (AUC0-8 h),"The area under the aqueous humor concentration versus time curve (AUC0-8 h) of MM3 (1859.76 ± 424.51 ng·h/mL) was ~2 fold higher (p < 0.0005) than the control, suggesting a significant improvement in aqueous humor bioavailability.",Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31083593/),[h·ng] / [ml],1859.76,118357,DB00218,Moxifloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.5,120294,DB00218,Moxifloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],1,120295,DB00218,Moxifloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"4, 0.8",120296,DB00218,Moxifloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.12,120297,DB00218,Moxifloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],1,120298,DB00218,Moxifloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"4, 0.8",120299,DB00218,Moxifloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.12,120300,DB00218,Moxifloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.25,120301,DB00218,Moxifloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"2, 0.25",120302,DB00218,Moxifloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],1,120303,DB00218,Moxifloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"4, 0.8",120304,DB00218,Moxifloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.12,120305,DB00218,Moxifloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.25,120306,DB00218,Moxifloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"2, 0.25",120307,DB00218,Moxifloxacin
,19217166,AUC/MIC,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),,234,120308,DB00218,Moxifloxacin
,19217166,AUC/MIC,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),,431,120309,DB00218,Moxifloxacin
,19217166,AUC/MIC,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),,568,120310,DB00218,Moxifloxacin
,27159505,area under the concentration-time curve (AUC0-24),"Median rifapentine area under the concentration-time curve (AUC0-24) was 313 mcg*h/mL, similar to recent studies of rifapentine dosed at 450-600 mg daily.",A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27159505/),[h·mcg] / [ml],313,120720,DB00218,Moxifloxacin
,27159505,AUC0-24,"Median moxifloxacin AUC0-24 was 28.0 mcg*h/mL, much lower than in trials where rifapentine was given only intermittently with moxifloxacin.",A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27159505/),[h·mcg] / [ml],28.0,120721,DB00218,Moxifloxacin
,30224529,time to peak plasma concentration (T max,"The time to peak plasma concentration (T max and C max, respectively) was about 2 h, and the half-life was 14 to 16 h.","A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224529/),h,2,123622,DB00218,Moxifloxacin
,30224529,C max,"The time to peak plasma concentration (T max and C max, respectively) was about 2 h, and the half-life was 14 to 16 h.","A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224529/),h,2,123623,DB00218,Moxifloxacin
,30224529,half-life,"The time to peak plasma concentration (T max and C max, respectively) was about 2 h, and the half-life was 14 to 16 h.","A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224529/),h,14 to 16,123624,DB00218,Moxifloxacin
,30224529,T max,"Food slightly affected the drug's rate and extent of absorption, increasing the T max from 1.60 to 2.59 h and reducing the C max by 13.6% and area under the concentration-time curve by 8.95%.","A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224529/),h,1.60,123625,DB00218,Moxifloxacin
,30224529,T max,"Food slightly affected the drug's rate and extent of absorption, increasing the T max from 1.60 to 2.59 h and reducing the C max by 13.6% and area under the concentration-time curve by 8.95%.","A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224529/),h,2.59,123626,DB00218,Moxifloxacin
,15842551,AUC,The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h).,Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),[h·mg] / [l],35.5,123708,DB00218,Moxifloxacin
,15842551,AUC,The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h).,Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),[h·mg] / [l],5.40,123709,DB00218,Moxifloxacin
,15842551,AUC,The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h).,Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),[h·mg] / [l],28.5,123710,DB00218,Moxifloxacin
,15842551,C(max),Concurrently peak concentrations were lowered C(max) = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05).,Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),[mg] / [l],3.38,123711,DB00218,Moxifloxacin
,15842551,C(max),Concurrently peak concentrations were lowered C(max) = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05).,Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),[mg] / [l],0.62,123712,DB00218,Moxifloxacin
,15842551,C(max),Concurrently peak concentrations were lowered C(max) = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05).,Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),[mg] / [l],2.97,123713,DB00218,Moxifloxacin
,15842551,Bioavailability,"Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C.",Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),%,15.4,123714,DB00218,Moxifloxacin
,15842551,Bioavailability,"Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C.",Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842551/),%,80.4,123715,DB00218,Moxifloxacin
,25185118,peak plasma concentrations (Cmax),"After intramuscular and oral administration of moxifloxacin, the peak plasma concentrations (Cmax) were 2.14 and 1.94 μg/ml and were obtained at 1.40 and 1.87 h (Tmax), post administration, respectively.",Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185118/),[μg] / [ml],2.14,124307,DB00218,Moxifloxacin
,25185118,peak plasma concentrations (Cmax),"After intramuscular and oral administration of moxifloxacin, the peak plasma concentrations (Cmax) were 2.14 and 1.94 μg/ml and were obtained at 1.40 and 1.87 h (Tmax), post administration, respectively.",Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185118/),[μg] / [ml],1.94,124308,DB00218,Moxifloxacin
,25185118,Tmax,"After intramuscular and oral administration of moxifloxacin, the peak plasma concentrations (Cmax) were 2.14 and 1.94 μg/ml and were obtained at 1.40 and 1.87 h (Tmax), post administration, respectively.",Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185118/),h,1.40,124309,DB00218,Moxifloxacin
,25185118,Tmax,"After intramuscular and oral administration of moxifloxacin, the peak plasma concentrations (Cmax) were 2.14 and 1.94 μg/ml and were obtained at 1.40 and 1.87 h (Tmax), post administration, respectively.",Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185118/),h,1.87,124310,DB00218,Moxifloxacin
,25185118,systemic bioavailabilities,"The systemic bioavailabilities following intramuscular and oral administration, respectively, of moxifloxacin were 92.48 and 87.94%.",Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185118/),%,92.48,124311,DB00218,Moxifloxacin
,25185118,systemic bioavailabilities,"The systemic bioavailabilities following intramuscular and oral administration, respectively, of moxifloxacin were 92.48 and 87.94%.",Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185118/),%,87.94,124312,DB00218,Moxifloxacin
<,15992072,MIC90,"The MIC90 values are < or = 0.25 mg/l for Streptococcus pneumoniae (irrespective of penicillin susceptibility), Haemophilus influenzae (beta-lactamase positive or negative), Morexella catarrhalis, Bordetella pertussis, Legionella sp., Mycoplasma pneumoniae, Clamydia pneumoniae, Mycobacterium tuberculosis, methicillin-sensitive Staphylococcus aureus, beta-haemolytic streptococci (macrolide-sensitive or -resistant), Listeria sp., most Enterobacteriaceae, Salmonella sp., Shigella sp., Neisseria gonorrhoeae, N. menigitidis, Pasteurella spp., Vibrio spp. and Yersinia enterocolitica.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.25,124986,DB00218,Moxifloxacin
,15992072,MIC90s,"For Mycobacterium intracellularae, methicillin-resistant S. aureus (MRSA), ciprofloxacin-resistant S. aureus, Citrobacter freundii, Providencia sp., Serratia sp., P. aeruginosa and other non-fermentive Gram-negative rods, MIC90s are in the range 0.5-4 mg/l.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.5-4,124987,DB00218,Moxifloxacin
,15992072,MIC90s,"For anaerobic bacteria species, MIC90s are also in the range 0.25-4 mg/l.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.25-4,124988,DB00218,Moxifloxacin
,15992072,maximum serum concentration,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],2.5-4.5,124989,DB00218,Moxifloxacin
,15992072,half-life,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),h,11-15,124990,DB00218,Moxifloxacin
,15992072,AUC,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[h·mg] / [l],25-40,124991,DB00218,Moxifloxacin
,15992072,volume of distribution,"A single dose of 400 mg produces a maximum serum concentration of 2.5-4.5 mg/l, half-life of 11-15 h, AUC of 25-40 mg x h/l and volume of distribution of 2.5-3.5 L/kg.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[l] / [kg],2.5-3.5,124992,DB00218,Moxifloxacin
,15992072,Protein binding,Protein binding is about 50% and two metabolites have been identified (M-1 and M-2).,Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),%,50,124993,DB00218,Moxifloxacin
>,15992072,Bioavailability,Bioavailability is > 85% and a minority of clearance is via the kidneys.,Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),%,85,124994,DB00218,Moxifloxacin
<,15992072,MICs,"At present undergoing clinical trials, with a focus on respiratory tract infection, it is likely that moxifloxacin will provide effective therapy for pathogens with MICs of < or = 0.25-0.5 mg/l.",Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15992072/),[mg] / [l],0.25-0.5,124995,DB00218,Moxifloxacin
,11642690,oral bioavailability,"The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include excellent oral bioavailability (90-99%), extensive penetration into tissues and body fluids, and an elimination half-life (6-12 hrs) that allows for once-daily dosing in patients with normal renal function.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),%,90-99,127439,DB00218,Moxifloxacin
,11642690,elimination half-life,"The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include excellent oral bioavailability (90-99%), extensive penetration into tissues and body fluids, and an elimination half-life (6-12 hrs) that allows for once-daily dosing in patients with normal renal function.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),h,6-12,127440,DB00218,Moxifloxacin
greater,11642690,Cmax:MIC,"For gram-negative infections, a Cmax:MIC greater than or equal to 10 and AUC(0-24hr):MIC greater than or equal to 125 are associated with increased probability of a successful outcome.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),,10,127441,DB00218,Moxifloxacin
greater,11642690,AUC(0-24hr):MIC,"For gram-negative infections, a Cmax:MIC greater than or equal to 10 and AUC(0-24hr):MIC greater than or equal to 125 are associated with increased probability of a successful outcome.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),,125,127442,DB00218,Moxifloxacin
,11642690,AUC(0-24hr):MIC,"For infections caused by Streptococcus pneumoniae, an AUC(0-24hr):MIC of 30 or more is suggested for favorable clinical outcomes.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),,30,127443,DB00218,Moxifloxacin
,21987240,maximum (C(max)),"After oral dosing, moxifloxacin plasma concentrations reached a maximum (C(max)) of 3.38 ± 1.41 mg/L after 1.75 h (0.75-4.00).",Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987240/),[mg] / [l],3.38,127639,DB00218,Moxifloxacin
,21987240,C(max),"After intravenous dosing, C(max) and T(max) were 4.53 ± 1.43 mg/L and 1.03 h (0.75-2.50), respectively.",Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987240/),[mg] / [l],4.53,127640,DB00218,Moxifloxacin
,21987240,T(max),"After intravenous dosing, C(max) and T(max) were 4.53 ± 1.43 mg/L and 1.03 h (0.75-2.50), respectively.",Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987240/),h,1.03,127641,DB00218,Moxifloxacin
,21987240,areas under the plasma concentration time curve extrapolated to infinity (AUC(∞)),"The mean areas under the plasma concentration time curve extrapolated to infinity (AUC(∞)) were 46.2 ± 1.4 mg · h/L after oral dosing and 52.3 ± 1.3 mg · h/L after intravenous dosing, resulting in a mean oral bioavailability of 88.32% [90% confidence interval (CI) 85.64%-91.08%].",Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987240/),[h·mg] / [l],46.2,127642,DB00218,Moxifloxacin
,21987240,areas under the plasma concentration time curve extrapolated to infinity (AUC(∞)),"The mean areas under the plasma concentration time curve extrapolated to infinity (AUC(∞)) were 46.2 ± 1.4 mg · h/L after oral dosing and 52.3 ± 1.3 mg · h/L after intravenous dosing, resulting in a mean oral bioavailability of 88.32% [90% confidence interval (CI) 85.64%-91.08%].",Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987240/),[h·mg] / [l],52.3,127643,DB00218,Moxifloxacin
,21987240,oral bioavailability,"The mean areas under the plasma concentration time curve extrapolated to infinity (AUC(∞)) were 46.2 ± 1.4 mg · h/L after oral dosing and 52.3 ± 1.3 mg · h/L after intravenous dosing, resulting in a mean oral bioavailability of 88.32% [90% confidence interval (CI) 85.64%-91.08%].",Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987240/),%,88.32,127644,DB00218,Moxifloxacin
,32935460,tmax,Solriamfetol median tmax was 2-3 hours; exposure was dose-proportional.,"A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935460/),h,2-3,128175,DB00218,Moxifloxacin
,16377219,clearance (Cl),The plasma moxifloxacin clearance (Cl) was mean standard deviation (+/-SD) 0.49+/-0.14 L/h kg.,Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377219/),[l] / [h·kg],0.49,128502,DB00218,Moxifloxacin
,16377219,apparent volume of distribution (V(z)),The apparent volume of distribution (V(z)) was 0.83+/-0.20 L/kg.,Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377219/),[l] / [kg],0.83,128503,DB00218,Moxifloxacin
,16377219,terminal half-life (t(1/2 lambda z)),The terminal half-life (t(1/2 lambda z)) was 1.31+/-0.64 h.,Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377219/),h,1.31,128504,DB00218,Moxifloxacin
,11352442,area under the concentration-time curve from zero to infinity (AUCinfinity),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),[mg] / [h·l],12.9,131625,DB00218,Moxifloxacin
,11352442,area under the concentration-time curve from zero to infinity (AUCinfinity),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),[mg] / [h·l],32.2,131626,DB00218,Moxifloxacin
,11352442,relative bioavailability,"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),%,40,131627,DB00218,Moxifloxacin
,11352442,time to maximum concentration (tmax),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),h,3.5,131628,DB00218,Moxifloxacin
,11352442,time to maximum concentration (tmax),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),h,1.0,131629,DB00218,Moxifloxacin
,33468465,half-lives,"Within each interval, we had an arm where half-lives of 12, 8, and 4 h were simulated.",Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33468465/),h,12,131646,DB00218,Moxifloxacin
,33468465,half-lives,"Within each interval, we had an arm where half-lives of 12, 8, and 4 h were simulated.",Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33468465/),h,8,131647,DB00218,Moxifloxacin
,33468465,half-lives,"Within each interval, we had an arm where half-lives of 12, 8, and 4 h were simulated.",Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33468465/),h,4,131648,DB00218,Moxifloxacin
,15908243,clearance (Cl),The plasma moxifloxacin clearance (Cl) for the IV route was 0.43 +/- 0.02 L/kg (mean +/- SE).,Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),[l] / [kg],0.43,132604,DB00218,Moxifloxacin
,15908243,steady-state volume of distribution (Vss),The steady-state volume of distribution (Vss) was 0.79 +/- 0.08 L/kg.,Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),[l] / [kg],0.79,132605,DB00218,Moxifloxacin
,15908243,terminal half-life (t1/2lambdaz),"The terminal half-life (t1/2lambdaz) was 1.94 +/- 0.41 and 2.98 +/- 0.48 h after IV and SC administration, respectively.",Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),h,1.94,132606,DB00218,Moxifloxacin
,15908243,terminal half-life (t1/2lambdaz),"The terminal half-life (t1/2lambdaz) was 1.94 +/- 0.41 and 2.98 +/- 0.48 h after IV and SC administration, respectively.",Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),h,2.98,132607,DB00218,Moxifloxacin
,15908243,absolute bioavailability,The absolute bioavailability was 96.87 +/- 10.27% after SC administration.,Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),%,96.87,132608,DB00218,Moxifloxacin
<,15908243,MIC,"From these data, it appears that a 5 mg/kg SC dose of moxifloxacin would be effective in lactating goats against bacterial isolates with MIC < or = 0.20 microg/mL in plasma and MIC < or = 0.40 microg/mL in milk.",Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),[μg] / [ml],0.20,132609,DB00218,Moxifloxacin
<,15908243,MIC,"From these data, it appears that a 5 mg/kg SC dose of moxifloxacin would be effective in lactating goats against bacterial isolates with MIC < or = 0.20 microg/mL in plasma and MIC < or = 0.40 microg/mL in milk.",Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908243/),[μg] / [ml],0.40,132610,DB00218,Moxifloxacin
,11062191,T:1/2,"With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12.1 h) and levofloxacin (T:(1/2) = 6.8 h) were simulated.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),h,12.1,133707,DB00218,Moxifloxacin
,11062191,T:(1/2),"With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12.1 h) and levofloxacin (T:(1/2) = 6.8 h) were simulated.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),h,6.8,133708,DB00218,Moxifloxacin
,11062191,ratios of area under the concentration-time curve (AUC) to the MIC,The respective eight-fold ranges of the ratios of area under the concentration-time curve (AUC) to the MIC were 58-475 and 114-934.,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,58-475,133709,DB00218,Moxifloxacin
,11062191,ratios of area under the concentration-time curve (AUC) to the MIC,The respective eight-fold ranges of the ratios of area under the concentration-time curve (AUC) to the MIC were 58-475 and 114-934.,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,114-934,133710,DB00218,Moxifloxacin
,11062191,AUC/MIC ratios,"The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,80,133711,DB00218,Moxifloxacin
,11062191,AUC/MIC ratios,"The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,130,133712,DB00218,Moxifloxacin
,11062191,MIC,The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin).,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),[mg] / [l],0.41,133713,DB00218,Moxifloxacin
,11062191,MIC,The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin).,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),[mg] / [l],0.35,133714,DB00218,Moxifloxacin
,11062191,I:(E),"To provide an 'acceptable' I:(E) = 200 (log cfu/mL)*h, the D:(24)s of moxifloxacin for all three organisms were much lower (150, 30 and 60 mg, respectively) than the clinically proposed 400 mg dose.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,200,133715,DB00218,Moxifloxacin
,16857688,AUC/MIC,It appears that the critical AUC/MIC necessary to prevent the acquisition of resistance for levofloxacin is 200 and approximately 400 for moxifloxacin.,Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16857688/),,200,134702,DB00218,Moxifloxacin
,16857688,AUC/MIC,It appears that the critical AUC/MIC necessary to prevent the acquisition of resistance for levofloxacin is 200 and approximately 400 for moxifloxacin.,Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16857688/),,400,134703,DB00218,Moxifloxacin
,19389877,Ba,"Moxifloxacin significantly increases QT and corrects QT intervals (QTc) compared with placebo in both studies (eg, Bazett-corrected QTc of 11.90 milliseconds [95% confidence interval, 2.68 to 21.11] and 5.06 [95% confidence interval, -2.26 to 12.38]).","Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19389877/),,11.90,135256,DB00218,Moxifloxacin
,14534522,clearance,"The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14.3 L/h (25%); central distribution volume, 62.9 L (14%); intercompartmental clearance, 27.2 L/h (36%); peripheral distribution volume; 71 L (32%); fraction of moxifloxacin clearance to bronchial secretions, 0.11 (range, 0.06-0.16); and elimination rate constant for bronchial secretions, 1.7 h(-1) (40%).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),[l] / [h],14.3,135357,DB00218,Moxifloxacin
,14534522,central distribution volume,"The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14.3 L/h (25%); central distribution volume, 62.9 L (14%); intercompartmental clearance, 27.2 L/h (36%); peripheral distribution volume; 71 L (32%); fraction of moxifloxacin clearance to bronchial secretions, 0.11 (range, 0.06-0.16); and elimination rate constant for bronchial secretions, 1.7 h(-1) (40%).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),l,62.9,135358,DB00218,Moxifloxacin
,14534522,intercompartmental clearance,"The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14.3 L/h (25%); central distribution volume, 62.9 L (14%); intercompartmental clearance, 27.2 L/h (36%); peripheral distribution volume; 71 L (32%); fraction of moxifloxacin clearance to bronchial secretions, 0.11 (range, 0.06-0.16); and elimination rate constant for bronchial secretions, 1.7 h(-1) (40%).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),[l] / [h],27.2,135359,DB00218,Moxifloxacin
,14534522,peripheral distribution volume,"The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14.3 L/h (25%); central distribution volume, 62.9 L (14%); intercompartmental clearance, 27.2 L/h (36%); peripheral distribution volume; 71 L (32%); fraction of moxifloxacin clearance to bronchial secretions, 0.11 (range, 0.06-0.16); and elimination rate constant for bronchial secretions, 1.7 h(-1) (40%).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),l,71,135360,DB00218,Moxifloxacin
,14534522,fraction of moxifloxacin clearance to,"The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14.3 L/h (25%); central distribution volume, 62.9 L (14%); intercompartmental clearance, 27.2 L/h (36%); peripheral distribution volume; 71 L (32%); fraction of moxifloxacin clearance to bronchial secretions, 0.11 (range, 0.06-0.16); and elimination rate constant for bronchial secretions, 1.7 h(-1) (40%).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),,0.11,135361,DB00218,Moxifloxacin
,14534522,elimination rate constant,"The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14.3 L/h (25%); central distribution volume, 62.9 L (14%); intercompartmental clearance, 27.2 L/h (36%); peripheral distribution volume; 71 L (32%); fraction of moxifloxacin clearance to bronchial secretions, 0.11 (range, 0.06-0.16); and elimination rate constant for bronchial secretions, 1.7 h(-1) (40%).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),1/[h],1.7,135362,DB00218,Moxifloxacin
,14534522,plasma terminal half-life,The plasma terminal half-life was 6.7 hours.,Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),h,6.7,135363,DB00218,Moxifloxacin
,14534522,bronchial-to-plasma exposure ratio,"The bronchial-to-plasma exposure ratio was 1.0 (range, 0.6-2.0).",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),,1.0,135364,DB00218,Moxifloxacin
,14534522,minimum inhibitory concentration (MIC(90)),"With a conservative 90% minimum inhibitory concentration (MIC(90)) of 0.25 mg/L, the maximum concentration/MIC(90) ratios were higher than 10 and the area under the curve/MIC(90) ratios were roughly 100 for plasma and bronchial secretions.",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),[mg] / [l],0.25,135365,DB00218,Moxifloxacin
higher,14534522,maximum concentration/MIC(90) ratios,"With a conservative 90% minimum inhibitory concentration (MIC(90)) of 0.25 mg/L, the maximum concentration/MIC(90) ratios were higher than 10 and the area under the curve/MIC(90) ratios were roughly 100 for plasma and bronchial secretions.",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),,10,135366,DB00218,Moxifloxacin
,14534522,area under the curve/MIC(90) ratios,"With a conservative 90% minimum inhibitory concentration (MIC(90)) of 0.25 mg/L, the maximum concentration/MIC(90) ratios were higher than 10 and the area under the curve/MIC(90) ratios were roughly 100 for plasma and bronchial secretions.",Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534522/),,100,135367,DB00218,Moxifloxacin
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,5.7,136991,DB00218,Moxifloxacin
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,3.9,136992,DB00218,Moxifloxacin
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,2.9,136993,DB00218,Moxifloxacin
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,1.1,136994,DB00218,Moxifloxacin
,17891537,delta delta QTcSS,"Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,10.5,136995,DB00218,Moxifloxacin
,17891537,delta delta QTcSS,"Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),m,13.4,136996,DB00218,Moxifloxacin
,20202656,elimination half life (t(1/2beta)),"Following intravenous administration, the elimination half life (t(1/2beta)), volume of distribution (Vd(area)) and total body clearance were 2.69+/-0.14 h, 1.43+/-0.08 L kg(-1) and 371.2+/-11.2 ml kg(-1)h(-1), respectively.",Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),h,2.69,140591,DB00218,Moxifloxacin
,20202656,volume of distribution (Vd(area)),"Following intravenous administration, the elimination half life (t(1/2beta)), volume of distribution (Vd(area)) and total body clearance were 2.69+/-0.14 h, 1.43+/-0.08 L kg(-1) and 371.2+/-11.2 ml kg(-1)h(-1), respectively.",Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),[l] / [kg],1.43,140592,DB00218,Moxifloxacin
,20202656,total body clearance,"Following intravenous administration, the elimination half life (t(1/2beta)), volume of distribution (Vd(area)) and total body clearance were 2.69+/-0.14 h, 1.43+/-0.08 L kg(-1) and 371.2+/-11.2 ml kg(-1)h(-1), respectively.",Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),[ml] / [kg],371.2,140593,DB00218,Moxifloxacin
,20202656,absorption half life (t(1/2ka)),"Following intramuscular administration, the absorption half life (t(1/2ka)) was 0.83+/-0.20 h.",Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),h,0.83,140594,DB00218,Moxifloxacin
,20202656,systemic bioavailability (F),The systemic bioavailability (F) of moxifloxacin in buffalo calves was 80.0+/-4.08%.,Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),%,80.0,140595,DB00218,Moxifloxacin
less,20202656,Urinary excretion,Urinary excretion of moxifloxacin was less than 14% after 24h of administration of drug.,Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),%,14,140596,DB00218,Moxifloxacin
,20202656,binding,In vitro binding of moxifloxacin to plasma proteins of buffalo calves was 28.4+/-3.77%.,Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),%,28.4,140597,DB00218,Moxifloxacin
<,20202656,MIC,"From the data of surrogate markers (AUC/MIC, C(max)/MIC), it was determined in the buffalo calves that when administered by intravenous or intramuscular route at 5 mg kg(-1), moxifloxacin is likely to be effective against bacterial isolates with MIC< or =0.1 microg ml(-1).",Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202656/),[μg] / [ml],0.1,140598,DB00218,Moxifloxacin
,11352441,area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],35.5,142404,DB00218,Moxifloxacin
,11352441,area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],34.3,142405,DB00218,Moxifloxacin
,11352441,relative bioavailability,"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,103,142406,DB00218,Moxifloxacin
,11352441,maximum plasma concentration (Cmax),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.98,142407,DB00218,Moxifloxacin
,11352441,maximum plasma concentration (Cmax),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.76,142408,DB00218,Moxifloxacin
,11352441,AUCinfinity,"When moxifloxacin was given simultaneously with Maalox 70, AUCinfinity ( 14.7 mg/L x h) and Cmax (1.00 mg/L) were reduced by approximately 60%.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],14.7,142409,DB00218,Moxifloxacin
,11352441,Cmax,"When moxifloxacin was given simultaneously with Maalox 70, AUCinfinity ( 14.7 mg/L x h) and Cmax (1.00 mg/L) were reduced by approximately 60%.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],1.00,142410,DB00218,Moxifloxacin
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],28.0,142411,DB00218,Moxifloxacin
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],26.7,142412,DB00218,Moxifloxacin
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],34.3,142413,DB00218,Moxifloxacin
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,9.4,142414,DB00218,Moxifloxacin
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,9.3,142415,DB00218,Moxifloxacin
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,12.3,142416,DB00218,Moxifloxacin
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.55,142417,DB00218,Moxifloxacin
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.38,142418,DB00218,Moxifloxacin
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.57,142419,DB00218,Moxifloxacin
,11352441,bioavailabilities,"The mean bioavailabilities corrected for the elimination rate constants (lambdaz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70 may interfere with the gastrointestinal recirculation of moxifloxacin.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,101,142420,DB00218,Moxifloxacin
,11352441,bioavailabilities,"The mean bioavailabilities corrected for the elimination rate constants (lambdaz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70 may interfere with the gastrointestinal recirculation of moxifloxacin.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,98,142421,DB00218,Moxifloxacin
,16189103,area under the concentration-time curve (AUC)/MIC ratios,"Initially, a dose-ranging study with area under the concentration-time curve (AUC)/MIC ratios of 6.7 to 890 was used to investigate the effect of anaerobic conditions on the AUC/MIC antibacterial effect (ABE) relationship with Escherichia coli.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,6.7 to 890,143013,DB00218,Moxifloxacin
,16189103,AUC/MIC ratios,"The AUC/MIC ratios for 50% and 90% effects, using a log CFU drop at 24 h as the antibacterial effect measure, were 34 and 59, respectively, aerobic and 54 and 96, respectively, anaerobic.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,34,143014,DB00218,Moxifloxacin
,16189103,AUC/MIC ratios,"The AUC/MIC ratios for 50% and 90% effects, using a log CFU drop at 24 h as the antibacterial effect measure, were 34 and 59, respectively, aerobic and 54 and 96, respectively, anaerobic.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,59,143015,DB00218,Moxifloxacin
,16189103,AUC/MIC ratios,"The AUC/MIC ratios for 50% and 90% effects, using a log CFU drop at 24 h as the antibacterial effect measure, were 34 and 59, respectively, aerobic and 54 and 96, respectively, anaerobic.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,54,143016,DB00218,Moxifloxacin
,16189103,AUC/MIC ratios,"The AUC/MIC ratios for 50% and 90% effects, using a log CFU drop at 24 h as the antibacterial effect measure, were 34 and 59, respectively, aerobic and 54 and 96, respectively, anaerobic.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,96,143017,DB00218,Moxifloxacin
,16189103,AUC/MIC ratios,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,9,143018,DB00218,Moxifloxacin
,16189103,AUC/MICs,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,10.5,143019,DB00218,Moxifloxacin
,16189103,AUC/MICs,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,25.7,143020,DB00218,Moxifloxacin
,16189103,AUC/MICs,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,8.6,143021,DB00218,Moxifloxacin
,16189103,AUC/MICs,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,16.2,143022,DB00218,Moxifloxacin
,16189103,AUC/MICs,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,7.3,143023,DB00218,Moxifloxacin
,16189103,AUC/MICs,"Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis, they were 10.5 and 25.7, respectively; for C. perfringens, they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4.",Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,17.4,143024,DB00218,Moxifloxacin
,16189103,AUC/MIC,Monte Carlo simulations using human serum AUC data and an AUC/MIC anaerobe target of 7.5 suggests a >90% target achievement at MICs of <2 mg/liter.,Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),,7.5,143025,DB00218,Moxifloxacin
<,16189103,MICs,Monte Carlo simulations using human serum AUC data and an AUC/MIC anaerobe target of 7.5 suggests a >90% target achievement at MICs of <2 mg/liter.,Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189103/),[mg] / [l],2,143026,DB00218,Moxifloxacin
,26268973,flow rate,"The chromatographic separation was accomplished by using an Agilent Extend C18 column (4.6×250 mm; 5 μm) with a mobile phase consisting of acetonitrile and distilled water (30:70, v/v) containing 5 mM ammonium formate (pH=8.82 adjusted by ammonia) at a flow rate of 1.0 mL/min.",A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26268973/),[ml] / [min],1.0,144163,DB00218,Moxifloxacin
,26268973,m/,A triple quadrupole tandem mass spectrometer with electrospray ionization source was used as a detector operated by multiple reaction monitoring in the negative-ion mode with m/z 480.2/436.3.,A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26268973/),,480,144164,DB00218,Moxifloxacin
,24741326,Maximum observed,"Maximum observed QTcF change was 4.15 ms (90% CI, 0.94 to 7.36) at Hour 3.","A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741326/),ms,4.15,144670,DB00218,Moxifloxacin
,24741326,maximum plasma concentration,"APF530 SC pharmacokinetics were as expected, with slow absorption (maximum plasma concentration 35.8 ng/mL, median time to maximum plasma concentration 11.1 hours) and slow elimination (mean half-life 18.6 hours; systemic clearance 20.2 L/hour) of granisetron versus the expected early peak concentration and elimination of granisetron IV.","A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741326/),[ng] / [ml],35.8,144671,DB00218,Moxifloxacin
,24741326,time to maximum plasma concentration,"APF530 SC pharmacokinetics were as expected, with slow absorption (maximum plasma concentration 35.8 ng/mL, median time to maximum plasma concentration 11.1 hours) and slow elimination (mean half-life 18.6 hours; systemic clearance 20.2 L/hour) of granisetron versus the expected early peak concentration and elimination of granisetron IV.","A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741326/),h,11.1,144672,DB00218,Moxifloxacin
,24741326,half-life,"APF530 SC pharmacokinetics were as expected, with slow absorption (maximum plasma concentration 35.8 ng/mL, median time to maximum plasma concentration 11.1 hours) and slow elimination (mean half-life 18.6 hours; systemic clearance 20.2 L/hour) of granisetron versus the expected early peak concentration and elimination of granisetron IV.","A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741326/),h,18.6,144673,DB00218,Moxifloxacin
,24741326,systemic clearance,"APF530 SC pharmacokinetics were as expected, with slow absorption (maximum plasma concentration 35.8 ng/mL, median time to maximum plasma concentration 11.1 hours) and slow elimination (mean half-life 18.6 hours; systemic clearance 20.2 L/hour) of granisetron versus the expected early peak concentration and elimination of granisetron IV.","A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741326/),[l] / [h],20.2,144674,DB00218,Moxifloxacin
,11352437,Elimination half-life,Elimination half-life averaged 12 to 13 hours for the 3 groups.,The influence of age and gender on the pharmacokinetics of moxifloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),h,12 to 13,145225,DB00218,Moxifloxacin
,11352437,Cmax/MIC,"These assessments indicated that, given the linear pharmacokinetics of moxifloxacin previously demonstrated, a dose of 400mg would produce mean Cmax/MIC values in the different subgroups ranging from 10.4 to 15.4 for an MIC of 0.25, and 20.8 to 30.8 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,10.4 to 15.4,145226,DB00218,Moxifloxacin
,11352437,Cmax/MIC,"These assessments indicated that, given the linear pharmacokinetics of moxifloxacin previously demonstrated, a dose of 400mg would produce mean Cmax/MIC values in the different subgroups ranging from 10.4 to 15.4 for an MIC of 0.25, and 20.8 to 30.8 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,20.8 to 30.8,145227,DB00218,Moxifloxacin
,11352437,MIC,"These assessments indicated that, given the linear pharmacokinetics of moxifloxacin previously demonstrated, a dose of 400mg would produce mean Cmax/MIC values in the different subgroups ranging from 10.4 to 15.4 for an MIC of 0.25, and 20.8 to 30.8 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,0.25,145228,DB00218,Moxifloxacin
,11352437,MIC,"These assessments indicated that, given the linear pharmacokinetics of moxifloxacin previously demonstrated, a dose of 400mg would produce mean Cmax/MIC values in the different subgroups ranging from 10.4 to 15.4 for an MIC of 0.25, and 20.8 to 30.8 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,20.8 to 30.8,145229,DB00218,Moxifloxacin
,11352437,MIC,"These assessments indicated that, given the linear pharmacokinetics of moxifloxacin previously demonstrated, a dose of 400mg would produce mean Cmax/MIC values in the different subgroups ranging from 10.4 to 15.4 for an MIC of 0.25, and 20.8 to 30.8 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,0.125,145230,DB00218,Moxifloxacin
,11352437,AUC/MIC ratios,"The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,112 to 158,145231,DB00218,Moxifloxacin
,11352437,AUC/MIC ratios,"The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,0.25,145232,DB00218,Moxifloxacin
,11352437,AUC/MIC ratios,"The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,224 to 314,145233,DB00218,Moxifloxacin
,11352437,MIC,"The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,0.25,145234,DB00218,Moxifloxacin
,11352437,MIC,"The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,224 to 314,145235,DB00218,Moxifloxacin
,11352437,MIC,"The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,0.125,145236,DB00218,Moxifloxacin
,11352437,AUC/MIC,"The accepted target values of AUC/MIC and Cmax/MIC for quinolones are 125 and 10, respectively.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,125,145237,DB00218,Moxifloxacin
,11352437,Cmax/MIC,"The accepted target values of AUC/MIC and Cmax/MIC for quinolones are 125 and 10, respectively.",The influence of age and gender on the pharmacokinetics of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352437/),,10,145238,DB00218,Moxifloxacin
,26572474,release,"Similarly, moxifloxacin release from HEC-moxifloxacin conjugates was 15 and 39% at pH 1.2 and 7.4, respectively.",Extended release and enhanced bioavailability of moxifloxacin conjugated with hydrophilic cellulose ethers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572474/),%,15,145562,DB00218,Moxifloxacin
,26572474,release,"Similarly, moxifloxacin release from HEC-moxifloxacin conjugates was 15 and 39% at pH 1.2 and 7.4, respectively.",Extended release and enhanced bioavailability of moxifloxacin conjugated with hydrophilic cellulose ethers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572474/),%,39,145563,DB00218,Moxifloxacin
less,9824247,Total run time,Total run time is less than 7 min using a 27 cm capillary on commercial instrumentation.,Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824247/),min,7,145675,DB00218,Moxifloxacin
less,9824247,analysis time,"An analysis time of less than 1 min was shown to be possible, however it could not be used routinely since appropriate instrumentation was not available.",Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824247/),min,1,145676,DB00218,Moxifloxacin
,20097298,QTc,"Moxifloxacin at 30 and 100 mg/kg elicited dose-dependent increases in QTc of 14.0+/-3.6 and 35.0+/-6.2 ms, respectively, with associated total moxifloxacin C(max) values of 6.5+/-0.5 and 16.5+/-1.6 microg/mL, respectively.",Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097298/),ms,14.0,146667,DB00218,Moxifloxacin
,20097298,QTc,"Moxifloxacin at 30 and 100 mg/kg elicited dose-dependent increases in QTc of 14.0+/-3.6 and 35.0+/-6.2 ms, respectively, with associated total moxifloxacin C(max) values of 6.5+/-0.5 and 16.5+/-1.6 microg/mL, respectively.",Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097298/),ms,35.0,146668,DB00218,Moxifloxacin
,20097298,C(max),"Moxifloxacin at 30 and 100 mg/kg elicited dose-dependent increases in QTc of 14.0+/-3.6 and 35.0+/-6.2 ms, respectively, with associated total moxifloxacin C(max) values of 6.5+/-0.5 and 16.5+/-1.6 microg/mL, respectively.",Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097298/),[μg] / [ml],6.5,146669,DB00218,Moxifloxacin
,20097298,C(max),"Moxifloxacin at 30 and 100 mg/kg elicited dose-dependent increases in QTc of 14.0+/-3.6 and 35.0+/-6.2 ms, respectively, with associated total moxifloxacin C(max) values of 6.5+/-0.5 and 16.5+/-1.6 microg/mL, respectively.",Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097298/),[μg] / [ml],16.5,146670,DB00218,Moxifloxacin
,20097298,QTc,"From the PK/PD relationship, the plasma concentration which would attain QTc of 5 to 10 ms was estimated to be 1.67-3.73 microg/mL.",Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097298/),,5 to 10,146671,DB00218,Moxifloxacin
,20097298,QTc,The results were consistent with typical clinical trial results (QTc of 6.6-14.8 ms at 2.5-3.5 microg/mL).,Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097298/),ms,6.6-14.8,146672,DB00218,Moxifloxacin
≥,31111505,unbound area under the plasma concentration-time curve/minimum inhibitory concentration (MIC) targets,"PK/PD target attainment was assessed in both matrices using unbound area under the plasma concentration-time curve/minimum inhibitory concentration (MIC) targets of ≥30 and ≥100, for gram-positive and gram-negative pathogens, respectively.",Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),,30,146780,DB00218,Moxifloxacin
≥,31111505,unbound area under the plasma concentration-time curve/minimum inhibitory concentration (MIC) targets,"PK/PD target attainment was assessed in both matrices using unbound area under the plasma concentration-time curve/minimum inhibitory concentration (MIC) targets of ≥30 and ≥100, for gram-positive and gram-negative pathogens, respectively.",Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),,100,146781,DB00218,Moxifloxacin
,31111505,area under the plasma concentration-time curve,Median (10th-90th percentile) area under the plasma concentration-time curve values after the third dose were 28.9 mg · h/L (18.6-42.0) in serum and 55.8 mg · h/L (23.7-81.4) in pancreatic juice.,Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[h·mg] / [l],28.9,146782,DB00218,Moxifloxacin
,31111505,area under the plasma concentration-time curve,Median (10th-90th percentile) area under the plasma concentration-time curve values after the third dose were 28.9 mg · h/L (18.6-42.0) in serum and 55.8 mg · h/L (23.7-81.4) in pancreatic juice.,Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[h·mg] / [l],55.8,146783,DB00218,Moxifloxacin
≥,31111505,Target attainment rate,Target attainment rate for the intraoperatively isolated bacterial strains was ≥0.88 after the third MXF dose.,Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),,0.88,146784,DB00218,Moxifloxacin
≤,31111505,MIC,"For gram-negatives, high probability of target attainment ≥0.84 was observed in serum for MIC ≤ 0.125 mg/L and in pancreatic juice for MIC ≤ 0.25 mg/L.",Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[mg] / [l],0.125,146785,DB00218,Moxifloxacin
≤,31111505,MIC,"For gram-negatives, high probability of target attainment ≥0.84 was observed in serum for MIC ≤ 0.125 mg/L and in pancreatic juice for MIC ≤ 0.25 mg/L.",Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[mg] / [l],0.25,146786,DB00218,Moxifloxacin
≤,31111505,MIC,"For gram-positives, the probability of target attainment was 0.84-1 in serum for MIC ≤ 0.5 mg/L and in pancreatic juice for MIC ≤ 1 mg/L.",Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[mg] / [l],0.5,146787,DB00218,Moxifloxacin
≤,31111505,MIC,"For gram-positives, the probability of target attainment was 0.84-1 in serum for MIC ≤ 0.5 mg/L and in pancreatic juice for MIC ≤ 1 mg/L.",Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[mg] / [l],1,146788,DB00218,Moxifloxacin
≤,31111505,MIC,The PK/PD analysis indicated that treatment of pancreatic infections by isolates with MIC ≤ 0.25 mg/L (gram-negative) and ≤1 mg/L (gram-positive) should be evaluated in further studies.,Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[mg] / [l],0.25,146789,DB00218,Moxifloxacin
≤,31111505,MIC,The PK/PD analysis indicated that treatment of pancreatic infections by isolates with MIC ≤ 0.25 mg/L (gram-negative) and ≤1 mg/L (gram-positive) should be evaluated in further studies.,Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111505/),[mg] / [l],1,146790,DB00218,Moxifloxacin
,16476886,sampling times,"Mean +/- SD sampling times after oral administration of the second moxifloxacin tablet for plasma, vitreous, and aqueous were 2.94 +/- 0.81 hours, 3.77 +/- 0.92 hours, and 3.71 +/- 0.89 hours, respectively.",Vitreous and aqueous penetration of orally administered moxifloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476886/),h,2.94,148647,DB00218,Moxifloxacin
,16476886,sampling times,"Mean +/- SD sampling times after oral administration of the second moxifloxacin tablet for plasma, vitreous, and aqueous were 2.94 +/- 0.81 hours, 3.77 +/- 0.92 hours, and 3.71 +/- 0.89 hours, respectively.",Vitreous and aqueous penetration of orally administered moxifloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476886/),h,3.77,148648,DB00218,Moxifloxacin
,16476886,sampling times,"Mean +/- SD sampling times after oral administration of the second moxifloxacin tablet for plasma, vitreous, and aqueous were 2.94 +/- 0.81 hours, 3.77 +/- 0.92 hours, and 3.71 +/- 0.89 hours, respectively.",Vitreous and aqueous penetration of orally administered moxifloxacin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476886/),h,3.71,148649,DB00218,Moxifloxacin
,17699357,blood,Treatment lasted 8 h; blood and dialysate flow rates were 160 ml/min.,Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699357/),[ml] / [min],160,149543,DB00218,Moxifloxacin
,17699357,dialysate flow rates,Treatment lasted 8 h; blood and dialysate flow rates were 160 ml/min.,Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699357/),[ml] / [min],160,149544,DB00218,Moxifloxacin
,25600294,V1,"For a 70 kg patient V1 was 68.1 L (interindividual variability, CV: 27.4%), V2 44.6 L, and CL 12.1 L/h (25.6%).",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),l,68.1,150950,DB00218,Moxifloxacin
,25600294,V2,"For a 70 kg patient V1 was 68.1 L (interindividual variability, CV: 27.4%), V2 44.6 L, and CL 12.1 L/h (25.6%).",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),l,44.6,150951,DB00218,Moxifloxacin
,25600294,CL,"For a 70 kg patient V1 was 68.1 L (interindividual variability, CV: 27.4%), V2 44.6 L, and CL 12.1 L/h (25.6%).",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),[l] / [h],12.1,150952,DB00218,Moxifloxacin
≥,25600294,fAUC/MIC targets,"Simulations were performed to calculate the probability of target attainment (PTA) for Gram-positive and Gram-negative pathogens with fAUC/MIC targets of ≥30 and ≥100, respectively.",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),,30,150953,DB00218,Moxifloxacin
≥,25600294,fAUC/MIC targets,"Simulations were performed to calculate the probability of target attainment (PTA) for Gram-positive and Gram-negative pathogens with fAUC/MIC targets of ≥30 and ≥100, respectively.",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),,100,150954,DB00218,Moxifloxacin
,25600294,PTA,"PTA was 0.68-1 for susceptible (MIC ≤0.5 mg/L according to EUCAST) Gram-positive, but <0.25 for Gram-negative pathogens with MIC ≥0.25 mg/L.",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),,0,150955,DB00218,Moxifloxacin
≤,25600294,PTA,"PTA was 0.68-1 for susceptible (MIC ≤0.5 mg/L according to EUCAST) Gram-positive, but <0.25 for Gram-negative pathogens with MIC ≥0.25 mg/L.",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),[mg] / [l],0.5,150956,DB00218,Moxifloxacin
≤,25600294,MIC,"PTA was 0.68-1 for susceptible (MIC ≤0.5 mg/L according to EUCAST) Gram-positive, but <0.25 for Gram-negative pathogens with MIC ≥0.25 mg/L.",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),[mg] / [l],0.5,150957,DB00218,Moxifloxacin
≥,25600294,MIC,"PTA was 0.68-1 for susceptible (MIC ≤0.5 mg/L according to EUCAST) Gram-positive, but <0.25 for Gram-negative pathogens with MIC ≥0.25 mg/L.",Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600294/),[mg] / [l],0.25,150958,DB00218,Moxifloxacin
,16227840,C(max),"For group 1, the mean +/- SD C(max) was 1.50 +/- 0.75 microg/mL and occurred at 0.5 hour after dosing.",Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227840/),[μg] / [ml],1.50,151689,DB00218,Moxifloxacin
,16227840,C(max),The mean C(max) for group 2 was 1.74 +/- 0.66 microg/mL and was reached at 1 to 2 hours.,Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227840/),[μg] / [ml],1.74,151690,DB00218,Moxifloxacin
,16227840,AUC(0-3h),"Mean AUC(0-3h) for groups 1 and 2 were 3.16 +/- 0.29 and 4.41 +/- 0.48 microg.h/mL, respectively.",Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227840/),[h·μg] / [ml],3.16,151691,DB00218,Moxifloxacin
,16227840,AUC(0-3h),"Mean AUC(0-3h) for groups 1 and 2 were 3.16 +/- 0.29 and 4.41 +/- 0.48 microg.h/mL, respectively.",Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227840/),[h·μg] / [ml],4.41,151692,DB00218,Moxifloxacin
,12615869,MICs,"The MICs of moxifloxacin for S. pneumoniae and P. multocida were 0.4 and 0.05 mg/L, respectively.",Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[mg] / [l],0.4,152765,DB00218,Moxifloxacin
,12615869,MICs,"The MICs of moxifloxacin for S. pneumoniae and P. multocida were 0.4 and 0.05 mg/L, respectively.",Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[mg] / [l],0.05,152766,DB00218,Moxifloxacin
,12615869,serum,"Mean serum and pleural empyema peak moxifloxacin levels (following the 25 mg/kg dose) were 7.6 (+/-3.2) and 4.8 (+/-2.5) mg/L, respectively.",Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[mg] / [l],7.6,152767,DB00218,Moxifloxacin
,12615869,peak moxifloxacin levels,"Mean serum and pleural empyema peak moxifloxacin levels (following the 25 mg/kg dose) were 7.6 (+/-3.2) and 4.8 (+/-2.5) mg/L, respectively.",Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[mg] / [l],4.8,152768,DB00218,Moxifloxacin
,12615869,Serum,"Serum and pleural empyema half-lives were approximately 1.5 and approximately 6 h, respectively.",Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),h,1.5,152769,DB00218,Moxifloxacin
,12615869,half-lives,"Serum and pleural empyema half-lives were approximately 1.5 and approximately 6 h, respectively.",Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),h,6,152770,DB00218,Moxifloxacin
,12615869,AUC(1-12),Serum AUC(1-12) was 29.4 (+/-6.8) mg.h/L and serum area under the inhibitory concentration curve (AUIC) was 73.5 mg.h/L.,Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[h·mg] / [l],29.4,152771,DB00218,Moxifloxacin
,12615869,area under the inhibitory concentration curve (AUIC),Serum AUC(1-12) was 29.4 (+/-6.8) mg.h/L and serum area under the inhibitory concentration curve (AUIC) was 73.5 mg.h/L.,Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[h·mg] / [l],73.5,152772,DB00218,Moxifloxacin
,12615869,AUC(1-12),Pleural empyema AUC(1-12) was 34.3 (+/-11.7) mg/L and pleural empyema AUIC was 85.8 mg.h/L.,Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[mg] / [l],34.3,152773,DB00218,Moxifloxacin
,12615869,AUIC,Pleural empyema AUC(1-12) was 34.3 (+/-11.7) mg/L and pleural empyema AUIC was 85.8 mg.h/L.,Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615869/),[h·mg] / [l],85.8,152774,DB00218,Moxifloxacin
,27067317,minimum bactericidal concentration,"The minimum bactericidal concentration and MIC were 8 and 2 mg/liter, respectively, in our M. abscessus strain, suggesting bactericidal activity.",Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),[mg] / [l],8,152790,DB00218,Moxifloxacin
,27067317,MIC,"The minimum bactericidal concentration and MIC were 8 and 2 mg/liter, respectively, in our M. abscessus strain, suggesting bactericidal activity.",Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),[mg] / [l],2,152791,DB00218,Moxifloxacin
,27067317,elimination rate constant (kel),Measurement of the moxifloxacin concentrations in each hollow-fiber system revealed an elimination rate constant (kel) of 0.11 ± 0.05 h(-1) (mean ± standard deviation) (half-life of 9.8 h).,Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),1/[h],0.11,152792,DB00218,Moxifloxacin
,27067317,half-life,Measurement of the moxifloxacin concentrations in each hollow-fiber system revealed an elimination rate constant (kel) of 0.11 ± 0.05 h(-1) (mean ± standard deviation) (half-life of 9.8 h).,Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),h,9.8,152793,DB00218,Moxifloxacin
,27067317,Emax,"Inhibitory sigmoid maximal effect (Emax) modeling revealed that the highest Emax was 3.15 ± 1.84 log10 CFU/ml on day 3, and the exposure mediating 50% of Emax (EC50) was a 0- to 24-h area under the concentration time curve (AUC0-24)-to-MIC ratio of 41.99 ± 31.78 (r(2) = 0.99).",Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),[cfu·log10] / [ml],3.15,152794,DB00218,Moxifloxacin
,27067317,area under the concentration time curve (AUC0-24)-to-MIC ratio,"Inhibitory sigmoid maximal effect (Emax) modeling revealed that the highest Emax was 3.15 ± 1.84 log10 CFU/ml on day 3, and the exposure mediating 50% of Emax (EC50) was a 0- to 24-h area under the concentration time curve (AUC0-24)-to-MIC ratio of 41.99 ± 31.78 (r(2) = 0.99).",Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),,41.99,152795,DB00218,Moxifloxacin
,27067317,AUC0-24/MIC ratio,The EC80 was an AUC0-24/MIC ratio of 102.11.,Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),,102.11,152796,DB00218,Moxifloxacin
>,27067317,MIC,"There was regrowth beyond day 3 in all doses, with replacement by a resistant subpopulation that had an MIC of >32 mg/liter by the end of the experiment.",Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),[mg] / [l],32,152797,DB00218,Moxifloxacin
,27067317,susceptibility breakpoint,"The moxifloxacin susceptibility breakpoint was 0.25 mg/liter, which means that almost all M. abscessus clinical strains are moxifloxacin resistant by these criteria.",Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067317/),[mg] / [l],0.25,152798,DB00218,Moxifloxacin
,21750119,half-lives,"With rifampin and moxifloxacin, there is a discordance between the half-lives of these agents (1.9 versus 6.5 h when employed in combination).",Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750119/),h,1.9,153488,DB00218,Moxifloxacin
,21750119,half-lives,"With rifampin and moxifloxacin, there is a discordance between the half-lives of these agents (1.9 versus 6.5 h when employed in combination).",Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750119/),h,6.5,153489,DB00218,Moxifloxacin
,25729270,Cmax,"In the plasma concentration versus time profile of moxifloxcinin rats, Cmax was 11.151 µg/mL at 5 min after the intravenous injection and t1/2 was 2.936 h.",Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25729270/),[μg] / [ml],11.151,153697,DB00218,Moxifloxacin
,25729270,t1/2,"In the plasma concentration versus time profile of moxifloxcinin rats, Cmax was 11.151 µg/mL at 5 min after the intravenous injection and t1/2 was 2.936 h.",Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25729270/),h,2.936,153698,DB00218,Moxifloxacin
,25729270,tissue to plasma concentration ratios,The predicted tissue to plasma concentration ratios in abdominal viscera were between 1.1 and 2.2.,Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25729270/),,1.1 and 2.2,153699,DB00218,Moxifloxacin
,18353805,MICs,"Bactericidal activity of CSF samples of groups III and IV was assessed by a microdilution technique against two penicillin-resistant isolates of Streptococcus pneumoniae with MICs of moxifloxacin of 0.19 and 0.125 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],0.19,153774,DB00218,Moxifloxacin
,18353805,MICs,"Bactericidal activity of CSF samples of groups III and IV was assessed by a microdilution technique against two penicillin-resistant isolates of Streptococcus pneumoniae with MICs of moxifloxacin of 0.19 and 0.125 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],0.125,153775,DB00218,Moxifloxacin
,18353805,CSF,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],0.19,153776,DB00218,Moxifloxacin
,18353805,CSF,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],0.87,153777,DB00218,Moxifloxacin
,18353805,CSF,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],3.00,153778,DB00218,Moxifloxacin
,18353805,CSF,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],4.07,153779,DB00218,Moxifloxacin
,18353805,CSF,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],1.82,153780,DB00218,Moxifloxacin
,18353805,concentrations,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],0.19,153781,DB00218,Moxifloxacin
,18353805,concentrations,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],0.87,153782,DB00218,Moxifloxacin
,18353805,concentrations,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],3.00,153783,DB00218,Moxifloxacin
,18353805,concentrations,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],4.07,153784,DB00218,Moxifloxacin
,18353805,concentrations,"Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively.",Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),[mg] / [l],1.82,153785,DB00218,Moxifloxacin
,18353805,b,The mean bactericidal activity of CSF of group III was 8 and that of group IV was 4.,Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),,8,153786,DB00218,Moxifloxacin
,18353805,b,The mean bactericidal activity of CSF of group III was 8 and that of group IV was 4.,Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353805/),,4,153787,DB00218,Moxifloxacin
,25218157,AUCprostate,"Moxifloxacin showed a significant tissue distribution in the prostate (AUCprostate,ISF/fu·AUCplasma=1.24±0.37), 59% higher than the value obtained for levofloxacin in a previous study.",Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25218157/),,1.24,156262,DB00218,Moxifloxacin
> or,11764770,bioavailability,"Recent analysis of the pharmacokinetic and pharmacodynamic properties of the new fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin) have shown high bioavailability (> or = 70%) and long serum half-lives (> or = 7 h), allowing for once-daily dosing.",Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11764770/),%,70,156773,DB00218,Moxifloxacin
> or =,11764770,serum half-lives,"Recent analysis of the pharmacokinetic and pharmacodynamic properties of the new fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin) have shown high bioavailability (> or = 70%) and long serum half-lives (> or = 7 h), allowing for once-daily dosing.",Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11764770/),h,7,156774,DB00218,Moxifloxacin
,23463212,absorption rate constant,"Parameter estimates (coefficient of variation of inter-individual variability) were: absorption rate constant, 1.09/h (135%); enteral bioavailability, 76% (20.0%); central volume of distribution, 55.6 L; peripheral volume of distribution, 59.6 L (15.3%); inter-compartmental clearance, 47.7 L/h; and clearance, 11.3 L/h (23.7%).",Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),1/[h],1.09,157168,DB00218,Moxifloxacin
,23463212,enteral bioavailability,"Parameter estimates (coefficient of variation of inter-individual variability) were: absorption rate constant, 1.09/h (135%); enteral bioavailability, 76% (20.0%); central volume of distribution, 55.6 L; peripheral volume of distribution, 59.6 L (15.3%); inter-compartmental clearance, 47.7 L/h; and clearance, 11.3 L/h (23.7%).",Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),%,76,157169,DB00218,Moxifloxacin
,23463212,central volume of distribution,"Parameter estimates (coefficient of variation of inter-individual variability) were: absorption rate constant, 1.09/h (135%); enteral bioavailability, 76% (20.0%); central volume of distribution, 55.6 L; peripheral volume of distribution, 59.6 L (15.3%); inter-compartmental clearance, 47.7 L/h; and clearance, 11.3 L/h (23.7%).",Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),l,55.6,157170,DB00218,Moxifloxacin
,23463212,peripheral volume of distribution,"Parameter estimates (coefficient of variation of inter-individual variability) were: absorption rate constant, 1.09/h (135%); enteral bioavailability, 76% (20.0%); central volume of distribution, 55.6 L; peripheral volume of distribution, 59.6 L (15.3%); inter-compartmental clearance, 47.7 L/h; and clearance, 11.3 L/h (23.7%).",Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),l,59.6,157171,DB00218,Moxifloxacin
,23463212,inter-compartmental clearance,"Parameter estimates (coefficient of variation of inter-individual variability) were: absorption rate constant, 1.09/h (135%); enteral bioavailability, 76% (20.0%); central volume of distribution, 55.6 L; peripheral volume of distribution, 59.6 L (15.3%); inter-compartmental clearance, 47.7 L/h; and clearance, 11.3 L/h (23.7%).",Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),[l] / [h],47.7,157172,DB00218,Moxifloxacin
,23463212,clearance,"Parameter estimates (coefficient of variation of inter-individual variability) were: absorption rate constant, 1.09/h (135%); enteral bioavailability, 76% (20.0%); central volume of distribution, 55.6 L; peripheral volume of distribution, 59.6 L (15.3%); inter-compartmental clearance, 47.7 L/h; and clearance, 11.3 L/h (23.7%).",Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),[l] / [h],11.3,157173,DB00218,Moxifloxacin
≤,23463212,MICs,Both intravenously and enterally administered standard-dose moxifloxacin reliably attained the PK/PD target values for pathogens with MICs ≤ 0.25 mg/L for CAP and ≤ 0.125 mg/L for HAP.,Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),[mg] / [l],0.25,157174,DB00218,Moxifloxacin
≤,23463212,MICs,Both intravenously and enterally administered standard-dose moxifloxacin reliably attained the PK/PD target values for pathogens with MICs ≤ 0.25 mg/L for CAP and ≤ 0.125 mg/L for HAP.,Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463212/),[mg] / [l],0.125,157175,DB00218,Moxifloxacin
,12408886,limit of detection (LOD),The limit of detection (LOD) for the method was 50 pg/ml based on a signal to noise ratio of 3.,Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408886/),[pg] / [ml],50,157308,DB00218,Moxifloxacin
,12408886,signal to noise ratio,The limit of detection (LOD) for the method was 50 pg/ml based on a signal to noise ratio of 3.,Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408886/),,3,157309,DB00218,Moxifloxacin
,24031955,Recovery,Recovery values were between 89.4 and 110.2%.,validated microbiological and HPLC methods for the determination of moxifloxacin in pharmaceutical preparations and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24031955/),%,89,157546,DB00218,Moxifloxacin
,24031955,Recovery,Recovery values were between 89.4 and 110.2%.,validated microbiological and HPLC methods for the determination of moxifloxacin in pharmaceutical preparations and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24031955/),%,110,157547,DB00218,Moxifloxacin
,24031955,Recovery,Recovery values were between 97.7 and 107.6%.,validated microbiological and HPLC methods for the determination of moxifloxacin in pharmaceutical preparations and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24031955/),%,97,157548,DB00218,Moxifloxacin
,24031955,Recovery,Recovery values were between 97.7 and 107.6%.,validated microbiological and HPLC methods for the determination of moxifloxacin in pharmaceutical preparations and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24031955/),%,107,157549,DB00218,Moxifloxacin
,23103177,area under the time-concentration curve up to 6 h after dose (AUC(0-6),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],78·7,161379,DB00218,Moxifloxacin
,23103177,area under the time-concentration curve up to 6 h after dose (AUC(0-6),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],26·0,161380,DB00218,Moxifloxacin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],22·1,161381,DB00218,Moxifloxacin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],6·3,161382,DB00218,Moxifloxacin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],0·60,161383,DB00218,Moxifloxacin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],0·21,161384,DB00218,Moxifloxacin
,23103177,plasma AUC(0-6),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],31·5,161385,DB00218,Moxifloxacin
,23103177,plasma AUC(0-6),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],15·1,161386,DB00218,Moxifloxacin
,23103177,C(max),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],7·4,161387,DB00218,Moxifloxacin
,23103177,C(max),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],3·9,161388,DB00218,Moxifloxacin
,23103177,concentrations,"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],2·43,161389,DB00218,Moxifloxacin
,23103177,concentrations,"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],1·52,161390,DB00218,Moxifloxacin
,19373726,half-lives,"The decline in plasma drug concentration was bi-exponential with half-lives of (t(1/2alpha)) 0.26 h and (t(1/2beta)) 2.27 h for distribution and elimination phases, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),h,0.26,163598,DB00218,Moxifloxacin
,19373726,t(1/2beta)),"The decline in plasma drug concentration was bi-exponential with half-lives of (t(1/2alpha)) 0.26 h and (t(1/2beta)) 2.27 h for distribution and elimination phases, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),h,2.27,163599,DB00218,Moxifloxacin
,19373726,peak plasma concentrations (C(max)),"5. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.23 and 1.99 microg/ml and were obtained at 1.56 and 1.90 h (T(max)), respectively, and the elimination half-lives (T(1/2el)) were 2.24 and 1.69 h, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),[μg] / [ml],2.23,163600,DB00218,Moxifloxacin
,19373726,peak plasma concentrations (C(max)),"5. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.23 and 1.99 microg/ml and were obtained at 1.56 and 1.90 h (T(max)), respectively, and the elimination half-lives (T(1/2el)) were 2.24 and 1.69 h, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),[μg] / [ml],1.99,163601,DB00218,Moxifloxacin
,19373726,T(max),"5. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.23 and 1.99 microg/ml and were obtained at 1.56 and 1.90 h (T(max)), respectively, and the elimination half-lives (T(1/2el)) were 2.24 and 1.69 h, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),h,1.56,163602,DB00218,Moxifloxacin
,19373726,T(max),"5. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.23 and 1.99 microg/ml and were obtained at 1.56 and 1.90 h (T(max)), respectively, and the elimination half-lives (T(1/2el)) were 2.24 and 1.69 h, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),h,1.90,163603,DB00218,Moxifloxacin
,19373726,elimination half-lives (T(1/2el)),"5. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.23 and 1.99 microg/ml and were obtained at 1.56 and 1.90 h (T(max)), respectively, and the elimination half-lives (T(1/2el)) were 2.24 and 1.69 h, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),h,2.24,163604,DB00218,Moxifloxacin
,19373726,elimination half-lives (T(1/2el)),"5. After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.23 and 1.99 microg/ml and were obtained at 1.56 and 1.90 h (T(max)), respectively, and the elimination half-lives (T(1/2el)) were 2.24 and 1.69 h, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),h,1.69,163605,DB00218,Moxifloxacin
,19373726,systemic bioavailabilities,"6. The systemic bioavailabilities were 97.11 and 90.01%, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),%,97.11,163606,DB00218,Moxifloxacin
,19373726,systemic bioavailabilities,"6. The systemic bioavailabilities were 97.11 and 90.01%, respectively.",Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),%,90.01,163607,DB00218,Moxifloxacin
,19373726,protein binding percent,In vitro protein binding percent was 37%.,Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373726/),%,37,163608,DB00218,Moxifloxacin
,12003977,plasma concentration,"The geometric mean moxifloxacin plasma concentration increased from 2.32 mg/L at 2 h to a maximum of 3.37 mg/L at 4 h post-dose, decreasing to 0.37 mg/L at 36 h post-dose.","A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12003977/),[mg] / [l],2.32,164003,DB00218,Moxifloxacin
,12003977,plasma concentration,"The geometric mean moxifloxacin plasma concentration increased from 2.32 mg/L at 2 h to a maximum of 3.37 mg/L at 4 h post-dose, decreasing to 0.37 mg/L at 36 h post-dose.","A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12003977/),[mg] / [l],3.37,164004,DB00218,Moxifloxacin
,12003977,plasma concentration,"The geometric mean moxifloxacin plasma concentration increased from 2.32 mg/L at 2 h to a maximum of 3.37 mg/L at 4 h post-dose, decreasing to 0.37 mg/L at 36 h post-dose.","A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12003977/),[mg] / [l],0.37,164005,DB00218,Moxifloxacin
,12003977,tissue/plasma ratio,"The tissue/plasma ratio was c. 200% between 2 and 6 h, and up to 328.9% at 36 h.","A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12003977/),%,c. 200,164006,DB00218,Moxifloxacin
,12003977,tissue/plasma ratio,"The tissue/plasma ratio was c. 200% between 2 and 6 h, and up to 328.9% at 36 h.","A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12003977/),%,328.9,164007,DB00218,Moxifloxacin
,12003977,MIC,Tissue levels exceeded the MIC(90) of all pathogens commonly causing acute sinusitis (e.g. 5-30 x MIC for Streptococcus pneumoniae: 0.25 mg/L).,"A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12003977/),[mg] / [l],0.25,164008,DB00218,Moxifloxacin
,24061442,flow rate,"After protein precipitation with acetonitrile:methanol (1:1, vol/vol), satisfactory separation was achieved on a Hypersil BDS C18 column (250 × 4.6 mm, 5 μm) using a mobile phase comprising 20 mM sodium dihydrogen phosphate-2 hydrate (pH = 3.2) and acetonitrile at a ratio of 75:25, vol/vol; the elution was isocratic at ambient temperature with a flow rate of 1.5 mL/min.","Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061442/),[ml] / [min],1.5,165179,DB00218,Moxifloxacin
,23107871,slope,"Exposure-response analysis yielded an estimated slope equal to 0.11 ms/μM, which was not statistically significant.",Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107871/),[ms] / [μM],0.11,167264,DB00218,Moxifloxacin
,23357835,of maximum concentration (Cmax),"The geometric mean of maximum concentration (Cmax) of the test product was 4,069.64 ng/ml, with median time to achieve maximum concentration (tmax) at 2 hours (range 0.25 - 6.00 hours), while the geometric mean Cmax and median tmax of the reference product was 4,211.98 ng/ml and 2.00 hours (range 0.25 - 8.00 hours).","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),[ng] / [ml],"4,069.64",167788,DB00218,Moxifloxacin
,23357835,time to achieve maximum concentration (tmax),"The geometric mean of maximum concentration (Cmax) of the test product was 4,069.64 ng/ml, with median time to achieve maximum concentration (tmax) at 2 hours (range 0.25 - 6.00 hours), while the geometric mean Cmax and median tmax of the reference product was 4,211.98 ng/ml and 2.00 hours (range 0.25 - 8.00 hours).","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),h,2,167789,DB00218,Moxifloxacin
,23357835,Cmax,"The geometric mean of maximum concentration (Cmax) of the test product was 4,069.64 ng/ml, with median time to achieve maximum concentration (tmax) at 2 hours (range 0.25 - 6.00 hours), while the geometric mean Cmax and median tmax of the reference product was 4,211.98 ng/ml and 2.00 hours (range 0.25 - 8.00 hours).","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),[ng] / [ml],"4,211.98",167790,DB00218,Moxifloxacin
,23357835,tmax,"The geometric mean of maximum concentration (Cmax) of the test product was 4,069.64 ng/ml, with median time to achieve maximum concentration (tmax) at 2 hours (range 0.25 - 6.00 hours), while the geometric mean Cmax and median tmax of the reference product was 4,211.98 ng/ml and 2.00 hours (range 0.25 - 8.00 hours).","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),h,2.00,167791,DB00218,Moxifloxacin
,23357835,AUC0-tlast,"Furthermore, the geometric means of AUC0-tlast and AUC0-∞ for the test product were 49,731.66 and 51,865.89 ng×h/ml while those of the reference product were 51,927.97 and 54,455.93 ng×h/ml.","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),[h·ng] / [ml],"49,731.66",167792,DB00218,Moxifloxacin
,23357835,AUC0-tlast,"Furthermore, the geometric means of AUC0-tlast and AUC0-∞ for the test product were 49,731.66 and 51,865.89 ng×h/ml while those of the reference product were 51,927.97 and 54,455.93 ng×h/ml.","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),[h·ng] / [ml],"51,927.97",167793,DB00218,Moxifloxacin
,23357835,AUC0-∞,"Furthermore, the geometric means of AUC0-tlast and AUC0-∞ for the test product were 49,731.66 and 51,865.89 ng×h/ml while those of the reference product were 51,927.97 and 54,455.93 ng×h/ml.","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),[h·ng] / [ml],"51,865.89",167794,DB00218,Moxifloxacin
,23357835,AUC0-∞,"Furthermore, the geometric means of AUC0-tlast and AUC0-∞ for the test product were 49,731.66 and 51,865.89 ng×h/ml while those of the reference product were 51,927.97 and 54,455.93 ng×h/ml.","Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357835/),[h·ng] / [ml],"54,455.93",167795,DB00218,Moxifloxacin
,20463802,concentrations,"The mean concentrations of besifloxacin, gatifloxacin, and moxifloxacin at 15 minutes were 2.30 +/- 1.42 mug/g, 4.03 +/- 3.84 mug/g, and 10.7 +/- 5.89 mug/g, respectively.","Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20463802/),[μg] / [g],4.03,168072,DB00218,Moxifloxacin
,20463802,concentrations,"The mean concentrations of besifloxacin, gatifloxacin, and moxifloxacin at 15 minutes were 2.30 +/- 1.42 mug/g, 4.03 +/- 3.84 mug/g, and 10.7 +/- 5.89 mug/g, respectively.","Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20463802/),[μg] / [g],10.7,168073,DB00218,Moxifloxacin
,20463802,mean residence time,Besifloxacin had the greatest mean residence time (4.7 hours) in the conjunctival tissue.,"Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20463802/),h,4.7,168074,DB00218,Moxifloxacin
,21306414,MCfB,"The placebo-corrected MCfB of QT(c) I was -1.1 (90% CI -2.7, 0.5) ms and -2.5 (-4.1, -0.9) ms for linagliptin 5 mg and 100 mg, respectively, thus within the non-inferiority margin of 10 ms according to ICH E14.",The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306414/),ms,2.5,169257,DB00218,Moxifloxacin
,21306414,MCfB,"Assay sensitivity was confirmed by a placebo-corrected MCfB of QT(c) I with moxifloxacin of 6.9 (90% CI 5.4, 8.5) ms.",The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306414/),ms,6.9,169258,DB00218,Moxifloxacin
,18054465,peak plasma concentration,The mean+/-S.D. peak plasma concentration of moxifloxacin was 2.8+/-0.5 mg/L observed after 1.6+/-0.9h.,"Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18054465/),[mg] / [l],2.8,169875,DB00218,Moxifloxacin
,18054465,prostatic fluid/plasma ratio,"In prostatic fluid, the concentration of moxifloxacin was 3.8+/-1.2 mg/L and the prostatic fluid/plasma ratio was 1.6+/-0.5.","Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18054465/),,1.6,169876,DB00218,Moxifloxacin
,18054465,ejaculate/plasma ratio,"In ejaculate, the concentration was 2.5+/-0.7 mg/L and the ejaculate/plasma ratio was 1.0+/-0.2.","Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18054465/),,1.0,169877,DB00218,Moxifloxacin
,27315376,half-lives,"The decline in plasma drug concentration was biexponential with half-lives of 0.3 hours and 2.18 hours for distribution and elimination phases, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),h,0.3,169898,DB00218,Moxifloxacin
,27315376,half-lives,"The decline in plasma drug concentration was biexponential with half-lives of 0.3 hours and 2.18 hours for distribution and elimination phases, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),h,2.18,169899,DB00218,Moxifloxacin
,27315376,Steady-state volume of distribution,"Steady-state volume of distribution and total body clearance after intravenous administration were estimated to be 1.12 L/kg and 0.41 L/h per kilogram, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),[l] / [kg],1.12,169900,DB00218,Moxifloxacin
,27315376,total body clearance,"Steady-state volume of distribution and total body clearance after intravenous administration were estimated to be 1.12 L/kg and 0.41 L/h per kilogram, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),[l] / [h·kg],0.41,169901,DB00218,Moxifloxacin
,27315376,peak plasma concentrations,"After intramuscular and oral administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.14 and 1.94 μg/mL and were obtained at 1.4 and 1.87 hours, respectively, and the elimination half-lives were 2.56 and 1.97 hours, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),[μg] / [ml],2.14,169902,DB00218,Moxifloxacin
,27315376,peak plasma concentrations,"After intramuscular and oral administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.14 and 1.94 μg/mL and were obtained at 1.4 and 1.87 hours, respectively, and the elimination half-lives were 2.56 and 1.97 hours, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),[μg] / [ml],1.94,169903,DB00218,Moxifloxacin
,27315376,elimination half-lives,"After intramuscular and oral administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.14 and 1.94 μg/mL and were obtained at 1.4 and 1.87 hours, respectively, and the elimination half-lives were 2.56 and 1.97 hours, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),h,2.56,169904,DB00218,Moxifloxacin
,27315376,elimination half-lives,"After intramuscular and oral administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.14 and 1.94 μg/mL and were obtained at 1.4 and 1.87 hours, respectively, and the elimination half-lives were 2.56 and 1.97 hours, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),h,1.97,169905,DB00218,Moxifloxacin
,27315376,systemic bioavailabilities,"The systemic bioavailabilities were 92.48% and 87.94%, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),%,92.48,169906,DB00218,Moxifloxacin
,27315376,systemic bioavailabilities,"The systemic bioavailabilities were 92.48% and 87.94%, respectively.",Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315376/),%,87.94,169907,DB00218,Moxifloxacin
≥,22088660,ratios of area under the plasma concentration-time curve over 24h to minimum inhibitory concentration (AUC(0-24)/MIC),"Garenoxacin showed excellent bactericidal activity against S. pneumoniae, including quinolone-resistant S. pneumoniae (QRSP), achieving ratios of area under the plasma concentration-time curve over 24h to minimum inhibitory concentration (AUC(0-24)/MIC) ≥ 26.3, without emerging resistant subpopulations.",In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22088660/),,26.3,171426,DB00218,Moxifloxacin
,17383732,MIC50,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],2,171471,DB00218,Moxifloxacin
,17383732,MIC50,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],3,171472,DB00218,Moxifloxacin
,17383732,MIC50,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],1,171473,DB00218,Moxifloxacin
,17383732,MIC50,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],0.25,171474,DB00218,Moxifloxacin
,17383732,MIC50,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],0.75,171475,DB00218,Moxifloxacin
,17383732,MIC90,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],3,171476,DB00218,Moxifloxacin
,17383732,MIC90,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],0.75,171477,DB00218,Moxifloxacin
,17383732,MIC90,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],32,171478,DB00218,Moxifloxacin
,17383732,MIC90,"The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml; quinupristin and dalfopristin, 0.25 microg/ml and 0.5 microg/ml; moxifloxacin, 0.75 microg/ml and > or =32 microg/ml; and gatifloxacin, 2 microg/ml and > or =32 microg/ml.",In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),[μg] / [ml],2,171479,DB00218,Moxifloxacin
<,17383732,C(max)/MIC90,Pharmacokinetic indices (C(max)/MIC90) for topical dosing were all <1.,In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383732/),,1,171480,DB00218,Moxifloxacin
,22011689,time to maximum serum concentration,"After tocilizumab dosing, median time to maximum serum concentration was 2 h postdose; mean apparent terminal half-life was 9.3 ± 1.2 (10 mg/kg) and 12.1 ± 1.5 (20 mg/kg) days.",Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011689/),h,2,171898,DB00218,Moxifloxacin
,22011689,apparent terminal half-life,"After tocilizumab dosing, median time to maximum serum concentration was 2 h postdose; mean apparent terminal half-life was 9.3 ± 1.2 (10 mg/kg) and 12.1 ± 1.5 (20 mg/kg) days.",Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011689/),d,9.3,171899,DB00218,Moxifloxacin
,22011689,apparent terminal half-life,"After tocilizumab dosing, median time to maximum serum concentration was 2 h postdose; mean apparent terminal half-life was 9.3 ± 1.2 (10 mg/kg) and 12.1 ± 1.5 (20 mg/kg) days.",Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011689/),d,12.1,171900,DB00218,Moxifloxacin
,25362206,area under the curve (AUC),An area under the curve (AUC) of 40-60 µg × h/mL following an oral moxifloxacin dose of 400 mg has been reported in adults.,Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),[h·μg] / [ml],40-60,173532,DB00218,Moxifloxacin
,25362206,maximum serum concentration (Cmax),"The median maximum serum concentration (Cmax), area under the curve from 0-8 hours (AUC0-8), time until Cmax (Tmax), and half-life for moxifloxacin were 3.08 (IQR, 2.85-3.82) µg/mL, 17.24 (IQR, 14.47-21.99) µg × h/mL, 2.0 (IQR, 1.0-8.0) h, and 4.14 (IQR, 3.45-6.11), respectively.",Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),[μg] / [ml],3.08,173533,DB00218,Moxifloxacin
,25362206,area under the curve from 0-8 hours (AUC0-8),"The median maximum serum concentration (Cmax), area under the curve from 0-8 hours (AUC0-8), time until Cmax (Tmax), and half-life for moxifloxacin were 3.08 (IQR, 2.85-3.82) µg/mL, 17.24 (IQR, 14.47-21.99) µg × h/mL, 2.0 (IQR, 1.0-8.0) h, and 4.14 (IQR, 3.45-6.11), respectively.",Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),[h·μg] / [ml],17.24,173534,DB00218,Moxifloxacin
,25362206,time until Cmax (Tmax),"The median maximum serum concentration (Cmax), area under the curve from 0-8 hours (AUC0-8), time until Cmax (Tmax), and half-life for moxifloxacin were 3.08 (IQR, 2.85-3.82) µg/mL, 17.24 (IQR, 14.47-21.99) µg × h/mL, 2.0 (IQR, 1.0-8.0) h, and 4.14 (IQR, 3.45-6.11), respectively.",Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),[h·μg] / [ml],17.24,173535,DB00218,Moxifloxacin
,25362206,half-life,"The median maximum serum concentration (Cmax), area under the curve from 0-8 hours (AUC0-8), time until Cmax (Tmax), and half-life for moxifloxacin were 3.08 (IQR, 2.85-3.82) µg/mL, 17.24 (IQR, 14.47-21.99) µg × h/mL, 2.0 (IQR, 1.0-8.0) h, and 4.14 (IQR, 3.45-6.11), respectively.",Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),,4.14,173536,DB00218,Moxifloxacin
,25362206,AUC0-8,"AUC0-8 was reduced by 6.85 µg × h/mL (95% confidence interval, -11.15 to -2.56) in HIV-infected children.",Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),[h·μg] / [ml],6,173537,DB00218,Moxifloxacin
,25362206,corrected QT interval,"Mean corrected QT interval was 403 (standard deviation, 30) ms, and no prolongation >450 ms occurred.",Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362206/),ms,403,173538,DB00218,Moxifloxacin
,11352440,area under the plasma concentration-time curve from zero to infinity [AUCinfinty,"Administration of moxifloxacin after yoghurt had no effect on the extent of absorption, as estimated by the area under the plasma concentration-time curve from zero to infinity [AUCinfinty; geometric means 31.8 versus 33.9 mg/L x h after test and reference, respectively; estimated true treatment ratio 94%, 90% confidence interval (CI) 90 to 98%].","Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352440/),[mg] / [h·l],31.8,174451,DB00218,Moxifloxacin
,11352440,area under the plasma concentration-time curve from zero to infinity [AUCinfinty,"Administration of moxifloxacin after yoghurt had no effect on the extent of absorption, as estimated by the area under the plasma concentration-time curve from zero to infinity [AUCinfinty; geometric means 31.8 versus 33.9 mg/L x h after test and reference, respectively; estimated true treatment ratio 94%, 90% confidence interval (CI) 90 to 98%].","Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352440/),[mg] / [h·l],33.9,174452,DB00218,Moxifloxacin
,11352440,maximum plasma,"The rate of absorption was slightly decreased, with a slight reduction in maximum plasma concentration (Cmax; geometric means 2.44 versus 2.87 mg/L; estimated true treatment ratio 85%, 90% CI 74 to 98%) and a prolonged time to reach Cmax (tmax; median 2.75 versus 0.88 hours).","Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352440/),mg,2.44,174453,DB00218,Moxifloxacin
,11352440,maximum plasma,"The rate of absorption was slightly decreased, with a slight reduction in maximum plasma concentration (Cmax; geometric means 2.44 versus 2.87 mg/L; estimated true treatment ratio 85%, 90% CI 74 to 98%) and a prolonged time to reach Cmax (tmax; median 2.75 versus 0.88 hours).","Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352440/),mg,2.87,174454,DB00218,Moxifloxacin
,11352440,time to reach Cmax (tmax,"The rate of absorption was slightly decreased, with a slight reduction in maximum plasma concentration (Cmax; geometric means 2.44 versus 2.87 mg/L; estimated true treatment ratio 85%, 90% CI 74 to 98%) and a prolonged time to reach Cmax (tmax; median 2.75 versus 0.88 hours).","Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352440/),h,2.75,174455,DB00218,Moxifloxacin
,11352440,time to reach Cmax (tmax,"The rate of absorption was slightly decreased, with a slight reduction in maximum plasma concentration (Cmax; geometric means 2.44 versus 2.87 mg/L; estimated true treatment ratio 85%, 90% CI 74 to 98%) and a prolonged time to reach Cmax (tmax; median 2.75 versus 0.88 hours).","Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352440/),h,0.88,174456,DB00218,Moxifloxacin
,15347636,Peak,"Peak and trough serum concentrations were 3.76 +/- 2.02 mg/L and 0.24 +/- 0.14 mg/L, respectively, at the arterial port after the first dose.",Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),[mg] / [l],3.76,174778,DB00218,Moxifloxacin
,15347636,trough serum concentrations,"Peak and trough serum concentrations were 3.76 +/- 2.02 mg/L and 0.24 +/- 0.14 mg/L, respectively, at the arterial port after the first dose.",Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),[mg] / [l],0.24,174779,DB00218,Moxifloxacin
,15347636,elimination half-life,"The mean elimination half-life was 9.87 +/- 3.26 h, the volume of distribution 270 +/- 133 L and the calculated AUC0-24 18.41 +/- 8.46 mg.h/L.",Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),h,9.87,174780,DB00218,Moxifloxacin
,15347636,volume of distribution,"The mean elimination half-life was 9.87 +/- 3.26 h, the volume of distribution 270 +/- 133 L and the calculated AUC0-24 18.41 +/- 8.46 mg.h/L.",Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),l,270,174781,DB00218,Moxifloxacin
,15347636,AUC0-24,"The mean elimination half-life was 9.87 +/- 3.26 h, the volume of distribution 270 +/- 133 L and the calculated AUC0-24 18.41 +/- 8.46 mg.h/L.",Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),[h·mg] / [l],18.41,174782,DB00218,Moxifloxacin
,15347636,Total clearance,Total clearance was 19.09 +/- 8.22 L/h and the clearance of haemodiafiltration 1.63 +/- 0.33 L/h.,Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),[l] / [h],19.09,174783,DB00218,Moxifloxacin
,15347636,clearance of haemodiafiltration,Total clearance was 19.09 +/- 8.22 L/h and the clearance of haemodiafiltration 1.63 +/- 0.33 L/h.,Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347636/),[l] / [h],1.63,174784,DB00218,Moxifloxacin
,18362660,Cmax,"The stromal Cmax was 48.5 versus 15.7 microg/g (P = 0.04), and the stromal AUC0-2 (area under the concentration-time curve from 0 to 2 hours) was 30.9 versus 13.6 mug.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[μg] / [g],48.5,175165,DB00218,Moxifloxacin
,18362660,Cmax,"The stromal Cmax was 48.5 versus 15.7 microg/g (P = 0.04), and the stromal AUC0-2 (area under the concentration-time curve from 0 to 2 hours) was 30.9 versus 13.6 mug.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[μg] / [g],15.7,175166,DB00218,Moxifloxacin
,18362660,AUC0-2 (area under the concentration-time curve from 0 to 2 hours),"The stromal Cmax was 48.5 versus 15.7 microg/g (P = 0.04), and the stromal AUC0-2 (area under the concentration-time curve from 0 to 2 hours) was 30.9 versus 13.6 mug.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[h·μg] / [g],30.9,175167,DB00218,Moxifloxacin
,18362660,AUC0-2 (area under the concentration-time curve from 0 to 2 hours),"The stromal Cmax was 48.5 versus 15.7 microg/g (P = 0.04), and the stromal AUC0-2 (area under the concentration-time curve from 0 to 2 hours) was 30.9 versus 13.6 mug.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[h·μg] / [g],13.6,175168,DB00218,Moxifloxacin
,18362660,Cmax,"The endothelial Cmax was 76.1 versus 7.3 microg/g (P > 0.05), and the endothelial AUC0-2 was 43.9 versus 9.8 microg.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[μg] / [g],76.1,175169,DB00218,Moxifloxacin
,18362660,Cmax,"The endothelial Cmax was 76.1 versus 7.3 microg/g (P > 0.05), and the endothelial AUC0-2 was 43.9 versus 9.8 microg.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[μg] / [g],7.3,175170,DB00218,Moxifloxacin
,18362660,AUC0-2,"The endothelial Cmax was 76.1 versus 7.3 microg/g (P > 0.05), and the endothelial AUC0-2 was 43.9 versus 9.8 microg.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[h·μg] / [g],43.9,175171,DB00218,Moxifloxacin
,18362660,AUC0-2,"The endothelial Cmax was 76.1 versus 7.3 microg/g (P > 0.05), and the endothelial AUC0-2 was 43.9 versus 9.8 microg.h/g (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[h·μg] / [g],9.8,175172,DB00218,Moxifloxacin
,18362660,Cmax,"The aqueous Cmax was 0.9 versus 0.3 microg/mL (P > 0.05), and the aqueous AUC0-2 was 1.2 versus 0.4 microg.h/mL (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[μg] / [ml],0.9,175173,DB00218,Moxifloxacin
,18362660,Cmax,"The aqueous Cmax was 0.9 versus 0.3 microg/mL (P > 0.05), and the aqueous AUC0-2 was 1.2 versus 0.4 microg.h/mL (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[μg] / [ml],0.3,175174,DB00218,Moxifloxacin
,18362660,AUC0-2,"The aqueous Cmax was 0.9 versus 0.3 microg/mL (P > 0.05), and the aqueous AUC0-2 was 1.2 versus 0.4 microg.h/mL (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[h·μg] / [ml],1.2,175175,DB00218,Moxifloxacin
,18362660,AUC0-2,"The aqueous Cmax was 0.9 versus 0.3 microg/mL (P > 0.05), and the aqueous AUC0-2 was 1.2 versus 0.4 microg.h/mL (P < 0.05).",Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362660/),[h·μg] / [ml],0.4,175176,DB00218,Moxifloxacin
,33739996,Cmax,"In vivo pharmacokinetics data indicates significant improvement of moxifloxacin bioavailability (p < 0.0001) from MH7, as evidenced by higher Cmax (727 ± 56 ng/ml) and greater AUC (2881 ± 108 ng h/ml), when compared with commercial eye drops (Cmax; 503 ± 85 ng/ml and AUC; 978 ± 86 ng h/ml).","Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33739996/),[ng] / [ml],727,176304,DB00218,Moxifloxacin
,33739996,AUC,"In vivo pharmacokinetics data indicates significant improvement of moxifloxacin bioavailability (p < 0.0001) from MH7, as evidenced by higher Cmax (727 ± 56 ng/ml) and greater AUC (2881 ± 108 ng h/ml), when compared with commercial eye drops (Cmax; 503 ± 85 ng/ml and AUC; 978 ± 86 ng h/ml).","Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33739996/),[h·ng] / [ml],2881,176305,DB00218,Moxifloxacin
,33739996,Cmax,"In vivo pharmacokinetics data indicates significant improvement of moxifloxacin bioavailability (p < 0.0001) from MH7, as evidenced by higher Cmax (727 ± 56 ng/ml) and greater AUC (2881 ± 108 ng h/ml), when compared with commercial eye drops (Cmax; 503 ± 85 ng/ml and AUC; 978 ± 86 ng h/ml).","Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33739996/),[ng] / [ml],503,176306,DB00218,Moxifloxacin
,33739996,AUC,"In vivo pharmacokinetics data indicates significant improvement of moxifloxacin bioavailability (p < 0.0001) from MH7, as evidenced by higher Cmax (727 ± 56 ng/ml) and greater AUC (2881 ± 108 ng h/ml), when compared with commercial eye drops (Cmax; 503 ± 85 ng/ml and AUC; 978 ± 86 ng h/ml).","Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33739996/),[h·ng] / [ml],978,176307,DB00218,Moxifloxacin
,32961034,ΔΔ,"The ΔΔQTcF for macimorelin showed a prolongation with a maximum mean value of 9.61 milliseconds (2-sided 90% confidence interval, 7.81 milliseconds and 11.41 milliseconds) at 4 hours after dosing.",Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32961034/),,9.61,176536,DB00218,Moxifloxacin
,16014428,initial maximum concentration,PK/PD assays of moxifloxacin were carried out with an initial maximum concentration of 4.0 mg l-1 and a half-life of 13 h.,Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014428/),[mg] / [l],4.0,178292,DB00218,Moxifloxacin
,16014428,half-life,PK/PD assays of moxifloxacin were carried out with an initial maximum concentration of 4.0 mg l-1 and a half-life of 13 h.,Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014428/),h,13,178293,DB00218,Moxifloxacin
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,4.0,179003,DB00218,Moxifloxacin
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,12.6,179004,DB00218,Moxifloxacin
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,19.1,179005,DB00218,Moxifloxacin
,11258173,absolute bioavailability,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),%,90,180720,DB00218,Moxifloxacin
,11258173,elimination half-life,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),h,12,180721,DB00218,Moxifloxacin
,20197659,half life of elimination,"Following intravenous administration, the half life of elimination, the volume of distribution at steady state and the area under the curve were 3.29 h, 0.94 l/kg and 24.72 microg x h/ml, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),h,3.29,180775,DB00218,Moxifloxacin
,20197659,volume of distribution at steady state,"Following intravenous administration, the half life of elimination, the volume of distribution at steady state and the area under the curve were 3.29 h, 0.94 l/kg and 24.72 microg x h/ml, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),[l] / [kg],0.94,180776,DB00218,Moxifloxacin
,20197659,area under the curve,"Following intravenous administration, the half life of elimination, the volume of distribution at steady state and the area under the curve were 3.29 h, 0.94 l/kg and 24.72 microg x h/ml, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),[h·μg] / [ml],24.72,180777,DB00218,Moxifloxacin
,20197659,peak plasma concentrations,"After intramuscular and subcutaneous administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.41 and 2.20 microg/ml and were obtained at 1.54 and 1.59 h, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),[μg] / [ml],2.41,180778,DB00218,Moxifloxacin
,20197659,peak plasma concentrations,"After intramuscular and subcutaneous administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.41 and 2.20 microg/ml and were obtained at 1.54 and 1.59 h, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),[μg] / [ml],2.20,180779,DB00218,Moxifloxacin
,20197659,systemic bioavailabilities,"The systemic bioavailabilities were 87.19 and 75.94%, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),%,87.19,180780,DB00218,Moxifloxacin
,20197659,systemic bioavailabilities,"The systemic bioavailabilities were 87.19 and 75.94%, respectively.",Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),%,75.94,180781,DB00218,Moxifloxacin
,20197659,plasma protein binding,The in vitro plasma protein binding of moxifloxacin in plasma of calves was 27%.,Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197659/),%,27,180782,DB00218,Moxifloxacin
,24313873,minimum inhibitory concentrations (MICs),"Furthermore, we showed that the probability of target attainment for bacterial eradication against a hypothetical Streptococcus pneumoniae infection is compromised in patients with higher LBM, especially when targeting microorganisms with minimum inhibitory concentrations (MICs) of 0.5 mg l(-1) or higher (probability of target attainment (PTA) approaching zero).",Moxifloxacin dosing in post-bariatric surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24313873/),[mg] / [l],0.5,181737,DB00218,Moxifloxacin
,24313873,probability of target attainment (PTA),"Furthermore, we showed that the probability of target attainment for bacterial eradication against a hypothetical Streptococcus pneumoniae infection is compromised in patients with higher LBM, especially when targeting microorganisms with minimum inhibitory concentrations (MICs) of 0.5 mg l(-1) or higher (probability of target attainment (PTA) approaching zero).",Moxifloxacin dosing in post-bariatric surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24313873/),,zero,181738,DB00218,Moxifloxacin
,24313873,MIC,"When considering the targets for suppression of bacterial resistance formation, even at MIC values as low as 0.25 mg l(-1) , standard moxifloxacin dosing does not attain adequate levels in this population.",Moxifloxacin dosing in post-bariatric surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24313873/),[mg] / [l],0.25,181739,DB00218,Moxifloxacin
,17879915,time to reach peak plasma concentration,The median time to reach peak plasma concentration for moxifloxacin was prolonged from 1 h to 2.5 h when combined with rifampicin and isoniazid (P=.003).,Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879915/),h,1,182552,DB00218,Moxifloxacin
,17879915,time to reach peak plasma concentration,The median time to reach peak plasma concentration for moxifloxacin was prolonged from 1 h to 2.5 h when combined with rifampicin and isoniazid (P=.003).,Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879915/),h,2.5,182553,DB00218,Moxifloxacin
,12878526,peak,"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4.5,183949,DB00218,Moxifloxacin
,12878526,half-life [t(1/2)],"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),h,12,183950,DB00218,Moxifloxacin
,12878526,peak,"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],6,183951,DB00218,Moxifloxacin
,12878526,t(1/2),"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),h,6,183952,DB00218,Moxifloxacin
,12878526,MICs,"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.125,183953,DB00218,Moxifloxacin
,12878526,MICs,"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.25,183954,DB00218,Moxifloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.125,183955,DB00218,Moxifloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.25,183956,DB00218,Moxifloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],8,183957,DB00218,Moxifloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4,183958,DB00218,Moxifloxacin
,12878526,MICs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],1,183959,DB00218,Moxifloxacin
,12878526,MICs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4,183960,DB00218,Moxifloxacin
,12878526,MICs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.5,183961,DB00218,Moxifloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4,183962,DB00218,Moxifloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.5,183963,DB00218,Moxifloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],2,183964,DB00218,Moxifloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],1,183965,DB00218,Moxifloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],64,183966,DB00218,Moxifloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],32,183967,DB00218,Moxifloxacin
,12878526,peak,"MPC-targeted moxifloxacin (lower-than-normal peak = 0.75 to 1.5 micro g/ml, administered at levofloxacin's t(1/2)) caused growth of a GyrA variant (S81Y) of KD2138 and a ParC variant (S79Y) of KD2139, while no mutants of ATCC 49619 were recovered.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.75 to 1.5,183968,DB00218,Moxifloxacin
,12878526,peak,"MPC-targeted levofloxacin (higher-than-normal peak = 14.5 to 29.5 micro g/ml, administered at moxifloxacin's t(1/2)) against KD2138 and KD2139 did not prevent the development of the mutations observed in therapeutic regimens, but resistance in the fluoroquinolone-susceptible ATCC 49619 was no longer noted.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],14.5 to 29.5,183969,DB00218,Moxifloxacin
,18947985,Mean serum concentrations,"Mean serum concentrations were 3.43, 2.74, 1.48 and 1.12microg/mL at 0.5, 3, 6 and 24h after the end of drug infusion, respectively.",Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947985/),[μg] / [ml],3.43,186226,DB00218,Moxifloxacin
,18947985,Mean serum concentrations,"Mean serum concentrations were 3.43, 2.74, 1.48 and 1.12microg/mL at 0.5, 3, 6 and 24h after the end of drug infusion, respectively.",Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947985/),[μg] / [ml],2.74,186227,DB00218,Moxifloxacin
,18947985,Mean serum concentrations,"Mean serum concentrations were 3.43, 2.74, 1.48 and 1.12microg/mL at 0.5, 3, 6 and 24h after the end of drug infusion, respectively.",Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947985/),[μg] / [ml],1.48,186228,DB00218,Moxifloxacin
,18947985,Mean serum concentrations,"Mean serum concentrations were 3.43, 2.74, 1.48 and 1.12microg/mL at 0.5, 3, 6 and 24h after the end of drug infusion, respectively.",Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947985/),[μg] / [ml],1.12,186229,DB00218,Moxifloxacin
,16679034,Cmax,"MOX produced significant dose-related increases in QTc at doses of 30 (Cmax=5.5+/-0.6 microM), 100 (Cmax=16.5+/-1.6 microM), and 175 (Cmax=17.3+/-0.7 microM) mg/kg with peak increases of 22 (8%), 27 (10%), and 47 (18%) ms, respectively (p<or=0.05; compared to vehicle).",Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679034/),μM,5.5,186461,DB00218,Moxifloxacin
,16679034,Cmax,"MOX produced significant dose-related increases in QTc at doses of 30 (Cmax=5.5+/-0.6 microM), 100 (Cmax=16.5+/-1.6 microM), and 175 (Cmax=17.3+/-0.7 microM) mg/kg with peak increases of 22 (8%), 27 (10%), and 47 (18%) ms, respectively (p<or=0.05; compared to vehicle).",Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679034/),μM,16.5,186462,DB00218,Moxifloxacin
,16679034,Cmax,"MOX produced significant dose-related increases in QTc at doses of 30 (Cmax=5.5+/-0.6 microM), 100 (Cmax=16.5+/-1.6 microM), and 175 (Cmax=17.3+/-0.7 microM) mg/kg with peak increases of 22 (8%), 27 (10%), and 47 (18%) ms, respectively (p<or=0.05; compared to vehicle).",Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679034/),μM,17.3,186463,DB00218,Moxifloxacin
,16679034,peak increases,"MOX produced significant dose-related increases in QTc at doses of 30 (Cmax=5.5+/-0.6 microM), 100 (Cmax=16.5+/-1.6 microM), and 175 (Cmax=17.3+/-0.7 microM) mg/kg with peak increases of 22 (8%), 27 (10%), and 47 (18%) ms, respectively (p<or=0.05; compared to vehicle).",Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679034/),ms,22,186464,DB00218,Moxifloxacin
,16679034,peak increases,"MOX produced significant dose-related increases in QTc at doses of 30 (Cmax=5.5+/-0.6 microM), 100 (Cmax=16.5+/-1.6 microM), and 175 (Cmax=17.3+/-0.7 microM) mg/kg with peak increases of 22 (8%), 27 (10%), and 47 (18%) ms, respectively (p<or=0.05; compared to vehicle).",Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679034/),ms,27,186465,DB00218,Moxifloxacin
,16679034,peak increases,"MOX produced significant dose-related increases in QTc at doses of 30 (Cmax=5.5+/-0.6 microM), 100 (Cmax=16.5+/-1.6 microM), and 175 (Cmax=17.3+/-0.7 microM) mg/kg with peak increases of 22 (8%), 27 (10%), and 47 (18%) ms, respectively (p<or=0.05; compared to vehicle).",Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679034/),ms,47,186466,DB00218,Moxifloxacin
,17938193,CFU counts,"After 56 days of treatment, lung CFU counts were 3.5 +/- 0.8 and 0.9 +/- 0.6 in 0.25% and 1.5% of the MXF-treated mice, respectively.",In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938193/),,3.5,187364,DB00218,Moxifloxacin
,17938193,CFU counts,"After 56 days of treatment, lung CFU counts were 3.5 +/- 0.8 and 0.9 +/- 0.6 in 0.25% and 1.5% of the MXF-treated mice, respectively.",In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938193/),,0.9,187365,DB00218,Moxifloxacin
,29803534,Tmax,"The Tmax of nemonoxacin was 1 to 2 hours after administration, and the elimination half-life was 5 to 7 hours, in the fasted conditions.","Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803534/),h,1 to 2,189341,DB00218,Moxifloxacin
,29803534,elimination half-life,"The Tmax of nemonoxacin was 1 to 2 hours after administration, and the elimination half-life was 5 to 7 hours, in the fasted conditions.","Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803534/),h,5 to 7,189342,DB00218,Moxifloxacin
,11352436,Steady-state peak concentrations,Steady-state peak concentrations were between 0.9 mg/L (100mg twice daily) and 5.7 mg/L (600mg once daily).,"Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352436/),[mg] / [l],0.9,192041,DB00218,Moxifloxacin
,11352436,Steady-state peak concentrations,Steady-state peak concentrations were between 0.9 mg/L (100mg twice daily) and 5.7 mg/L (600mg once daily).,"Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352436/),[mg] / [l],5.7,192042,DB00218,Moxifloxacin
,11352436,terminal elimination half-life,"The terminal elimination half-life was 14 to 15 hours, supporting once daily administration of the drug.","Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352436/),h,14 to 15,192043,DB00218,Moxifloxacin
,11352436,Accumulation ratios,"Accumulation ratios ranged between 87% for the lowest dosage and 111% after repeated doses of 600mg once daily, indicating the absence of clinically relevant accumulation due to non-linear pharmacokinetics.","Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352436/),%,87,192044,DB00218,Moxifloxacin
,11352436,Accumulation ratios,"Accumulation ratios ranged between 87% for the lowest dosage and 111% after repeated doses of 600mg once daily, indicating the absence of clinically relevant accumulation due to non-linear pharmacokinetics.","Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352436/),%,111,192045,DB00218,Moxifloxacin
,28566592,AUC0→24,"The estimated PK parameters of MFLX were as follows: AUC0→24, 61.04±17.74 μg h/mL; Cmax, 5.25±1.12 μg/mL; and Ctrough, 1.15±0.45 μg/mL.","A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28566592/),[h·μg] / [ml],61.04,193106,DB00218,Moxifloxacin
,28566592,Cmax,"The estimated PK parameters of MFLX were as follows: AUC0→24, 61.04±17.74 μg h/mL; Cmax, 5.25±1.12 μg/mL; and Ctrough, 1.15±0.45 μg/mL.","A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28566592/),[μg] / [ml],5.25,193107,DB00218,Moxifloxacin
,28566592,Ctrough,"The estimated PK parameters of MFLX were as follows: AUC0→24, 61.04±17.74 μg h/mL; Cmax, 5.25±1.12 μg/mL; and Ctrough, 1.15±0.45 μg/mL.","A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28566592/),[μg] / [ml],1.15,193108,DB00218,Moxifloxacin
,26088895,Peak ΔΔQTcF,Peak ΔΔQTcF was 2.34 ms at 1.5h postdose for perampanel 6 mg and 3.92 ms at 0.5h postdose for perampanel 12 mg.,Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088895/),ms,2.34,193518,DB00218,Moxifloxacin
,26088895,Peak ΔΔQTcF,Peak ΔΔQTcF was 2.34 ms at 1.5h postdose for perampanel 6 mg and 3.92 ms at 0.5h postdose for perampanel 12 mg.,Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088895/),ms,3.92,193519,DB00218,Moxifloxacin
<,26088895,ΔΔQTcF,"At every time point, the upper 95% confidence limit of ΔΔQTcF for perampanel 6 and 12 mg was <10 ms.",Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088895/),ms,10,193520,DB00218,Moxifloxacin
,10382878,Bioavailability,Bioavailability was high to moderate (91-52%) in all species.,"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),%,91-52,193997,DB00218,Moxifloxacin
,10382878,Protein binding (f(u)),Protein binding (f(u)) was low (55-71%) in all species.,"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),%,55-71,193998,DB00218,Moxifloxacin
,10382878,volume of distribution at steady state (Vss),The volume of distribution at steady state (Vss) was medium to large (2.0-4.9 L/kg) in all species.,"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),[l] / [kg],2.0-4.9,193999,DB00218,Moxifloxacin
,10382878,maximum concentrations (C(max,"There were considerable differences in maximum concentrations (C(max,norm), 0.430-0.070 kg/L) and in AUCnorm values (oral, 6.18-0.184 kg x h/L; i.v., 7.51-0.237 kg x h/L).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),[kg] / [l],0.430-0.070,194000,DB00218,Moxifloxacin
,10382878,AUCnorm,"There were considerable differences in maximum concentrations (C(max,norm), 0.430-0.070 kg/L) and in AUCnorm values (oral, 6.18-0.184 kg x h/L; i.v., 7.51-0.237 kg x h/L).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),[h·kg] / [l],6.18-0.184,194001,DB00218,Moxifloxacin
,10382878,AUCnorm,"There were considerable differences in maximum concentrations (C(max,norm), 0.430-0.070 kg/L) and in AUCnorm values (oral, 6.18-0.184 kg x h/L; i.v., 7.51-0.237 kg x h/L).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),[h·kg] / [l],7.51-0.237,194002,DB00218,Moxifloxacin
,10382878,Total body clearance (CL),Total body clearance (CL) decreased with increasing bodyweight (4.21-0.132 L/(h x kg)).,"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),[l] / [h·kg],4.21-0.132,194003,DB00218,Moxifloxacin
,10382878,mean residence time (MRT),The mean residence time (MRT) decreased with decreasing bodyweight (15-0.88 h).,"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),h,15-0.88,194004,DB00218,Moxifloxacin
,10382878,half-life (t(1/2)),"The half-life (t(1/2)) decreased with decreasing bodyweight (oral, 12-1.3 h, i.v., 13-0.93 h).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),h,12-1.3,194005,DB00218,Moxifloxacin
,10382878,half-life (t(1/2)),"The half-life (t(1/2)) decreased with decreasing bodyweight (oral, 12-1.3 h, i.v., 13-0.93 h).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),h,13-0.93,194006,DB00218,Moxifloxacin
,10382878,renal excretion,"There was moderate to low renal excretion (i.v., 20-6.2%), the renal clearance, (CL(R)) was in the range 0.615-0.0222 L/(h x kg).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),%,20-6.2,194007,DB00218,Moxifloxacin
,10382878,"renal clearance, (CL(R))","There was moderate to low renal excretion (i.v., 20-6.2%), the renal clearance, (CL(R)) was in the range 0.615-0.0222 L/(h x kg).","Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382878/),[l] / [h·kg],0.615-0.0222,194008,DB00218,Moxifloxacin
,16901274,half-life,"Mean half-life for IV, SC and SC-P407 routes was 2.15, 5.41 and 11.09 h.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),h,2.15,195290,DB00218,Moxifloxacin
,16901274,half-life,"Mean half-life for IV, SC and SC-P407 routes was 2.15, 5.41 and 11.09 h.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),h,5.41,195291,DB00218,Moxifloxacin
,16901274,half-life,"Mean half-life for IV, SC and SC-P407 routes was 2.15, 5.41 and 11.09 h.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),h,11.09,195292,DB00218,Moxifloxacin
,16901274,Clearance,Clearance value after IV dosing was 0.78 l/kg/h.,"Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),[l] / [h·kg],0.78,195293,DB00218,Moxifloxacin
,16901274,absolute bioavailability,"After SC administration, the mean absolute bioavailability was 117% and the C(max) was 1.61 +/- 0.49 mg/l.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),%,117,195294,DB00218,Moxifloxacin
,16901274,C(max),"After SC administration, the mean absolute bioavailability was 117% and the C(max) was 1.61 +/- 0.49 mg/l.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),[mg] / [l],1.61,195295,DB00218,Moxifloxacin
,16901274,bioavailability,"After SC-P407 administration, the bioavailability was 44% and the C(max) 1.83 was +/-0.62 mg/l.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),%,44,195296,DB00218,Moxifloxacin
,16901274,C(max),"After SC-P407 administration, the bioavailability was 44% and the C(max) 1.83 was +/-0.62 mg/l.","Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16901274/),[mg] / [l],1.83,195297,DB00218,Moxifloxacin
,28408267,absorption rate constant,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],0.305,195737,DB00218,Moxifloxacin
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],9.37,195738,DB00218,Moxifloxacin
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],0.135,195739,DB00218,Moxifloxacin
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],0.510,195740,DB00218,Moxifloxacin
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],30.8,195741,DB00218,Moxifloxacin
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],1.67,195742,DB00218,Moxifloxacin
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],3.75,195743,DB00218,Moxifloxacin
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),l,56.7,195744,DB00218,Moxifloxacin
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),l,79.4,195745,DB00218,Moxifloxacin
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],1.67,195746,DB00218,Moxifloxacin
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],3.75,195747,DB00218,Moxifloxacin
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),l,15.2,195748,DB00218,Moxifloxacin
,16872782,limits of detection,"The limits of detection and quantitation were 6 and 15 ng/mL, respectively.",High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16872782/),[ng] / [ml],6,196052,DB00218,Moxifloxacin
,16872782,limits of detection,"The limits of detection and quantitation were 6 and 15 ng/mL, respectively.",High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16872782/),[ng] / [ml],15,196053,DB00218,Moxifloxacin
less,10730681,minimum inhibitory concentration for 90% of organisms (MIC90),"The minimum inhibitory concentration for 90% of organisms (MIC90) is less than 0.25 mg/L for commonly isolated community-acquired respiratory tract pathogens including penicillin-susceptible and -resistant Streptococcus pneumoniae, Haemophilus sp, and Moraxella catarrhalis, and less than 1.0 mg/L for atypical pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),[mg] / [l],0.25,196058,DB00218,Moxifloxacin
less,10730681,minimum inhibitory concentration for 90% of organisms (MIC90),"The minimum inhibitory concentration for 90% of organisms (MIC90) is less than 0.25 mg/L for commonly isolated community-acquired respiratory tract pathogens including penicillin-susceptible and -resistant Streptococcus pneumoniae, Haemophilus sp, and Moraxella catarrhalis, and less than 1.0 mg/L for atypical pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),[mg] / [l],1.0,196059,DB00218,Moxifloxacin
,10730681,maximum concentration (Cmax),"Human pharmacokinetics in healthy volunteers after a single 400-mg oral dose were mean maximum concentration (Cmax) 3.2 mg/L, area under the curve (AUC) 37 mg x hour/L, and terminal elimination half-life 12.0 hours.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),[mg] / [l],3.2,196060,DB00218,Moxifloxacin
,10730681,area under the curve (AUC),"Human pharmacokinetics in healthy volunteers after a single 400-mg oral dose were mean maximum concentration (Cmax) 3.2 mg/L, area under the curve (AUC) 37 mg x hour/L, and terminal elimination half-life 12.0 hours.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),[h·mg] / [l],37,196061,DB00218,Moxifloxacin
,10730681,terminal elimination half-life,"Human pharmacokinetics in healthy volunteers after a single 400-mg oral dose were mean maximum concentration (Cmax) 3.2 mg/L, area under the curve (AUC) 37 mg x hour/L, and terminal elimination half-life 12.0 hours.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),h,12.0,196062,DB00218,Moxifloxacin
,10730681,Cmax,"At steady-state, Cmax and AUC were approximately 4.5 mg/L and 48 mg x hour/L, respectively.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),[mg] / [l],4.5,196063,DB00218,Moxifloxacin
,10730681,AUC,"At steady-state, Cmax and AUC were approximately 4.5 mg/L and 48 mg x hour/L, respectively.","Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730681/),[h·mg] / [l],48,196064,DB00218,Moxifloxacin
,21325873,maximum concentrations,"After topical administration, the maximum concentrations of MFLX in the aqueous and vitreous samples were 10.2 ± 1.6 μg/ml (30 min; n = 6) and 0.10 ± 0.03 μg/ml (30 min; n = 6), respectively.",Vitreous and aqueous penetration of orally and topically administered moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325873/),[μg] / [ml],10.2,196326,DB00218,Moxifloxacin
,21325873,maximum concentrations,"After topical administration, the maximum concentrations of MFLX in the aqueous and vitreous samples were 10.2 ± 1.6 μg/ml (30 min; n = 6) and 0.10 ± 0.03 μg/ml (30 min; n = 6), respectively.",Vitreous and aqueous penetration of orally and topically administered moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325873/),[μg] / [ml],0.10,196327,DB00218,Moxifloxacin
,21325873,maximum concentrations,"After oral administration, the maximum concentrations in the aqueous, vitreous and serum samples were 0.9 ± 0.3 μg/ml (120 min; n = 6), 0.7 ± 0.2 μg/ml (240 min; n = 6) and 1.6 ± 0.9 μg/ml (120 min; n = 6), respectively.",Vitreous and aqueous penetration of orally and topically administered moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325873/),[μg] / [ml],0.9,196328,DB00218,Moxifloxacin
,21325873,maximum concentrations,"After oral administration, the maximum concentrations in the aqueous, vitreous and serum samples were 0.9 ± 0.3 μg/ml (120 min; n = 6), 0.7 ± 0.2 μg/ml (240 min; n = 6) and 1.6 ± 0.9 μg/ml (120 min; n = 6), respectively.",Vitreous and aqueous penetration of orally and topically administered moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325873/),[μg] / [ml],0.7,196329,DB00218,Moxifloxacin
,21325873,maximum concentrations,"After oral administration, the maximum concentrations in the aqueous, vitreous and serum samples were 0.9 ± 0.3 μg/ml (120 min; n = 6), 0.7 ± 0.2 μg/ml (240 min; n = 6) and 1.6 ± 0.9 μg/ml (120 min; n = 6), respectively.",Vitreous and aqueous penetration of orally and topically administered moxifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325873/),[μg] / [ml],1.6,196330,DB00218,Moxifloxacin
exceeded,14994771,tissue-to-blood ratios,"The tissue-to-blood ratios exceeded 4:1 at most sites, with mucosal concentration levels well above the MIC90 values of the drug against a wide range of microorganisms.",Sinus tissue concentration of moxifloxacin after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14994771/),,4:1,196858,DB00218,Moxifloxacin
,19272845,Excitation/emission wavelengths,"Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),nm,279/,198151,DB00218,Moxifloxacin
,19272845,Excitation/emission wavelengths,"Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),nm,442,198152,DB00218,Moxifloxacin
,19272845,Excitation/emission wavelengths,"Excitation/emission wavelengths were 279/442nm for ciprofloxacin and 290/500nm for ofloxacin, moxifloxacin and internal standard.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),nm,290,198153,DB00218,Moxifloxacin
,19272845,recovery,"Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),%,95,198154,DB00218,Moxifloxacin
,19272845,recovery,"Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),%,86.4,198155,DB00218,Moxifloxacin
,19272845,recovery,"Ofloxacin, ciprofloxacin and moxifloxacin were extracted from plasma with a mean recovery of 95%, 86.4% and 94.2%, respectively.","Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272845/),%,94.2,198156,DB00218,Moxifloxacin
,24808668,flow rate,"Analytes were separated using an Agilent LCMS system equipped with a Zorbax eclipse XBD C18 column (150 mm × 4.6 mm i.d., 5 μm) and using a mobile phase consisting of a mixture of acetonitrile, methanol and 0.5% formic acid in a ratio of 23:10:67% v/v and flow rate was set at 0.6 mL/min.",A conventional HPLC-MS method for the simultaneous determination of ofloxacin and cefixime in plasma: Development and validation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24808668/),[ml] / [min],0.6,198365,DB00218,Moxifloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,4,198508,DB00218,Moxifloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,7.4,198509,DB00218,Moxifloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,6.8,198510,DB00218,Moxifloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,12.1,198511,DB00218,Moxifloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,730,198512,DB00218,Moxifloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,1,198513,DB00218,Moxifloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,130,198514,DB00218,Moxifloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,920,198515,DB00218,Moxifloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,690,198516,DB00218,Moxifloxacin
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,13.7,198581,DB00218,Moxifloxacin
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.5,198582,DB00218,Moxifloxacin
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.2,198583,DB00218,Moxifloxacin
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,6.9,198584,DB00218,Moxifloxacin
,21820876,maximum tolerated dose,The maximum tolerated dose of UB-8902 was 512 mg/kg.,Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],512,198759,DB00218,Moxifloxacin
,21820876,PD(50),"PD(50) values were 16, 128 and 32 mg/kg for Ab58, Ab661 and Ab33, respectively.",Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],16,198760,DB00218,Moxifloxacin
,21820876,PD(50),"PD(50) values were 16, 128 and 32 mg/kg for Ab58, Ab661 and Ab33, respectively.",Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],128,198761,DB00218,Moxifloxacin
,21820876,PD(50),"PD(50) values were 16, 128 and 32 mg/kg for Ab58, Ab661 and Ab33, respectively.",Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21820876/),[mg] / [kg],32,198762,DB00218,Moxifloxacin
,25317848,zeta potential (ZP),"The developed nanoemulsion MONe6 (size 168 ± 28 nm and zeta potential (ZP) 24.78 ± 0.45 mV, respectively) was effective for intracellular delivery and sustaining the release of MOX.",Moxifloxacin-loaded nanoemulsions having tocopheryl succinate as the integral component improves pharmacokinetics and enhances survival in E. coli-induced complicated intra-abdominal infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25317848/),mv,24.78,200143,DB00218,Moxifloxacin
,20004428,t(1/2)(beta)),"Following intravenous injection, the decline in plasma drug concentration was bi-exponential with half-lives of (t(1/2)(alpha)) 0.22+/-0.10h and (t(1/2)(beta)) 2.49+/-0.26h for distribution and elimination phases, respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),h,2.49,202087,DB00218,Moxifloxacin
,20004428,volume of distribution at steady-state (V(dss)),"The volume of distribution at steady-state (V(dss)) was 1.02+/-0.14 l kg(-1) and the total body clearance (Cl(tot)) was 0.32+/-0.11 l kg(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),[l] / [kg],1.02,202088,DB00218,Moxifloxacin
,20004428,total body clearance (Cl(tot)),"The volume of distribution at steady-state (V(dss)) was 1.02+/-0.14 l kg(-1) and the total body clearance (Cl(tot)) was 0.32+/-0.11 l kg(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),[l] / [kg],0.32,202089,DB00218,Moxifloxacin
,20004428,peak plasma concentrations (C(max)),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),[μg] / [ml],2.38,202090,DB00218,Moxifloxacin
,20004428,peak plasma concentrations (C(max)),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),[μg] / [ml],2.11,202091,DB00218,Moxifloxacin
,20004428,T(max),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),h,1.47,202092,DB00218,Moxifloxacin
,20004428,T(max),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),h,1.83,202093,DB00218,Moxifloxacin
,20004428,elimination half-lives (T(1/2el)),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),h,3.14,202094,DB00218,Moxifloxacin
,20004428,elimination half-lives (T(1/2el)),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),h,2.63,202095,DB00218,Moxifloxacin
,20004428,AUC(0-24),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),[μg] / [ml],15.87,202096,DB00218,Moxifloxacin
,20004428,AUC(0-24),"After intramuscular and oral administration of moxifloxacin at the same dose the peak plasma concentrations (C(max)) were 2.38+/-0.43 and 2.11+/-0.36 microg ml(-1) and were obtained at 1.47+/-0.26 and 1.83+/-0.16h (T(max)), respectively, the elimination half-lives (T(1/2el)) were 3.14+/-0.42 and 2.63+/-0.44h, respectively, and AUC(0-24) were 15.87+/-2.35 and 14.52+/-2.37 microg ml(-1)h(-1), respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),[μg] / [ml],14.52,202097,DB00218,Moxifloxacin
,20004428,systemic bioavailabilities,"The systemic bioavailabilities were 96.36+/-11.54% and 86.79+/-12.64%, respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),%,96.36,202098,DB00218,Moxifloxacin
,20004428,systemic bioavailabilities,"The systemic bioavailabilities were 96.36+/-11.54% and 86.79+/-12.64%, respectively.","Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),%,86.79,202099,DB00218,Moxifloxacin
,20004428,plasma protein binding percent,In vitro plasma protein binding percent was 32%.,"Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004428/),%,32,202100,DB00218,Moxifloxacin
,26660898,maximum plasma concentration,"The maximum plasma concentration and the area under the plasma concentration-time curve were 3.97 µg/ml and 51.74 µg·h/ml, respectively; these values were nearly equivalent to those of healthy adult men.",Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660898/),[μg] / [ml],3.97,202346,DB00218,Moxifloxacin
,26660898,area under the plasma concentration-time curve,"The maximum plasma concentration and the area under the plasma concentration-time curve were 3.97 µg/ml and 51.74 µg·h/ml, respectively; these values were nearly equivalent to those of healthy adult men.",Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660898/),[h·μg] / [ml],51.74,202347,DB00218,Moxifloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),,34:1,202408,DB00218,Moxifloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),,56:,202409,DB00218,Moxifloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),:,95,202410,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,"Monte Carlo simulations were used to analyze the potential for garenoxacin 400 mg QD, gemifloxacin 320 mg QD, and moxifloxacin 400 mg QD to achieve target fAUC(0-24)/MIC(90) ratios of 30, 40, 100, and 120 against S pneumoniae in serum and ELF from hospitalized patients with CAP.","Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,30,204729,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,"Monte Carlo simulations were used to analyze the potential for garenoxacin 400 mg QD, gemifloxacin 320 mg QD, and moxifloxacin 400 mg QD to achieve target fAUC(0-24)/MIC(90) ratios of 30, 40, 100, and 120 against S pneumoniae in serum and ELF from hospitalized patients with CAP.","Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,40,204730,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,"Monte Carlo simulations were used to analyze the potential for garenoxacin 400 mg QD, gemifloxacin 320 mg QD, and moxifloxacin 400 mg QD to achieve target fAUC(0-24)/MIC(90) ratios of 30, 40, 100, and 120 against S pneumoniae in serum and ELF from hospitalized patients with CAP.","Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,100,204731,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,"Monte Carlo simulations were used to analyze the potential for garenoxacin 400 mg QD, gemifloxacin 320 mg QD, and moxifloxacin 400 mg QD to achieve target fAUC(0-24)/MIC(90) ratios of 30, 40, 100, and 120 against S pneumoniae in serum and ELF from hospitalized patients with CAP.","Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,120,204732,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,Monte Carlo simulations indicated that all 3 fluoroquinolones had a high probability (>90%) of attaining target fAUC(0-24)/MIC(90) ratios of 30 and 40 against S pneumoniae in both serum and ELF.,"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,30,204733,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,Monte Carlo simulations indicated that all 3 fluoroquinolones had a high probability (>90%) of attaining target fAUC(0-24)/MIC(90) ratios of 30 and 40 against S pneumoniae in both serum and ELF.,"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,40,204734,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,Garenoxacin 400 mg QD was associated with a >95% probability of achieving target fAUC(0-24)/MIC(90) ratios of 100 and 120 in both serum and ELF.,"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,100,204735,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,Garenoxacin 400 mg QD was associated with a >95% probability of achieving target fAUC(0-24)/MIC(90) ratios of 100 and 120 in both serum and ELF.,"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,120,204736,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,Both gemifloxacin 320 mg QD and moxifloxacin 400 mg QD were associated with high probabilities of attaining fAUC(0-24)/MIC(90) ratios of 100 and 120 in ELF (>95%); the probability of gemifloxacin and moxifloxacin attaining these targets in serum ranged from 78.3% to 88.0%.,"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,100,204737,DB00218,Moxifloxacin
,18201584,fAUC(0-24)/MIC(90) ratios,Both gemifloxacin 320 mg QD and moxifloxacin 400 mg QD were associated with high probabilities of attaining fAUC(0-24)/MIC(90) ratios of 100 and 120 in ELF (>95%); the probability of gemifloxacin and moxifloxacin attaining these targets in serum ranged from 78.3% to 88.0%.,"Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201584/),,120,204738,DB00218,Moxifloxacin
,12654762,T > MIC,Antibacterial effects were bacteriostatic when T > MIC was 48% and bactericidal when values exceeded 55%.,AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),%,48,205830,DB00218,Moxifloxacin
,12654762,AUC0-t/MICs,"Bactericidal activity and bacterial eradication were associated with AUC0-t/MICs of 28 and 135, respectively.",AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),,28,205831,DB00218,Moxifloxacin
,12654762,AUC0-t/MICs,"Bactericidal activity and bacterial eradication were associated with AUC0-t/MICs of 28 and 135, respectively.",AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),,135,205832,DB00218,Moxifloxacin
,12654762,AUC0-t/MIC,"AUC0-t/MIC was also highly predictive of bacterial kill curves produced by simulated clinical doses of moxifloxacin and levofloxacin (precision 0.36 log10 cfu/mL, bias 0.02 log10 cfu/mL).",AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),,0,205833,DB00218,Moxifloxacin
,23553534,ΔΔQTcF,"The maximum ΔΔQTcF value for zanamivir 1200 mg was 1.73 msec (90% CI -0.40 to 3.87 msec), which was observed within 30 minutes after dosing, and 11.21 msec (90% CI 8.81-13.60) for moxifloxacin, observed at 4 hours after dosing.",Effect of intravenous zanamivir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23553534/),ms,1.73,207861,DB00218,Moxifloxacin
,23553534,ΔΔQTcF,"The maximum ΔΔQTcF value for zanamivir 1200 mg was 1.73 msec (90% CI -0.40 to 3.87 msec), which was observed within 30 minutes after dosing, and 11.21 msec (90% CI 8.81-13.60) for moxifloxacin, observed at 4 hours after dosing.",Effect of intravenous zanamivir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23553534/),ms,11.21,207862,DB00218,Moxifloxacin
,22325733,ddQTcIb,"The maximum ddQTcIb values were 0.7 msec (upper 95% confidence limit [CL], 3.0) with gabapentin enacarbil 1200 mg; 1.3 msec (upper CL, 3.6) with gabapentin enacarbil 6000 mg; and 7.4 msec (lower CL, 5.1) with moxifloxacin.","Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22325733/),ms,0.7,207903,DB00218,Moxifloxacin
,22325733,ddQTcIb,"The maximum ddQTcIb values were 0.7 msec (upper 95% confidence limit [CL], 3.0) with gabapentin enacarbil 1200 mg; 1.3 msec (upper CL, 3.6) with gabapentin enacarbil 6000 mg; and 7.4 msec (lower CL, 5.1) with moxifloxacin.","Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22325733/),ms,1.3,207904,DB00218,Moxifloxacin
,22325733,ddQTcIb,"The maximum ddQTcIb values were 0.7 msec (upper 95% confidence limit [CL], 3.0) with gabapentin enacarbil 1200 mg; 1.3 msec (upper CL, 3.6) with gabapentin enacarbil 6000 mg; and 7.4 msec (lower CL, 5.1) with moxifloxacin.","Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22325733/),ms,7.4,207905,DB00218,Moxifloxacin
>,19223648,fAUC(SERUM)/MIC,"Moxifloxacin achieved robust (> or = 90%) probabilities of target attainment (PTAs) in serum, cortical bone, and cancellous bone up to MICs of < or = 0.375 mg/liter based on the targets fAUC(SERUM)/MIC > or = 40 and AUC(BONE)/MIC > or = 33.",Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223648/),,40,208186,DB00218,Moxifloxacin
>,19223648,AUC(BONE)/MIC,"Moxifloxacin achieved robust (> or = 90%) probabilities of target attainment (PTAs) in serum, cortical bone, and cancellous bone up to MICs of < or = 0.375 mg/liter based on the targets fAUC(SERUM)/MIC > or = 40 and AUC(BONE)/MIC > or = 33.",Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223648/),,33,208187,DB00218,Moxifloxacin
,18655224,flow rate,"The resolution of peaks was achieved with phosphate buffer (pH 2.5)-acetonitrile (80:20, v/v) at a flow rate of 1 mL/min on a Kromasil C(18) column.","Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655224/),[ml] / [min],1,208521,DB00218,Moxifloxacin
,18655224,total chromatographic run time,"The total chromatographic run time was 18.0 min and the simultaneous elution of GFC, SFC, MFC and IS occurred at approximately 10.8, 12.8, 17.0 and 6.0 min, respectively.","Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655224/),min,18.0,208522,DB00218,Moxifloxacin
>,27128611,ΔΔQTcF,"The ΔΔQTcF for moxifloxacin (lower confidence interval) was significantly >5 milliseconds at 1, 2, and 3 hours post-dose.",Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128611/),,5,209178,DB00218,Moxifloxacin
,17057790,half-life,The concentration of intravitreal moxifloxacin showed an exponential decay with a half-life of 1.72 hours.,Intravitreal clearance of moxifloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17057790/),h,1.72,209750,DB00218,Moxifloxacin
,20145260,time to maximum plasma concentration,Median time to maximum plasma concentration of the IV infusion was 1.00 hour.,Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145260/),h,1.00,214504,DB00218,Moxifloxacin
,24375070,Tmax,Plasma concentrations of loxapine increased with a median Tmax of 1 minute and a mean Cmax of 312 ng/mL.,Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),min,1,215120,DB00218,Moxifloxacin
,24375070,Cmax,Plasma concentrations of loxapine increased with a median Tmax of 1 minute and a mean Cmax of 312 ng/mL.,Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),[ng] / [ml],312,215121,DB00218,Moxifloxacin
,24375070,terminal half-life,"After an initial rapid distribution phase, plasma concentrations of loxapine declined with a terminal half-life of 8 hours.",Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),h,8,215122,DB00218,Moxifloxacin
,24375070,terminal half-life,Exposure to the active metabolite 7-OH-loxapine was 15% of the parent compound based on mean AUCinf and its terminal half-life was 12 hours.,Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),h,12,215123,DB00218,Moxifloxacin
,18211115,abscess fluid/plasma concentration ratio,"The abscess fluid/plasma concentration ratio increased continuously from 0.083 (95% CI 0.047, 0.147) at 2 hours after administration to 1.66 (95% CI 0.935, 2.946) at 24 hours; concentrations in abscess fluid tended to exceed those in plasma after 12-24 hours.",Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211115/),,0,217456,DB00218,Moxifloxacin
,27194905,Cmax,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[μg] / [ml],1.43,218335,DB00218,Moxifloxacin
,27194905,Cmax,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[μg] / [ml],0.87,218336,DB00218,Moxifloxacin
,27194905,AUC0-6,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[min·μg] / [ml],6.1,218337,DB00218,Moxifloxacin
,27194905,AUC0-6,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[min·μg] / [ml],3.8,218338,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],3.45,221130,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],1.89,221131,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],1.43,221132,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],3.73,221133,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],1.81,221134,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],1.56,221135,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],6.26,221136,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],2.97,221137,DB00218,Moxifloxacin
,16551691,concentrations,"Mean plasma, cancellous bone and cortical bone concentrations were, respectively: 3.45, 1.89 and 1.43 mg/L for group A; 3.73, 1.81 and 1.56 mg/L for group B; and 6.26, 2.97 and 2.54 mg/L for group C.",Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551691/),[mg] / [l],2.54,221138,DB00218,Moxifloxacin
>,25450804,ratios of fAUC0-24h/MIC90,"Monte Carlo simulations were used with LFX 500 mg every 24h (q24 h) or every 12h (q12h), LFX 750 mg q24 h and MOX 400mg q24 h in non-compliance scenarios to derive the proportion of patients achieving target ratios of fAUC0-24h/MIC90>33.8 for Streptococcus pneumoniae and >100 for Haemophilus influenzae and Moraxella catarrhalis (PTA>90%).",Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25450804/),,33.8,221176,DB00218,Moxifloxacin
>,25450804,ratios of fAUC0-24h/MIC90,"Monte Carlo simulations were used with LFX 500 mg every 24h (q24 h) or every 12h (q12h), LFX 750 mg q24 h and MOX 400mg q24 h in non-compliance scenarios to derive the proportion of patients achieving target ratios of fAUC0-24h/MIC90>33.8 for Streptococcus pneumoniae and >100 for Haemophilus influenzae and Moraxella catarrhalis (PTA>90%).",Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25450804/),,100,221177,DB00218,Moxifloxacin
,14998080,steady-state moxifloxacin ratios,The mean +/- SD steady-state moxifloxacin ratios between lung and plasma concentrations were respectively: 3.53 +/- 1.89 and 4.36 +/- 1.48 for i.v. and oral administration.,Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998080/),,3.53,223205,DB00218,Moxifloxacin
,14998080,steady-state moxifloxacin ratios,The mean +/- SD steady-state moxifloxacin ratios between lung and plasma concentrations were respectively: 3.53 +/- 1.89 and 4.36 +/- 1.48 for i.v. and oral administration.,Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998080/),,4.36,223206,DB00218,Moxifloxacin
,14998080,maximal lung concentrations (Cmax),The mean steady-state moxifloxacin maximal lung concentrations (Cmax) were respectively 12.37 microg/g and 16.21 microg/g for i.v. and oral administration.,Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998080/),[μg] / [g],12.37,223207,DB00218,Moxifloxacin
,14998080,maximal lung concentrations (Cmax),The mean steady-state moxifloxacin maximal lung concentrations (Cmax) were respectively 12.37 microg/g and 16.21 microg/g for i.v. and oral administration.,Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998080/),[μg] / [g],16.21,223208,DB00218,Moxifloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [ml],10.16,223793,DB00218,Moxifloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [g],156.07,223794,DB00218,Moxifloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [g],11.92,223795,DB00218,Moxifloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [ml],0.099,223796,DB00218,Moxifloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,150.67,223797,DB00218,Moxifloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,10.6,223798,DB00218,Moxifloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,9.69,223799,DB00218,Moxifloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,3,223800,DB00218,Moxifloxacin
exceeded,26501204,ΔΔTcI,"Post loxapine dosing, no ΔΔTcI 95% upper CI exceeded 10 msec; the largest was 6.31 msec 5 minutes post dose 2.","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),ms,10,225454,DB00218,Moxifloxacin
,26501204,ΔΔTcI,"Post loxapine dosing, no ΔΔTcI 95% upper CI exceeded 10 msec; the largest was 6.31 msec 5 minutes post dose 2.","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),ms,6.31,225455,DB00218,Moxifloxacin
,26501204,Cmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),[ng] / [ml],177,225456,DB00218,Moxifloxacin
,26501204,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),min,2,225457,DB00218,Moxifloxacin
,26501204,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),h,2.03,225458,DB00218,Moxifloxacin
,25534740,MIC,"When used alone, timcodar weakly inhibited M. tuberculosis growth in broth culture (MIC, 19 μg/ml); however, it demonstrated synergism in drug combination studies with rifampin, bedaquiline, and clofazimine but not with other anti-TB agents.",The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534740/),[μg] / [ml],19,225521,DB00218,Moxifloxacin
,25534740,50% inhibitory concentration,"When M. tuberculosis was cultured in host macrophage cells, timcodar had about a 10-fold increase (50% inhibitory concentration, 1.9 μg/ml) in the growth inhibition of M. tuberculosis and demonstrated synergy with rifampin, moxifloxacin, and bedaquiline.",The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534740/),[μg] / [ml],1.9,225522,DB00218,Moxifloxacin
,20871984,maximum observed plasma concentration (C (max)),"In the PO and IV subgroups, the mean maximum observed plasma concentration (C (max)) in plasma was 2.69 and 4.77 mg/l at a median of 2 [time to reach C (max) (T (max)) range 1.0-8.0 h] and 1 h after administration, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),[mg] / [l],2.69,227902,DB00218,Moxifloxacin
,20871984,maximum observed plasma concentration (C (max)),"In the PO and IV subgroups, the mean maximum observed plasma concentration (C (max)) in plasma was 2.69 and 4.77 mg/l at a median of 2 [time to reach C (max) (T (max)) range 1.0-8.0 h] and 1 h after administration, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),[mg] / [l],4.77,227903,DB00218,Moxifloxacin
,20871984,maximum observed plasma concentration (C (max)),"In the PO and IV subgroups, the mean maximum observed plasma concentration (C (max)) in plasma was 2.69 and 4.77 mg/l at a median of 2 [time to reach C (max) (T (max)) range 1.0-8.0 h] and 1 h after administration, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),h,2,227904,DB00218,Moxifloxacin
,20871984,time to reach C (max) (T (max)),"In the PO and IV subgroups, the mean maximum observed plasma concentration (C (max)) in plasma was 2.69 and 4.77 mg/l at a median of 2 [time to reach C (max) (T (max)) range 1.0-8.0 h] and 1 h after administration, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),h,1.0-8.0,227905,DB00218,Moxifloxacin
,20871984,time to reach C (max) (T (max)),"In the PO and IV subgroups, the mean maximum observed plasma concentration (C (max)) in plasma was 2.69 and 4.77 mg/l at a median of 2 [time to reach C (max) (T (max)) range 1.0-8.0 h] and 1 h after administration, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),h,1,227906,DB00218,Moxifloxacin
,20871984,area under the plasma concentration-time curve from time 0 until the last quantifiable plasma concentration (AUC(0-24 h)),A mean area under the plasma concentration-time curve from time 0 until the last quantifiable plasma concentration (AUC(0-24 h)) of 29.36 mg h/l (PO) and 27.09 mg h/l (IV) was achieved.,Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),[h·mg] / [l],29.36,227907,DB00218,Moxifloxacin
,20871984,area under the plasma concentration-time curve from time 0 until the last quantifiable plasma concentration (AUC(0-24 h)),A mean area under the plasma concentration-time curve from time 0 until the last quantifiable plasma concentration (AUC(0-24 h)) of 29.36 mg h/l (PO) and 27.09 mg h/l (IV) was achieved.,Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),[h·mg] / [l],27.09,227908,DB00218,Moxifloxacin
,20871984,MIC(90) (minimum inhibitory concentration required to inhibit,"Mean moxifloxacin concentrations in perinecrotic tissue of infected diabetic foot wounds following PO or IV administration were 1.79 ± 0.82 and 2.20 ± 1.54 μg/g, thus exceeding the MIC(90) (minimum inhibitory concentration required to inhibit growth of 90% of organisms) for Staphylococcus aureus (0.25 mg/l) by seven- and eightfold and the MIC(90) for Escherichia coli (0.06 mg/l) by 29-fold and 36-fold, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),[mg] / [l],0.25,227909,DB00218,Moxifloxacin
,20871984,MIC(90),"Mean moxifloxacin concentrations in perinecrotic tissue of infected diabetic foot wounds following PO or IV administration were 1.79 ± 0.82 and 2.20 ± 1.54 μg/g, thus exceeding the MIC(90) (minimum inhibitory concentration required to inhibit growth of 90% of organisms) for Staphylococcus aureus (0.25 mg/l) by seven- and eightfold and the MIC(90) for Escherichia coli (0.06 mg/l) by 29-fold and 36-fold, respectively.",Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),[mg] / [l],0.06,227910,DB00218,Moxifloxacin
,20871984,tissue-to-plasma ratios,The mean tissue-to-plasma ratios of moxifloxacin concentration 3 h after administration were 1.01 ± 0.57 (PO) and 1.09 ± 0.69 (IV).,Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),,1.01,227911,DB00218,Moxifloxacin
,20871984,tissue-to-plasma ratios,The mean tissue-to-plasma ratios of moxifloxacin concentration 3 h after administration were 1.01 ± 0.57 (PO) and 1.09 ± 0.69 (IV).,Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20871984/),,1.09,227912,DB00218,Moxifloxacin
,20027105,Cmax,"Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.",A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027105/),nM,1947.4,228949,DB00218,Moxifloxacin
,20027105,Cmax,"Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.",A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027105/),nM,739.2,228950,DB00218,Moxifloxacin
,20027105,Cmax,"Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.",A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027105/),nM,54.8,228951,DB00218,Moxifloxacin
,16050813,clearance (Cl),The plasma moxifloxacin clearance (Cl) for the i.v route was (mean +/- SD) 0.80 +/- 0.02 L/h.kg.,"Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),[l] / [h·kg],0.80,229367,DB00218,Moxifloxacin
,16050813,steady-state volume of distribution (Vss),The steady-state volume of distribution (Vss) was 1.95 +/- 0.18 L/kg.,"Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),[l] / [kg],1.95,229368,DB00218,Moxifloxacin
,16050813,terminal half-life (t(1/2lambdaz)),"The terminal half-life (t(1/2lambdaz)) was (mean +/- SD) 1.84 +/- 0.12, 2.09 +/- 0.05 and 2.15 +/- 0.07 h after i.v., i.m. and oral, respectively.","Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),h,1.84,229369,DB00218,Moxifloxacin
,16050813,terminal half-life (t(1/2lambdaz)),"The terminal half-life (t(1/2lambdaz)) was (mean +/- SD) 1.84 +/- 0.12, 2.09 +/- 0.05 and 2.15 +/- 0.07 h after i.v., i.m. and oral, respectively.","Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),h,2.09,229370,DB00218,Moxifloxacin
,16050813,terminal half-life (t(1/2lambdaz)),"The terminal half-life (t(1/2lambdaz)) was (mean +/- SD) 1.84 +/- 0.12, 2.09 +/- 0.05 and 2.15 +/- 0.07 h after i.v., i.m. and oral, respectively.","Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),h,2.15,229371,DB00218,Moxifloxacin
<,16050813,MIC,"From these data, it is concluded that a 5 mg/kg dose moxifloxacin would be effective by i.m. and oral routes in rabbits against bacterial isolates with MIC < or = 0.06 microg/mL and possibly for MIC < or = 0.12 microg/mL, but in the latter case a higher dose would be required.","Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),[μg] / [ml],0.06,229372,DB00218,Moxifloxacin
<,16050813,MIC,"From these data, it is concluded that a 5 mg/kg dose moxifloxacin would be effective by i.m. and oral routes in rabbits against bacterial isolates with MIC < or = 0.06 microg/mL and possibly for MIC < or = 0.12 microg/mL, but in the latter case a higher dose would be required.","Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050813/),[μg] / [ml],0.12,229373,DB00218,Moxifloxacin
,21729931,Oral bioavailability,Oral bioavailability was 79.6% ± 11.5%.,Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21729931/),%,79.6,230278,DB00218,Moxifloxacin
,21729931,plasma clearance,"After intravenous administration, plasma clearance was 9.6 ± 2.0 L/h, volume of distribution was 165 ± 30 L and area under the curve was 43.7 ± 11.8 mg·h/L.",Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21729931/),[l] / [h],9.6,230279,DB00218,Moxifloxacin
,21729931,volume of distribution,"After intravenous administration, plasma clearance was 9.6 ± 2.0 L/h, volume of distribution was 165 ± 30 L and area under the curve was 43.7 ± 11.8 mg·h/L.",Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21729931/),l,165,230280,DB00218,Moxifloxacin
,21729931,area under the curve,"After intravenous administration, plasma clearance was 9.6 ± 2.0 L/h, volume of distribution was 165 ± 30 L and area under the curve was 43.7 ± 11.8 mg·h/L.",Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21729931/),[h·mg] / [l],43.7,230281,DB00218,Moxifloxacin
≥,25666151,Cmax/MIC,"PK-PD targets adopted were a Cmax/MIC of ≥12.2 for all pathogens, an fAUC0-24/MIC of >34 for S. pneumoniae, and an fAUC0-24/MIC of >75 for H. influenzae and L. pneumophila.",Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666151/),,12.2,231271,DB00218,Moxifloxacin
>,25666151,fAUC0-24/MIC,"PK-PD targets adopted were a Cmax/MIC of ≥12.2 for all pathogens, an fAUC0-24/MIC of >34 for S. pneumoniae, and an fAUC0-24/MIC of >75 for H. influenzae and L. pneumophila.",Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666151/),,34,231272,DB00218,Moxifloxacin
>,25666151,fAUC0-24/MIC,"PK-PD targets adopted were a Cmax/MIC of ≥12.2 for all pathogens, an fAUC0-24/MIC of >34 for S. pneumoniae, and an fAUC0-24/MIC of >75 for H. influenzae and L. pneumophila.",Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666151/),,75,231273,DB00218,Moxifloxacin
,29186509,serum concentration,The median free moxifloxacin serum concentration at time of surgical resection was 1.23 μg/mL (range = 0.12-1.80) and the median free lung tissue concentration was 3.37 μg/mL (range = 0.81-5.76).,Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29186509/),[μg] / [ml],1.23,232907,DB00218,Moxifloxacin
,29186509,free lung tissue concentration,The median free moxifloxacin serum concentration at time of surgical resection was 1.23 μg/mL (range = 0.12-1.80) and the median free lung tissue concentration was 3.37 μg/mL (range = 0.81-5.76).,Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29186509/),[μg] / [ml],3.37,232908,DB00218,Moxifloxacin
,29186509,free-tissue/free-serum concentration ratio,The median free-tissue/free-serum concentration ratio was 3.20 (range = 0.66-28.08).,Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29186509/),,3.20,232909,DB00218,Moxifloxacin
,21415283,clearance,"The population estimates for clearance and central volume of distribution were 10.0 L/h per 60 kg of LBM and 131 L per 60 kg of LBM, respectively.",Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21415283/),[l] / [60·h·kg],10.0,234614,DB00218,Moxifloxacin
,21415283,central volume of distribution,"The population estimates for clearance and central volume of distribution were 10.0 L/h per 60 kg of LBM and 131 L per 60 kg of LBM, respectively.",Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21415283/),[l] / [60·kg],131,234615,DB00218,Moxifloxacin
,23837923,area under the concentration-time curve over 12 h (AUC(0-12 h),"Exposure to clarithromycin when combined with rifampicin was very low [area under the concentration-time curve over 12 h (AUC(0-12 h), geometric mean 2.6 h·mg/L, range 1.6-3.2 h·mg/L; peak concentration in plasma (C(max)), geometric mean 0.3 mg/L, range 0.1-0.7 mg/L].",Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23837923/),[h·mg] / [l],2.6,234788,DB00218,Moxifloxacin
,23837923,peak concentration in plasma (C(max)),"Exposure to clarithromycin when combined with rifampicin was very low [area under the concentration-time curve over 12 h (AUC(0-12 h), geometric mean 2.6 h·mg/L, range 1.6-3.2 h·mg/L; peak concentration in plasma (C(max)), geometric mean 0.3 mg/L, range 0.1-0.7 mg/L].",Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23837923/),[mg] / [l],0.3,234789,DB00218,Moxifloxacin
,16890030,recovery,"The method was fully validated and validation parameters were: linearity range 3-1300microg/L; correlation coefficient, 0.99986; mean recovery, 92.5%; limit of quantification, 3.0microg/L and limit of detection, 1.0microg/L.",Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890030/),%,92.5,235210,DB00218,Moxifloxacin
,16890030,limit of quantification,"The method was fully validated and validation parameters were: linearity range 3-1300microg/L; correlation coefficient, 0.99986; mean recovery, 92.5%; limit of quantification, 3.0microg/L and limit of detection, 1.0microg/L.",Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890030/),[μg] / [l],3.0,235211,DB00218,Moxifloxacin
,16890030,limit of detection,"The method was fully validated and validation parameters were: linearity range 3-1300microg/L; correlation coefficient, 0.99986; mean recovery, 92.5%; limit of quantification, 3.0microg/L and limit of detection, 1.0microg/L.",Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890030/),[μg] / [l],1.0,235212,DB00218,Moxifloxacin
,27137718,tmax,"After a single oral administrations of 50 and 800 mg opicapone, opicapone was the major entity in the circulation, with a median tmax of 1.5-2.0 hours.",Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137718/),h,1.5-2.0,236675,DB00218,Moxifloxacin
,27137718,elimination half-life,"Opicapone was rapidly eliminated, with an elimination half-life of 1-2 hours.",Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137718/),h,1-2,236676,DB00218,Moxifloxacin
,12709331,MIC,"Concentrations determined in the vitreous cavity following a 20-mg/kg administration showed a 3.5-fold decrease of the bacterial density within 5 h for MSSA (MIC, 0.125 micro g/ml) and a 1.6-fold decrease for MRSA (MIC, 4 micro g/ml) strains, respectively.",Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709331/),[μg] / [ml],0.125,239124,DB00218,Moxifloxacin
,12709331,MIC,"Concentrations determined in the vitreous cavity following a 20-mg/kg administration showed a 3.5-fold decrease of the bacterial density within 5 h for MSSA (MIC, 0.125 micro g/ml) and a 1.6-fold decrease for MRSA (MIC, 4 micro g/ml) strains, respectively.",Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709331/),[μg] / [ml],4,239125,DB00218,Moxifloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.125,239150,DB00218,Moxifloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.006-4,239151,DB00218,Moxifloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0,239152,DB00218,Moxifloxacin
,16518709,MIC90,"To describe the PD function the MIC distribution pattern of more than 3,000 isolates of S. pneumoniae as the representative pathogen for RTI (MIC90, range: 0.125; 0.006-4 mg/l) was built into the population PK/PD model for RTI, while 126 isolates of methicillin-susceptible Staphylococcus aureus strains (MIC90, range: 0.125; 0.03-4 mg/l) were the basis for the PD function in cSSSI.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.03-4,239153,DB00218,Moxifloxacin
>,16518709,AUIC,"Overall, a target hit rate was THR = 99% for RTI, while it amounted to THR = 97.5% for cSSSI when applying a threshold of AUIC > 30 [h] as the PK/PD surrogate parameter which is predictive for a positive clinical outcome.",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),,30,239154,DB00218,Moxifloxacin
>,16518709,AUIC,"A target hit rate of THR = 93.6 % (RTI) and 97.3% (cSSSI), respectively, was predicted when assuming that an AUIC of > 125 [h] is indicative of clinical success (as shown for ciprofloxacin and severe RTIs due to gram-negative infections).",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[h],125,239155,DB00218,Moxifloxacin
,16518709,MIC,From the simulations performed for RTI an analysis of the overall likelihood of therapeutic failure broken down according to MICs suggests that the risk of a negative clinical outcome at a MIC = 1 mg/l is approximately 0.25% (for MIC = 2 mg/l: predicted likelihood approximately 0.5%) assuming that a cutoff of AUIC = 30 [h] is applicable.,The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],1,239156,DB00218,Moxifloxacin
,16518709,MIC,From the simulations performed for RTI an analysis of the overall likelihood of therapeutic failure broken down according to MICs suggests that the risk of a negative clinical outcome at a MIC = 1 mg/l is approximately 0.25% (for MIC = 2 mg/l: predicted likelihood approximately 0.5%) assuming that a cutoff of AUIC = 30 [h] is applicable.,The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),,2,239157,DB00218,Moxifloxacin
,16518709,AUIC,From the simulations performed for RTI an analysis of the overall likelihood of therapeutic failure broken down according to MICs suggests that the risk of a negative clinical outcome at a MIC = 1 mg/l is approximately 0.25% (for MIC = 2 mg/l: predicted likelihood approximately 0.5%) assuming that a cutoff of AUIC = 30 [h] is applicable.,The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),h,30,239158,DB00218,Moxifloxacin
,16518709,MIC,"Likewise, for cSSSI the probability to fail is predicted as 1.6% at a MIC = 2 mg/l (no strains with MICs between 0.5 and 1 mg/l available from the clinical isolates).",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],2,239159,DB00218,Moxifloxacin
,16518709,MICs,"Likewise, for cSSSI the probability to fail is predicted as 1.6% at a MIC = 2 mg/l (no strains with MICs between 0.5 and 1 mg/l available from the clinical isolates).",The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16518709/),[mg] / [l],0.5 and 1,239160,DB00218,Moxifloxacin
,24247125,C2/MIC ratios,"Three subjects with the lowest TDA result (<1.5, a finding indicative of poor killing) had significantly lower kanamycin C2/MIC ratios than subjects with a TDA of ≥1.5 (9.8 ± 8.7 versus 27.0 ± 19.1; P = 0.04).",Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,9.8,240091,DB00218,Moxifloxacin
,24247125,C2/MIC ratios,"Three subjects with the lowest TDA result (<1.5, a finding indicative of poor killing) had significantly lower kanamycin C2/MIC ratios than subjects with a TDA of ≥1.5 (9.8 ± 8.7 versus 27.0 ± 19.1; P = 0.04).",Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,27.0,240092,DB00218,Moxifloxacin
,24247125,TDAs,The mean TDAs were 2.52 ± 0.76 in subjects converting to negative in ≤2 months and 1.88 ± 0.57 in subjects converting to negative in >2 months (P = 0.08).,Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,2.52,240093,DB00218,Moxifloxacin
,24247125,TDAs,The mean TDAs were 2.52 ± 0.76 in subjects converting to negative in ≤2 months and 1.88 ± 0.57 in subjects converting to negative in >2 months (P = 0.08).,Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,1.88,240094,DB00218,Moxifloxacin
≥,24189253,fAUC0-24/MIC ratios,"For a specific MIC, the probability of target attainment (PTA) was determined for target fAUC0-24/MIC ratios of ≥53 and ≥100.",Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189253/),,53,240378,DB00218,Moxifloxacin
≥,24189253,fAUC0-24/MIC ratios,"For a specific MIC, the probability of target attainment (PTA) was determined for target fAUC0-24/MIC ratios of ≥53 and ≥100.",Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189253/),,100,240379,DB00218,Moxifloxacin
≥,24189253,target ratio,"Using a target ratio of ≥100 for multidrug-resistant strains (without resistance to injectable agents or fluoroquinolones), the CFR was 88% for moxifloxacin and only 43% for ofloxacin, and the higher dose of 800 mg moxifloxacin was needed to achieve a CFR target of >90%.",Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189253/),,100,240380,DB00218,Moxifloxacin
,24242939,aerodynamic diameters,"The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively.",A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242939/),μm,2.58,241021,DB00218,Moxifloxacin
,24242939,aerodynamic diameters,"The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively.",A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242939/),μm,2.51,241022,DB00218,Moxifloxacin
,24242939,fine,"The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively.",A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242939/),%,55.5,241023,DB00218,Moxifloxacin
,23762598,flow rate,"Following a single step liquid-liquid extraction, analytes along with an internal standard (IS) were separated using an isocratic mobile phase of 0.1% triethylamine (adjusted pH to 4.8 with phosphoric acid)/acetonitrile (80/20, v/v) at flow rate of 1 mL/min on reverse phase Kromasil C18 column (250 mm × 4.6 mm, 5 μ m) at room temperature.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),[ml] / [min],1,242011,DB00218,Moxifloxacin
,23762598,Total analytical run time,Total analytical run time for selecting moxifloxacin was 15 min.,Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),min,15,242012,DB00218,Moxifloxacin
,23762598,absolute recovery rate,"The absolute recovery rate of low, medium, and high concentrations were 69.88%, 78.86%, and 78.51%, respectively.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),%,69.88,242013,DB00218,Moxifloxacin
,23762598,absolute recovery rate,"The absolute recovery rate of low, medium, and high concentrations were 69.88%, 78.86%, and 78.51%, respectively.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),%,78.86,242014,DB00218,Moxifloxacin
,23762598,absolute recovery rate,"The absolute recovery rate of low, medium, and high concentrations were 69.88%, 78.86%, and 78.51%, respectively.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),%,78.51,242015,DB00218,Moxifloxacin
,23762598,relative recovery rates,"The relative recovery rates were 98.50%, 96.61%, and 101.79%, respectively.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),%,98.50,242016,DB00218,Moxifloxacin
,23762598,relative recovery rates,"The relative recovery rates were 98.50%, 96.61%, and 101.79%, respectively.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),%,96.61,242017,DB00218,Moxifloxacin
,23762598,relative recovery rates,"The relative recovery rates were 98.50%, 96.61%, and 101.79%, respectively.",Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762598/),%,101.79,242018,DB00218,Moxifloxacin
,24271137,apparent elimination half-life,"Maximum plasma concentrations of evacetrapib occurred at a median time of approximately 2 hours, and the mean apparent elimination half-life was approximately 41 hours.",Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271137/),h,41,245644,DB00218,Moxifloxacin
,10382880,dissolution,"Following oral administration, absorption was fast with low to medium variability (mean dissolution and absorption time 2.4 h).",Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382880/),h,2.4,249113,DB00218,Moxifloxacin
,10382880,absorption time,"Following oral administration, absorption was fast with low to medium variability (mean dissolution and absorption time 2.4 h).",Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382880/),h,2.4,249114,DB00218,Moxifloxacin
,10382880,absolute bioavailability,The absolute bioavailability was 86%.,Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10382880/),%,86,249115,DB00218,Moxifloxacin
,11249827,times to 99.9% kill,"Moxifloxacin was bactericidal against all 6 staphylococci (times to 99.9% kill, 1-3 h).",Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249827/),h,1-3,250858,DB00218,Moxifloxacin
,11249827,total kills,"Against most strains, bacterial killing continued through 36 h, with total kills exceeding 5.5 logs.",Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249827/),logs,5,250859,DB00218,Moxifloxacin
,28654209,peak plasma concentrations,"The peak plasma concentrations of moxifloxacin and terfenadine after doses of 3 mg/kg were 4.81 and 10.15 μg/mL, respectively, which were both 1.5 times less in microminipigs than those previously reported in dogs.",Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28654209/),[μg] / [ml],4.81,251153,DB00218,Moxifloxacin
,28654209,peak plasma concentrations,"The peak plasma concentrations of moxifloxacin and terfenadine after doses of 3 mg/kg were 4.81 and 10.15 μg/mL, respectively, which were both 1.5 times less in microminipigs than those previously reported in dogs.",Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28654209/),[μg] / [ml],10.15,251154,DB00218,Moxifloxacin
,11352443,area under the plasma concentration-time curve,"The concomitant administration of Eryfer reduced the bioavailability of moxifloxacin [geometric mean area under the plasma concentration-time curve 20.7 versus 34.0 mg/L x h; relative bioavailability 61%, 90% confidence interval (CI) 54 to 69%] and slowed down the absorption rate (median time to maximum concentration 2.79 versus 1.0 hours), with a reduction in the mean maximum concentration (Cmax) [geometric mean Cmax 1.17 and 2.86 mg/L; estimated true ratio of Cmax 41%, 90% CI 34 to 49%].","Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352443/),[mg] / [h·l],20.7,253328,DB00218,Moxifloxacin
,11352443,area under the plasma concentration-time curve,"The concomitant administration of Eryfer reduced the bioavailability of moxifloxacin [geometric mean area under the plasma concentration-time curve 20.7 versus 34.0 mg/L x h; relative bioavailability 61%, 90% confidence interval (CI) 54 to 69%] and slowed down the absorption rate (median time to maximum concentration 2.79 versus 1.0 hours), with a reduction in the mean maximum concentration (Cmax) [geometric mean Cmax 1.17 and 2.86 mg/L; estimated true ratio of Cmax 41%, 90% CI 34 to 49%].","Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352443/),[mg] / [h·l],34.0,253329,DB00218,Moxifloxacin
,11352443,relative bioavailability,"The concomitant administration of Eryfer reduced the bioavailability of moxifloxacin [geometric mean area under the plasma concentration-time curve 20.7 versus 34.0 mg/L x h; relative bioavailability 61%, 90% confidence interval (CI) 54 to 69%] and slowed down the absorption rate (median time to maximum concentration 2.79 versus 1.0 hours), with a reduction in the mean maximum concentration (Cmax) [geometric mean Cmax 1.17 and 2.86 mg/L; estimated true ratio of Cmax 41%, 90% CI 34 to 49%].","Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352443/),%,61,253330,DB00218,Moxifloxacin
,11352443,time to maximum concentration,"The concomitant administration of Eryfer reduced the bioavailability of moxifloxacin [geometric mean area under the plasma concentration-time curve 20.7 versus 34.0 mg/L x h; relative bioavailability 61%, 90% confidence interval (CI) 54 to 69%] and slowed down the absorption rate (median time to maximum concentration 2.79 versus 1.0 hours), with a reduction in the mean maximum concentration (Cmax) [geometric mean Cmax 1.17 and 2.86 mg/L; estimated true ratio of Cmax 41%, 90% CI 34 to 49%].","Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352443/),h,2.79,253331,DB00218,Moxifloxacin
,11352443,time to maximum concentration,"The concomitant administration of Eryfer reduced the bioavailability of moxifloxacin [geometric mean area under the plasma concentration-time curve 20.7 versus 34.0 mg/L x h; relative bioavailability 61%, 90% confidence interval (CI) 54 to 69%] and slowed down the absorption rate (median time to maximum concentration 2.79 versus 1.0 hours), with a reduction in the mean maximum concentration (Cmax) [geometric mean Cmax 1.17 and 2.86 mg/L; estimated true ratio of Cmax 41%, 90% CI 34 to 49%].","Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352443/),h,1.0,253332,DB00218,Moxifloxacin
,26747976,"Peak (2R,4R","Peak (2R,4R)-monatin plasma concentration (1720 ± 538 ng/mL) was reached at 3.1 h (mean tmax).","Detection of ECG effects of (2R,4R)-monatin, a sweet flavored isomer of a component first identified in the root bark of the Sclerochitin ilicifolius plant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26747976/),[ng] / [ml],1720,254080,DB00218,Moxifloxacin
,26467592,Cmax,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[mg] / [l],3.9,256414,DB00218,Moxifloxacin
,26467592,AUC24,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[h·mg] / [l],29.1,256415,DB00218,Moxifloxacin
,26467592,Cmax,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[mg] / [l],4.1,256416,DB00218,Moxifloxacin
,26467592,AUC24,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[h·mg] / [l],36.5,256417,DB00218,Moxifloxacin
,22980315,terminal elimination t(½),The terminal elimination t(½) was ∼53 hours.,Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22980315/),h,∼53,256609,DB00218,Moxifloxacin
,30604928,exudate/plasma levels,"At 1 hour post-administration, the exudate/plasma levels (mg/L) were 1.92/3.07; at 12 hours, 0.80/1.14; at 24 hours, 0.26/0.43; and at 120 hours (steady state), 0.42/0.47.",Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604928/),[mg] / [l],1.92,256610,DB00218,Moxifloxacin
,30604928,exudate/plasma levels,"At 1 hour post-administration, the exudate/plasma levels (mg/L) were 1.92/3.07; at 12 hours, 0.80/1.14; at 24 hours, 0.26/0.43; and at 120 hours (steady state), 0.42/0.47.",Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604928/),[mg] / [l],0.80,256611,DB00218,Moxifloxacin
,30604928,exudate/plasma levels,"At 1 hour post-administration, the exudate/plasma levels (mg/L) were 1.92/3.07; at 12 hours, 0.80/1.14; at 24 hours, 0.26/0.43; and at 120 hours (steady state), 0.42/0.47.",Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604928/),[mg] / [l],0.26,256612,DB00218,Moxifloxacin
,30604928,exudate/plasma levels,"At 1 hour post-administration, the exudate/plasma levels (mg/L) were 1.92/3.07; at 12 hours, 0.80/1.14; at 24 hours, 0.26/0.43; and at 120 hours (steady state), 0.42/0.47.",Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604928/),[mg] / [l],0.42,256613,DB00218,Moxifloxacin
,30604928,steady state,"At 1 hour post-administration, the exudate/plasma levels (mg/L) were 1.92/3.07; at 12 hours, 0.80/1.14; at 24 hours, 0.26/0.43; and at 120 hours (steady state), 0.42/0.47.",Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy? ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604928/),[mg] / [l],0.42,256614,DB00218,Moxifloxacin
,15919770,MICs,The MICs were 0.0156 mg/L for moxifloxacin and 0.5 mg/L for erythromycin.,Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919770/),[mg] / [l],0.0156,259292,DB00218,Moxifloxacin
,15919770,MICs,The MICs were 0.0156 mg/L for moxifloxacin and 0.5 mg/L for erythromycin.,Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919770/),[mg] / [l],0.5,259293,DB00218,Moxifloxacin
,15919770,initial antibiotic concentration,The human pharmacokinetics were simulated in the model with a mean initial antibiotic concentration of 2.4 mg/L for moxifloxacin and 8.4 mg/L for erythromycin.,Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919770/),[mg] / [l],2.4,259294,DB00218,Moxifloxacin
,15919770,initial antibiotic concentration,The human pharmacokinetics were simulated in the model with a mean initial antibiotic concentration of 2.4 mg/L for moxifloxacin and 8.4 mg/L for erythromycin.,Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919770/),[mg] / [l],8.4,259295,DB00218,Moxifloxacin
,15919770,half-life,The mean half-life was 9 h for moxifloxacin and 3.4 h for erythromycin.,Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919770/),h,9,259296,DB00218,Moxifloxacin
,15919770,half-life,The mean half-life was 9 h for moxifloxacin and 3.4 h for erythromycin.,Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919770/),h,3.4,259297,DB00218,Moxifloxacin
,23481660,maximum drug concentration (C(max)),"Mean ± standard deviation maximum drug concentration (C(max)) (5.12 ± 1.58 μg/mL), AUC (36.5 ± 5.40 μgh/mL), VSS (2.03 ± 0.30 L/kg), CL (11.2 ± 1.91 L/h), t(1/2) (9.47 ± 0.92 h) and MRT (12.9 ± 1.52 h) were comparable with historical data for healthy volunteers.",Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23481660/),[μg] / [ml],5.12,260699,DB00218,Moxifloxacin
,23481660,AUC,"Mean ± standard deviation maximum drug concentration (C(max)) (5.12 ± 1.58 μg/mL), AUC (36.5 ± 5.40 μgh/mL), VSS (2.03 ± 0.30 L/kg), CL (11.2 ± 1.91 L/h), t(1/2) (9.47 ± 0.92 h) and MRT (12.9 ± 1.52 h) were comparable with historical data for healthy volunteers.",Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23481660/),[μgh] / [ml],36.5,260700,DB00218,Moxifloxacin
,23481660,VSS,"Mean ± standard deviation maximum drug concentration (C(max)) (5.12 ± 1.58 μg/mL), AUC (36.5 ± 5.40 μgh/mL), VSS (2.03 ± 0.30 L/kg), CL (11.2 ± 1.91 L/h), t(1/2) (9.47 ± 0.92 h) and MRT (12.9 ± 1.52 h) were comparable with historical data for healthy volunteers.",Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23481660/),[l] / [kg],2.03,260701,DB00218,Moxifloxacin
,23481660,CL,"Mean ± standard deviation maximum drug concentration (C(max)) (5.12 ± 1.58 μg/mL), AUC (36.5 ± 5.40 μgh/mL), VSS (2.03 ± 0.30 L/kg), CL (11.2 ± 1.91 L/h), t(1/2) (9.47 ± 0.92 h) and MRT (12.9 ± 1.52 h) were comparable with historical data for healthy volunteers.",Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23481660/),[l] / [h],11.2,260702,DB00218,Moxifloxacin
,23481660,t(1/2),"Mean ± standard deviation maximum drug concentration (C(max)) (5.12 ± 1.58 μg/mL), AUC (36.5 ± 5.40 μgh/mL), VSS (2.03 ± 0.30 L/kg), CL (11.2 ± 1.91 L/h), t(1/2) (9.47 ± 0.92 h) and MRT (12.9 ± 1.52 h) were comparable with historical data for healthy volunteers.",Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23481660/),h,9.47,260703,DB00218,Moxifloxacin
,23481660,MRT,"Mean ± standard deviation maximum drug concentration (C(max)) (5.12 ± 1.58 μg/mL), AUC (36.5 ± 5.40 μgh/mL), VSS (2.03 ± 0.30 L/kg), CL (11.2 ± 1.91 L/h), t(1/2) (9.47 ± 0.92 h) and MRT (12.9 ± 1.52 h) were comparable with historical data for healthy volunteers.",Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23481660/),h,12.9,260704,DB00218,Moxifloxacin
,22526014,peak concentration at the end of moxifloxacin infusion (C(max)),"Median (interquartile range) PK parameters were as follows: peak concentration at the end of moxifloxacin infusion (C(max)), 6.0 mg/L (4.8-7.1 mg/L); area under the concentration-time curve extrapolated to infinity (AUC(0-∞)), 51.1 mgh/L (40.3-57.7 mgh/L); elimination half-life, 13.2h (11.0-14.1 h); volume of distribution at steady state (V(ss)), 138.7 L (102.7-168.5 L); and total body clearance (CL), 7.8 L/h (6.9-9.9L/h).",Penetration of moxifloxacin into liver tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[mg] / [l],6.0,261233,DB00218,Moxifloxacin
,22526014,area under the concentration-time curve extrapolated to infinity (AUC(0-∞)),"Median (interquartile range) PK parameters were as follows: peak concentration at the end of moxifloxacin infusion (C(max)), 6.0 mg/L (4.8-7.1 mg/L); area under the concentration-time curve extrapolated to infinity (AUC(0-∞)), 51.1 mgh/L (40.3-57.7 mgh/L); elimination half-life, 13.2h (11.0-14.1 h); volume of distribution at steady state (V(ss)), 138.7 L (102.7-168.5 L); and total body clearance (CL), 7.8 L/h (6.9-9.9L/h).",Penetration of moxifloxacin into liver tissue. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[mgh] / [l],51.1,261234,DB00218,Moxifloxacin
,22526014,elimination half-life,"Median (interquartile range) PK parameters were as follows: peak concentration at the end of moxifloxacin infusion (C(max)), 6.0 mg/L (4.8-7.1 mg/L); area under the concentration-time curve extrapolated to infinity (AUC(0-∞)), 51.1 mgh/L (40.3-57.7 mgh/L); elimination half-life, 13.2h (11.0-14.1 h); volume of distribution at steady state (V(ss)), 138.7 L (102.7-168.5 L); and total body clearance (CL), 7.8 L/h (6.9-9.9L/h).",Penetration of moxifloxacin into liver tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),h,13.2,261235,DB00218,Moxifloxacin
,22526014,volume of distribution at steady state (V(ss)),"Median (interquartile range) PK parameters were as follows: peak concentration at the end of moxifloxacin infusion (C(max)), 6.0 mg/L (4.8-7.1 mg/L); area under the concentration-time curve extrapolated to infinity (AUC(0-∞)), 51.1 mgh/L (40.3-57.7 mgh/L); elimination half-life, 13.2h (11.0-14.1 h); volume of distribution at steady state (V(ss)), 138.7 L (102.7-168.5 L); and total body clearance (CL), 7.8 L/h (6.9-9.9L/h).",Penetration of moxifloxacin into liver tissue. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),l,138.7,261236,DB00218,Moxifloxacin
,22526014,total body clearance (CL),"Median (interquartile range) PK parameters were as follows: peak concentration at the end of moxifloxacin infusion (C(max)), 6.0 mg/L (4.8-7.1 mg/L); area under the concentration-time curve extrapolated to infinity (AUC(0-∞)), 51.1 mgh/L (40.3-57.7 mgh/L); elimination half-life, 13.2h (11.0-14.1 h); volume of distribution at steady state (V(ss)), 138.7 L (102.7-168.5 L); and total body clearance (CL), 7.8 L/h (6.9-9.9L/h).",Penetration of moxifloxacin into liver tissue. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[l] / [h],7.8,261237,DB00218,Moxifloxacin
,22526014,tissue concentrations,"Mean tissue concentrations were 9.13 mg/kg after 1.6-2.4 h, 7.62 mg/kg after 2.6-4.9h, 7.48 mg/kg after 5.6-10.0 h and 6.24 mg/kg after 22.9-26.5 h.",Penetration of moxifloxacin into liver tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[mg] / [kg],9.13,261238,DB00218,Moxifloxacin
,22526014,tissue concentrations,"Mean tissue concentrations were 9.13 mg/kg after 1.6-2.4 h, 7.62 mg/kg after 2.6-4.9h, 7.48 mg/kg after 5.6-10.0 h and 6.24 mg/kg after 22.9-26.5 h.",Penetration of moxifloxacin into liver tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[mg] / [kg],7.62,261239,DB00218,Moxifloxacin
,22526014,tissue concentrations,"Mean tissue concentrations were 9.13 mg/kg after 1.6-2.4 h, 7.62 mg/kg after 2.6-4.9h, 7.48 mg/kg after 5.6-10.0 h and 6.24 mg/kg after 22.9-26.5 h.",Penetration of moxifloxacin into liver tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[mg] / [kg],7.48,261240,DB00218,Moxifloxacin
,22526014,tissue concentrations,"Mean tissue concentrations were 9.13 mg/kg after 1.6-2.4 h, 7.62 mg/kg after 2.6-4.9h, 7.48 mg/kg after 5.6-10.0 h and 6.24 mg/kg after 22.9-26.5 h.",Penetration of moxifloxacin into liver tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),[mg] / [kg],6.24,261241,DB00218,Moxifloxacin
,22526014,tissue:serum ratios,"Mean tissue:serum ratios were 2.9, 3.4, 5.0 and 12.3, respectively.",Penetration of moxifloxacin into liver tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),,2.9,261242,DB00218,Moxifloxacin
,22526014,tissue:serum ratios,"Mean tissue:serum ratios were 2.9, 3.4, 5.0 and 12.3, respectively.",Penetration of moxifloxacin into liver tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),,3.4,261243,DB00218,Moxifloxacin
,22526014,tissue:serum ratios,"Mean tissue:serum ratios were 2.9, 3.4, 5.0 and 12.3, respectively.",Penetration of moxifloxacin into liver tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),,5.0,261244,DB00218,Moxifloxacin
,22526014,tissue:serum ratios,"Mean tissue:serum ratios were 2.9, 3.4, 5.0 and 12.3, respectively.",Penetration of moxifloxacin into liver tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526014/),,12.3,261245,DB00218,Moxifloxacin
,23830621,Peak,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],4.81,261422,DB00218,Moxifloxacin
,23830621,Peak,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],6.42,261423,DB00218,Moxifloxacin
,23830621,trough concentrations,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.59,261424,DB00218,Moxifloxacin
,23830621,trough concentrations,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.79,261425,DB00218,Moxifloxacin
,23830621,CL,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[l] / [h],10.27,261426,DB00218,Moxifloxacin
,23830621,CL,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[l] / [h],22.66,261427,DB00218,Moxifloxacin
,23830621,t1/2,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),h,13.43,261428,DB00218,Moxifloxacin
,23830621,t1/2,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),h,6.75,261429,DB00218,Moxifloxacin
,23830621,Vss,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),l,163.03,261430,DB00218,Moxifloxacin
,23830621,Vss,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),l,170.73,261431,DB00218,Moxifloxacin
,23830621,AUC(0-24),"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[h·mg] / [l],39.38,261432,DB00218,Moxifloxacin
,23830621,AUC(0-24),"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[h·mg] / [l],47.06,261433,DB00218,Moxifloxacin
≤,23830621,MICs,Moxifloxacin proved to be pharmacodynamically efficacious against Gram-positive bacteria with MICs ≤ 0.79 mg/L and Gram-negative bacteria with MICs ≤ 0.32 mg/L.,Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.79,261434,DB00218,Moxifloxacin
≤,23830621,MICs,Moxifloxacin proved to be pharmacodynamically efficacious against Gram-positive bacteria with MICs ≤ 0.79 mg/L and Gram-negative bacteria with MICs ≤ 0.32 mg/L.,Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.32,261435,DB00218,Moxifloxacin
,23830621,MIC threshold,"These MIC thresholds for levofloxacin were 1.1 mg/L and 0.38 mg/L, respectively.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],1.1,261436,DB00218,Moxifloxacin
,23830621,MIC threshold,"These MIC thresholds for levofloxacin were 1.1 mg/L and 0.38 mg/L, respectively.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.38,261437,DB00218,Moxifloxacin
≥,23830621,MICs,"However, the predicted efficacy against Gram-negative bacteria with MICs ≥ 0.5 mg/L appears to be low.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.5,261438,DB00218,Moxifloxacin
,20925517,C(max),"The conjunctival moxifloxacin C(max), 43.8 μg/g, for MAF was achieved at 0.25 h.",Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),[μg] / [g],43.8,261800,DB00218,Moxifloxacin
,20925517,C(max),"This was 1.8-fold higher than the C(max) for Moxi (24.1 μg/g), which was reached at 0.5 h post-dose.",Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),[μg] / [g],24.1,261801,DB00218,Moxifloxacin
,20925517,AUC(0-3),MAF AUC(0-3) was significantly greater than the AUC(0-3) of Moxi [50.5 (μg·h)/g vs. 27.1 (μg·h)/g; P < 0.05].,Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),[h·μg] / [g],50.5,261802,DB00218,Moxifloxacin
,20925517,AUC(0-3),MAF AUC(0-3) was significantly greater than the AUC(0-3) of Moxi [50.5 (μg·h)/g vs. 27.1 (μg·h)/g; P < 0.05].,Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),[h·μg] / [g],27.1,261803,DB00218,Moxifloxacin
,20925517,C(max):MIC(90) ratios,The C(max):MIC(90) ratios for Moxi ranged from 185 to 402.,Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),,185 to 402,261804,DB00218,Moxifloxacin
,20925517,AUC(0-24):MIC(90) ratios,"Conjunctival AUC(0-24):MIC(90) ratios ranged from 777 to 1,683 for MAF and from 625 to 1,355 for Moxi.",Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),,"777 to 1,683",261805,DB00218,Moxifloxacin
,20925517,AUC(0-24):MIC(90) ratios,"Conjunctival AUC(0-24):MIC(90) ratios ranged from 777 to 1,683 for MAF and from 625 to 1,355 for Moxi.",Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),,625,261806,DB00218,Moxifloxacin
,20925517,AUC(0-24):MIC(90) ratios,"Conjunctival AUC(0-24):MIC(90) ratios ranged from 777 to 1,683 for MAF and from 625 to 1,355 for Moxi.",Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925517/),,1,261807,DB00218,Moxifloxacin
,32088331,MIC breakpoint,"For both bacterial species, the predicted MIC breakpoint for stasis at 400 mg/day was 0.25 mg/L.","A pharmacometric approach to define target site-specific breakpoints for bacterial killing and resistance suppression integrating microdialysis, time-kill curves and heteroresistance data: a case study with moxifloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32088331/),[mg] / [l],0.25,262964,DB00218,Moxifloxacin
,12019103,half-life,Moxifloxacin (MXF) is a new 8-methoxyquinolone with potent activity against Mycobacterium tuberculosis and a half-life of 9 to 12 h in humans.,Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019103/),h,9 to 12,263412,DB00218,Moxifloxacin
,17145798,MICs,"MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]).","Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145798/),[mg] / [l],0.1,263778,DB00218,Moxifloxacin
,17145798,MICs,"MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]).","Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145798/),[mg] / [l],0.5,263779,DB00218,Moxifloxacin
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,4.5,264164,DB00218,Moxifloxacin
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,12.3,264165,DB00218,Moxifloxacin
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,19.8,264166,DB00218,Moxifloxacin
,14756383,relative bioavailability,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,111.6,265643,DB00218,Moxifloxacin
,14756383,C(max) ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,103.7,265644,DB00218,Moxifloxacin
,14756383,AUC ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,107.7,265645,DB00218,Moxifloxacin
,14756383,C(max) ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,105.8,265646,DB00218,Moxifloxacin
,34087298,zeta potential,"The average particle size of nanoparticles was 87 nm, zeta potential of NTC3 was ± 19 and SEM showed the spherical shape of nanoparticles.",Moxifloxacin loaded nanoparticles of disulfide bridged thiolated chitosan-eudragit RS100 for controlled drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34087298/),,19,270223,DB00218,Moxifloxacin
,34087298,encapsulation efficiency,"The loading, encapsulation efficiency and release of moxifloxacin from NTC3 were 100.3%, 89.67% and 88.49% respectively.",Moxifloxacin loaded nanoparticles of disulfide bridged thiolated chitosan-eudragit RS100 for controlled drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34087298/),%,89.67,270224,DB00218,Moxifloxacin
,34087298,encapsulation efficiency,"The loading, encapsulation efficiency and release of moxifloxacin from NTC3 were 100.3%, 89.67% and 88.49% respectively.",Moxifloxacin loaded nanoparticles of disulfide bridged thiolated chitosan-eudragit RS100 for controlled drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34087298/),%,88.49,270225,DB00218,Moxifloxacin
,12587622,peak concentration,"In serum, moxifloxacin exhibited a mean peak concentration of 3.1 +/- 0.6 mg/l after a time to peak concentration of 1.67 +/- 0.96 h on day 1, with a significant increase to 3.98 +/- 1.10 mg/l on day 7 (p < 0.05).","Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),[mg] / [l],3.1,272068,DB00218,Moxifloxacin
,12587622,time to peak concentration,"In serum, moxifloxacin exhibited a mean peak concentration of 3.1 +/- 0.6 mg/l after a time to peak concentration of 1.67 +/- 0.96 h on day 1, with a significant increase to 3.98 +/- 1.10 mg/l on day 7 (p < 0.05).","Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),h,1.67,272069,DB00218,Moxifloxacin
,12587622,time to peak concentration,"In serum, moxifloxacin exhibited a mean peak concentration of 3.1 +/- 0.6 mg/l after a time to peak concentration of 1.67 +/- 0.96 h on day 1, with a significant increase to 3.98 +/- 1.10 mg/l on day 7 (p < 0.05).","Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),-1·mg,3.98,272070,DB00218,Moxifloxacin
,12587622,area under the curve-12,The area under the curve-12 revealed a highly significant increase from 28.2 + 4.1 mg*h/l on day 1 to 39.5 +/- 6.6 mg*h/l on day 7 (p < 0.01).,"Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),[h·mg] / [l],28.2,272071,DB00218,Moxifloxacin
,12587622,area under the curve-12,The area under the curve-12 revealed a highly significant increase from 28.2 + 4.1 mg*h/l on day 1 to 39.5 +/- 6.6 mg*h/l on day 7 (p < 0.01).,"Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),[h·mg] / [l],39.5,272072,DB00218,Moxifloxacin
,12587622,terminal half-life,There were also significant differences in terminal half-life between day 1 and day 7 [10.6 h (range 9.0-12.8) vs 14.9 h (range 12.6-28.1); p < 0.01] and in mean residence time (15.1 +/- 1.9 vs 18.2 +/- 2.4 h; p < 0.01).,"Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),h,10.6,272073,DB00218,Moxifloxacin
,12587622,terminal half-life,There were also significant differences in terminal half-life between day 1 and day 7 [10.6 h (range 9.0-12.8) vs 14.9 h (range 12.6-28.1); p < 0.01] and in mean residence time (15.1 +/- 1.9 vs 18.2 +/- 2.4 h; p < 0.01).,"Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),h,14.9,272074,DB00218,Moxifloxacin
,12587622,mean residence time,There were also significant differences in terminal half-life between day 1 and day 7 [10.6 h (range 9.0-12.8) vs 14.9 h (range 12.6-28.1); p < 0.01] and in mean residence time (15.1 +/- 1.9 vs 18.2 +/- 2.4 h; p < 0.01).,"Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),h,15.1,272075,DB00218,Moxifloxacin
,12587622,mean residence time,There were also significant differences in terminal half-life between day 1 and day 7 [10.6 h (range 9.0-12.8) vs 14.9 h (range 12.6-28.1); p < 0.01] and in mean residence time (15.1 +/- 1.9 vs 18.2 +/- 2.4 h; p < 0.01).,"Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587622/),h,18.2,272076,DB00218,Moxifloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],6.21,273557,DB00218,Moxifloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],4.34,273558,DB00218,Moxifloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],3.42,273559,DB00218,Moxifloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,12.12,273560,DB00218,Moxifloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,5.37,273561,DB00218,Moxifloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],44.8,273562,DB00218,Moxifloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],39.3,273563,DB00218,Moxifloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],30,273564,DB00218,Moxifloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],5.75,273565,DB00218,Moxifloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.48,273566,DB00218,Moxifloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.17,273567,DB00218,Moxifloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.09,273568,DB00218,Moxifloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.7,273569,DB00218,Moxifloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.5,273570,DB00218,Moxifloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],4.6,273571,DB00218,Moxifloxacin
,10348784,maximum concentrations,The mean maximum concentrations observed in plasma were 4.98 microg/ml after oral dosing and 5.09 microg/ml after i.v. dosing.,Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),[μg] / [ml],4.98,273710,DB00218,Moxifloxacin
,10348784,maximum concentrations,The mean maximum concentrations observed in plasma were 4.98 microg/ml after oral dosing and 5.09 microg/ml after i.v. dosing.,Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),[μg] / [ml],5.09,273711,DB00218,Moxifloxacin
,10348784,maximum concentrations,"The mean maximum concentrations attained in the inflammatory fluid were 2.62 and 3.23 microg/ml, respectively.",Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),[μg] / [ml],2.62,273712,DB00218,Moxifloxacin
,10348784,maximum concentrations,"The mean maximum concentrations attained in the inflammatory fluid were 2.62 and 3.23 microg/ml, respectively.",Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),[μg] / [ml],3.23,273713,DB00218,Moxifloxacin
,10348784,elimination half-lives,"The mean elimination half-lives from plasma were 8.32 and 8.17 h, respectively.",Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),h,8.32,273714,DB00218,Moxifloxacin
,10348784,elimination half-lives,"The mean elimination half-lives from plasma were 8.32 and 8.17 h, respectively.",Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),h,8.17,273715,DB00218,Moxifloxacin
,10348784,overall penetration into the inflammatory fluid,The overall penetration into the inflammatory fluid was 103.4 and 104.2%.,Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),%,103.4,273716,DB00218,Moxifloxacin
,10348784,overall penetration into the inflammatory fluid,The overall penetration into the inflammatory fluid was 103.4 and 104.2%.,Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348784/),%,104.2,273717,DB00218,Moxifloxacin
